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Abstract 
Plants have been used traditionally for the treatment of diabetes mellitus all over the 
world. One such example is the bitter-tasting unripe fruit of Momordica charantia 
Linn. (Cucurbitaceae), commonly known as karela. 
Numerous studies in humans, animals and in vitro models have demonstrated a 
potential beneficial effect of karela juice or extracts in diabetes. However, the mode 
of action and active components of karela have not been satisfactorily explained. The 
present study aimed to use a systematic, relevant approach (bioassay-guided 
fractionation) to isolate and identify orally active anti-diabetic phytochemicals in 
karela, and to elucidate its mode of action. 
Our results showed that karela from different geographical origins varied in both their 
physical appearance and chemical constituents. Two varieties (Thai and Kenyan) of 
karela juice exhibited anti-hyperglycaemic (significant improvement in oral glucose 
tolerance) but not hypoglycaemic (no effect on basal glycaemia) activities in 
streptozotocin-induced non-insulin-dependent diabetic (NIDD) rats. Thai karela, 
being more potent, was studied further. We observed for the first time in vivo insulin 
secretagogue activity by karela juice. The water extract of karela juice significantly 
improved oral glucose tolerance but not intraperitoneal or intravenous glucose 
tolerance, implying that it inhibits glucose absorption from the gut or influences 
glucose sensitive gut hormones. The hexane extract improved oral and intraperitgneal 
but not intravenous glucose tolerance suggesting that it may possess a hepatic insulin 
sensitising effect, possibly in addition to an effect on the gut. This extract also 
inhibited in vitro intestinal glucose absorption in a brush border membrane vesicle 
model. 
Bioassay-guided fractionation of the hexane extract led to the isolation and 
identification of 3 compounds: 5,25-stigmastadien-3-ol (approx. 0.15%w/w yield), 
momordicine I (0.05%w/w) and ß-sitosterol. Both 5,25-stigmastadienol and ß- 
sitosterol were shown to improve oral glucose tolerance at doses of 4.6mg/kg and 
3.1mg/kg respectively in NIDD rats. Momordicine I was not tested. 
We concluded that karela is most likely to contain more than a single anti-diabetic 
component and it exhibits its anti-hyperglycaemic activity via a combination of 
modes of action. 
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Chapter 1: Introduction 
1.1 Diabetes mellitus 
According to the World Health Organisation estimates (Leslie, 1992), there are at 
least 120 million people world-wide suffering from diabetes mellitus. In the UK, 
around 1.4 million people are known to have diabetes, which accounts for 2% of its 
population (BDA, 1995). "Diabetes mellitus", which comes from the Greek and Latin 
words for syphon and sugar, describes one of the symptoms of uncontrolled diabetes - 
the passing of a large amount of urine containing sugar (glucose). In fact, it is a 
chronic metabolic disorder characterised by a high blood glucose concentration, 
known as hyperglycaemia (a fasting venous plasma glucose >_ 7.8 mmol/L), which is 
due to insulin deficiency and/or insulin resistance (defective cellular insulin action). 
The characteristic symptoms include excessive thirst and hunger, muscular weakness, 
excessive urination (polyuria) and glycosuria (glucose is excreted in the urine when 
the renal threshold for its reabsorption is exceeded), and sometimes weight loss. The 
metabolic disturbance involves the metabolism of carbohydrates, fat and protein. As a 
consequence of the metabolic derangements in diabetes, various complications often 
develop which result in a considerably reduced life expectancy. These complications 
are mainly due to diseases of blood vessels, either macrovascular disease which leads 
to an increased prevalence of coronary artery disease and peripheral vascular disease, 
or microvascular damage -which -contributes to diabetic nephropathy and diabetic 
retinopathy. Other potential complications . 
include foot trauma and ulceration, and 
increased susceptibility to infection (Gale, 1990; Nathan, 1993). 
The current classification and diagnostic criteria for diabetes mellitus were introduced 
by the United States National Diabetes Data Group (1979) and' with some 
modifications by the World Health Organisation (WHO) (1980,1985 and 1994). 
Diabetes mellitus can be categorised into various types: insulin-dependent diabetes 
mellitus (IDDM), non-insulin-dependent diabetes mellitus (NIDDM) which 'is 
subdivided into obese NIDDM and non-obese NIDDM, malnutrition-related diabetes 
mellitus (MRDM), diabetes secondary to pancreatic-disease, e. g. chronic pancreatitis, 
haemochromatosis and pancreatectomy, -diabetes secondary to endocrine disease, e. g. 
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Cushing's syndrome, acromegaly and phaeochromocytoma, drug-induced diabetes 
caused by the administration of certain drugs such as tricyclic antidepressants and 
thiazides, diabetes associated with genetic syndromes, e. g. Friedreich's ataxia and 
myotonic dystrophy, impaired glucose tolerance (IGT) and gestational diabetes 
mellitus (GDM). Some of these are described in more detail below. 
1.1.1 Insulin-dependent diabetes mellitus (IDDM) 
About one-fifth of all diabetic sufferers are insulin-dependent. IDDM or Type I 
diabetes is usually characterised clinically by abrupt onset of symptoms, insulinopenia 
and dependence on exogenous insulin therapy for survival, and proneness to ketosis 
and ketoacidosis. Patients with insulin dependent diabetes are virtually devoid of 
endogenous insulin secreting activity (with an absolute insulin deficiency), which 
results from the extensive destruction of beta cells from the islets of Langerhans in 
the pancreas. The loss of ß-cells may be due to exogenous chemicals from the 
environment, viral infection (with Coxsackie or Echo virus), or immunological 
factors such as an autoimmune disorder.. IDDM patients are usually young and not 
obese when they first develop symptoms. IDDM is also strongly associated with 
histocompatibility antigens HLA-DR3 (B8, B18) or HLA-DR4 (BW15) on 
chromosome 6 (Cudworth and Woodrow, 1976; Gale, 1990; Vadheim and Rotter, 
1992). 
1.1.2 Non-insulin-dependent diabetes mellitus (NIDDM) 
The majority (80%) of diabetic sufferers are non-insulin-dependent. Unlike IDDM 
where the primary defect is lack of insulin production, in NIDDM (also referred to as 
Type- II diabetes), there are both hepatic and peripheral insulin resistance,, i. e. 
decreased insulin effectiveness (Turner, 1996) and impaired insulin secretion 
(Robertson, 1992). Insulin resistance is, characterised, by impaired uptake and 
utilisation of glucose in insulin-sensitive target organs such as adipocytes and skeletal 
muscle, and by impaired inhibition of hepatic glucose output. Thus normal glycaemic 
control is, maintained only if the pancreatic ß-cells, can increase their insulin-secreting 
capacity to compensate for the extent of insulin resistance.. Thus in many patients 
with impaired glucose tolerance, insulin , resistance,, 
is also associated with 
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hyperinsulinaemia. Unlike IDDM, patients with NIDDM are not dependent on insulin 
for prevention of ketonuria and are not prone to ketosis. The onset is typically in later 
life (usually after age 40), and it is often associated with obesity (approximately 80% 
of affected individuals are obese). NIDDM also has a stronger genetic basis than in 
IDDM, however, characteristic aggregation of HLA types and islet cell antibodies 
have not been found in this type of diabetes. 
1.1.3 Malnutrition-related diabetes mellitus (MRDM) 
This distinct variety of diabetes is only found in tropical developing countries, thus it 
is also known as tropical diabetes (Gale, 1990). As the name implies, the diabetic 
sufferers of this group have histories of severe malnutrition. In addition, it is 
associated with insulin dependence, sometimes with severe but fluctuating insulin 
resistance. One of the two subclasses, fibrocalculous pancreatic diabetes (FCPD), is 
associated with exocrine pancreatic deficiency, pancreatic fibrosis and calcification, 
and the presence of stones in the pancreatic duct. The cause is believed to be related 
to the consumption of foods containing cyanogenic glycosides, such as cassava 
(Manihot esculenta Crantz, Euphorbiaceae), which may result in pancreatic damage. 
The other subclass, protein-deficient pancreatic diabetes, appears to be a direct 
consequence of early childhood malnutrition, such as kwashiorkor in which 0-cell 
damage occurs. 
1.1.4 Impaired glucose tolerance (IGT) 
The diagnosis of IGT is established by glucose concentrations during an oral glucose 
tolerance test (OGTT). After an overnight fast, 75g of glucose is taken in 250-350m1 
of water. Blood samples are 
, 
taken in the fasting state and 2 hours after glucose 
administration. IGT is defined solely by the abnormal glucose values during an OGTT 
that lie between the normal and diabetic ranges, i. e. the fasting venous plasma glucose 
concentration is below 7.8mmol/L and the 2-hour OGTT value is between 7.8 and 
11.1 mmol/L (National Diabetes Data Group, 1979). 
While individuals in this class are pot considered to be diabetic, they are_ at higher risk 
than the general population for. the development of diabetes. IGT probably represents 
a key stage in the natural history of NIDDM (and less frequently of IDDM), and it can 
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be expected that 1-5% of persons with IGT will proceed to overt clinical diabetes per 
year. Subjects with IGT have a heightened risk of macrovascular disease (Harris and 
Zimmet, 1992) and because of this and the association with other cardiovascular 
disease risk factors including hypertension, dyslipidaemia and central obesity, the 
diagnosis of IGT particularly in otherwise healthy individuals, may have important 
prognostic implications. IGT is widely accepted as a precursor of NIDDM (Edelman, 
1995). 
1.1.5 Gestational diabetes mellitus (GDM) 
The term gestational diabetes mellitus is restricted to pregnant women in whom the 
onset or first recognition of glucose intolerance occurs during pregnancy and the life- 
time risk for IGT and NIDDM is substantially increased (WHO, 1994). Thus, 
diabetics who become pregnant are not included in this class. GDM is associated with 
increased perinatal complications and with increased risk for progression to diabetes 
within 5-10 years after parturition (Harris and Zimmet, 1992). 
Many women with GDM may be treated with diet alone or, if necessary, also with 
insulin. Oral hypoglycaemic agents are avoided due to, the potential risk to the foetus. 
1.1.6 Management of diabetes mellitus 
The therapeutic goal for diabetes is initially to relieve the immediate symptoms of the 
disorder (thirst, polyuria, glycosuria and weight loss) without causing hypoglycaemia, 
and in the long term, to prevent diabetic complications and reduce the mortality of 
diabetes. 
Monitoring of therapy is the key to management of diabetes. The monitoring of blood 
glucose has generally superseded the detection of glycosuria, though urine testing for 
glucose is useful in patients who have difficulty in blood glucose monitoring. For 
adequate glycaemic control, the aim is to reduce fasting blood glucose concentrations 
to within the range of 3.3 to 5.6 mmol/L venous whole blood, while postprandial 
blood glucose concentrations should be below 10 mmol/L. Blood glucose 
concentration evaluation can be carried out using blood glucose reagent test strips 
which can be read by visual comparison with a colour chart, or automatically by 
means of a meter (BNF, 1998). In addition, detection of urinary ketones is useful in 
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diabetic patients prone to ketosis; and the degree of haemoglobin glycosylation (HbAI or) 
HbAIc) is used as an indicator of mean glycaemic control over the preceding two to 
three months. 
All diabetic patients require careful consideration of the diet. Each patient requires an 
individually tailored diet plan according to his or her needs, taking account of the 
patient's usual eating habits, lifestyle, work patterns and culture. The typical dietary 
advice includes: not restricting carbohydrate intake, but meals should consist of 
unrefined carbohydrates (starch, soluble fibre) instead of simple sugars such as 
sucrose, increasing dietary fibre, and reducing saturated fat intake (Lean et al., 1992; 
BDA, 1996). Correction of obesity is desirable in NIDDM patients, since it will 
remove one of the factors associated with insulin resistance. Moreover, all diabetic 
patients are encouraged to exercise. Exercise improves metabolism and enhances the 
action of insulin on tissues (Devlin and Horton, 1987). 
1.1.7 Insulin and its use in diabetes mellitus 
Insulin is the main form of treatment for patients with IDDM, who have little or no 
endogenous insulin secretory capacity. Since its discovery in 1922 (Banting et al., 
1922), insulin has provided life-saving treatment for millions of diabetic patients 
around the world. Insulin (Rang et al., 1995; Laurence et al., 1997) is a peptide 
macromolecule (composed of 51 amino acid residues with approximate molecular 
weight of 6000 daltons) consisting of two peptide chains (A chain, 21 and B chain, 30 
amino acids) connected by two disulphide bridges. It is derived by proteolytic 
cleavage from a larger single-chain protein precursor known as proinsulin of 
approximate 9000 daltons molecular weight (Fig. 1.1). Insulin is synthesised in the ß- 
cells of the pancreatic islets in the form of proinsulin, which is stored in secretory 
granules. A peptide fragment known as connecting C-peptide breaks off from 
proinsulin during the secretory process (by exocytosis), so that equimolar quantities 
of insulin and C-peptide are released into the circulation. Insulin enters the portal 
circulation and eventually reaches the liver which is its prime target organ. About 
50% of secreted -insulin is extracted and degraded in the liver; the remaining is broken 
down by the kidney. 
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The insulin receptor (Fig. 1.2), a glycoprotein of approximate 350000 daltons 
molecular weight, is present on many target cells (Gale, 1990). The receptor straddles 
the cell membrane and consists of a dimer with two a subunits, which include the 
binding sites for insulin, and two ß subunits, which transverse the cell membrane and 
initiate the intracellular actions of insulin. Insulin molecules bind to the receptors, 
forming a complex that promotes glucose uptake. 
About 25% of total pancreatic insulin content is secreted daily. The main parameter 
controlling the synthesis and secretion of insulin is the blood glucose concentration. 
In normal subjects, there is a steady basal insulin release and also a response to a rise 
in blood glucose. It is a two-phase response: an initial rapid phase (first phase) 
reflecting release of stored insulin, and a slower, delayed phase (second phase) 
reflecting the release of both stored insulin and new synthesis (Pfeifer et al., 1981; 
Rang et al., 1995). However, this response is abnormal in diabetic patients; the first 
phase is missing in NIDDM and both phases are missing in IDDM (Fig. 1.3). Apart 
from glucose, the first phase insulin release can also be stimulated by glucagon, 
amino acids (particularly arginine and leucine), fatty acids, various gastrointestinal 
tract hormones (gastrin, secretin, cholecystokinin, gastric inhibitory peptide and 
enteroglucagon) and sulphonylureas (Section 1.1.9(a)). On the other hand, insulin 
release is inhibited by somatostatin and amylin. 
Insulin is the major regulator of intermediary metabolism (Rang et al., 1995). It exerts 
its effects mainly on the carbohydrate, fat and protein metabolism in liver, muscle and 
adipose tissues (Table 1.1). Its most obvious effect is to reduce blood glucose by 
decreasing glycogenolysis (glycogen breakdown) and gluconeogenesis (synthesis of 
glucose from non-carbohydrate source) and increasing glycogen synthesis. It also 
increases glucose utilisation (glycolysis), fatty acid and amino acid synthesis, and 
decreases lipolysis. 
The aim of insulin therapy is to achieve the best possible control of blood 
glucose concentrations without the risk of hypoglycaemia. Insulin may be of bovine or 
porcine origins, or it can be human insulin produced by either enzymatic modification 
and suitable purification of porcine insulin or by recombinant DNA technology using 
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Escherichia coli (Johnson, 1983; Martindale, 1996) and yeast. Due to the slight variations in 
the amino acid sequence of insulin molecules among species, they may be antigenic 
when administered to a different species. Thus human insulins are particularly chosen 
in patients who have shown allergic or resistance problems with animal insulins, and 
for those newly diagnosed IDDM patients. 
There are 4 main types of insulin preparations available commercially (Martindale, 
1996; BNF, 1998): 
Q Rapid-acting: e. g. Insulin Lispro 
Q Short-acting: e. g. Soluble insulin 
Q Intermediate-acting: e. g. Isophane insulin 
0 Long-acting: e. g. Insulin Zinc Suspension (Crystalline) 
The type of insulin used and its dose and frequency of administration depend on the 
particular needs of the patient. Most patients are best started on insulins of 
intermediate action twice daily and a short-acting insulin can be added to cover any 
hyperglycaemia which may occur after breakfast or evening meal. 
Insulin is inactivated by gastrointestinal enzymes, thus it is commonly administered 
by the subcutaneous route. However, the intravenous route, and rarely, the 
intramuscular route have also been used for the continuous administration of insulin 
when more rapid onset of action is required. Other routes of administration of insulin 
have also been investigated (Chien and Banga, 1989), such as intranasal and rectal 
administration. 
1.1.8 Pancreatic transplantation 
Transplantation of the whole pancreas, alone or in combination with a kidney 
transplant, may be necessary for those IDDM patients whose glycaemic control is 
poorly controlled by insulin therapy (Remuzzi et al., 1994; Stratta, 1996). However, a 
more advanced and promising development is the transplantation of pancreatic islets 
(Morris et al., 1989; Pyzdrowski et al., 1992). A recent study by Secchi et al. (1997) 
showed that islet transplantation has a 45% success rate in terms of insulin- 
independence or relevant reduction of exogenous insulin requirement, although 
success can be transient. 
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1.1.9 Oral hypoglycaemic agents (Table 1.2) 
Unlike patients with IDDM who require insulin for survival, all newly diagnosed 
NIDDM patients are treated with diet alone in the first instance. Drug treatment 
should be started only when glycaemic control is not achieved after about 3 months 
trial of dietary modification and increased physical activity. The four major classes of 
oral hypoglycaemic agents for NIDDM patients are the sulphonylureas, the 
biguanides, the thiazolidinediones and the a-glucosidase inhibitors. 
1.1.9(a) Sulphonylureas 
Sulphonylureas are generally used as first line supplement treatment in NIDDM when 
diet modification has not proved effective on its own. This group of drugs are 
sulphonamide derivatives; they all possess the sulphonylurea moiety, but different 
substitutions (Fig. 1.4) result in differences in pharmacokinetics and side effect 
profile. Sulphonylureas (Grodsky et al., 1977) act mainly by stimulating insulin 
secretion and consequently are effective only when some residual pancreatic ß-cell 
activity is present (about 30% of normal ß-cell function). The site of action of 
sulphonylureas is the ATP-sensitive potassium channel in the membrane of (3-cells 
(Sturgess et al., 1985). In addition, they inhibit hepatic glucose production and reduce 
peripheral resistance to insulin action (Gale, 1990). Several sulphonylureas are 
available but there is no evidence for any difference in their effectiveness. However, 
the duration of action of sulphonylureas is variable; drugs such as tolbutamide and 
gliclazide are relatively short-acting (approximately 8 and 12 hours respectively), 
while chlorpropamide has a prolonged action of 48 hours. 
Sulphonylureas are usually well tolerated. Hypoglycaemia is the most common side 
effect and its incidence is related to the potency and duration of action of the drug. 
Skin rashes, gastrointestinal disturbances and headache may also occur (Paice et al., 
1985). In addition, sulphonylureas stimulate appetite and thus cause weight gain 
which is the major concern in obese NIDDM patients. However, unlike other 
sulphonylureas, chlorpropamide has a wider range of side effects (facial flushing after 
alcohol intake, enhanced antidiuretic hormone and very rarely hyponatraemia) and is 
now less widely prescribed. 
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The main selection factors for a particular sulphonylurea include the age of the patient 
(the long-acting drugs such as chlorpropamide and glibenclamide should be avoided 
in elderly patients who are particularly prone to the danger of hypoglycaemia) and 
renal function (the short-acting tolbutamide may be used in renal impairment, as well 
as gliquidone and gliclazide which are metabolised in the liver). 
Many compounds have been reported to interact with sulphonylureas (Martindale, 
1996). Drugs that increase the hypoglycaemic effect of sulphonylureas include non- 
steroidal anti-inflammatory agents, monoamine oxidase inhibitors, some 
antibacterials, antifungals and some uricosuric drugs. The interaction is due to 
competition for metabolising enzymes, and interference with plasma protein binding 
since all sulphonylureas bind strongly to plasma albumin. Some compounds such as 
rifampicin, thiazide diuretics, and corticosteroids diminish the hypoglycaemic effect 
of sulphonylureas. ' 
1.1.9(b) Biguanides 
Metformin (Fig. 1.5), the only biguanide available in the UK, is used in the treatment 
of NIDDM when strict dieting and sulphonylurea treatment have failed to control 
diabetes. Metformin can also be used as initial therapy, especially in obese NIDDM 
patients since it is not associated with weight gain. It can be used alone or in 
combination with the sulphonylureas. 
Metformin (Perriello, 1995; Bailey and Turner, 1996) has a different mode of action 
from the sulphonylureas. It exerts its effect mainly by inhibiting hepatic 
gluconeogenesis and by increasing peripheral utilisation of glucose. Metformin 
therapy also improves insulin sensitivity; since it only acts in the presence of 
endogenous insulin, it is only effective in diabetic patients with some residual functioning 
pancreatic islet cells. It may also act by delaying glucose absorption from the 
gastrointestinal tract, although overall absorption of a glucose load is not reduced. In 
addition, metformin decreases fatty-acid oxidation, this results in a reduction in 
plasma glucose concentration by means of the glucose-fatty-acid cycle. 
Metformin is absorbed from the gastrointestinal tract, mainly from the small intestine. 
It has a plasma half-life of about 3 hours and is excreted unchanged in the urine. 
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Unlike sulphonylureas, metformin is not bound to plasma proteins and thus results in 
fewer drug interactions. The main drug interaction is with cimetidine (ulcer-healing 
drug) which inhibits renal tubular secretion of metformin and thus increases plasma 
metformin concentrations (Somogyi et al., 1987). Intestinal absorption of vitamin B12 
and folic acid may be impaired during long-term treatment (Bailey, 1992). 
Metformin has the advantages of low incidence of weight gain and lower plasma 
insulin levels. It does not induce hypoglycaemia in normal subjects. Lactic acidosis is 
a rare but serious adverse effect in metformin-treated patients; it occurs almost 
exclusively in patients with renal impairment in whom the use of metformin is contra- 
indicated. Other side effects include anorexia, nausea, vomiting and diarrhoea. 
Patients may experience a metallic taste and there may be weight loss. 
1.1.9(c) Thiazolidinediones 
Thiazolidinediones belong to a new class of oral hypoglycaemic agents. They are 
potent and specific activators of peroxisome proliferator-activated receptor y (PPAR y), a 
member of the ligand activated nuclear receptor subfamily. 'There is a striking correlation 
between the clinical activity of the various thiazolidinediones and their ability to 
activate PPAR y (Grossman and Lessem, 1997). PPAR y is expressed more 
specifically in adipose tissue and is implicated in adipogenesis. In cell culture models, 
thiazolidinediones act as potent adipogenic agents reflecting their ability to activate 
PPAR y (Wilson et al., 1996). These observations led to the suggestion that the anti- 
diabetic actions of thiazolidinediones result from their ability to alter adipocyte 
differentiation and/or metabolism resulting in lower serum lipid levels and to possibly 
decrease the secretion of humoral factors from adipocytes, such as TNF-a, which 
would result in the improvement of insulin sensitivity (Grossman and Lessem, 1997). 
Troglitazone (Fig. 1.6) is the first thiazolidinedione which was very recently launched 
in UK as a new treatment for diabetes (Anonymous, 1997a). It was indicated for the 
treatment of NIDDM, either as monotherapy in patients inadequately controlled by 
diet, or in combination with sulphonylureas or insulin to improve glycaemic control. 
In clinical studies, troglitazone has been shown to decrease insulin resistance 
(enhances insulin action), reduce hyperinsulinaemia, reduce hepatic glucose 
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production and improve both fasting and postprandial glycaemia in NIDDM patients 
(Iwamoto et al., 1991; Suter et al., 1992; Nolan et al., 1994). It is hoped that 
troglitazone will reduce both microvascular complications of NIDDM (e. g. 
retinopathy and nephropathy) by its effects on glucose control, and macrovascular 
complications (e. g. myocardial infarction and stroke) by its effects on insulin and 
lipid levels, though the long term effect on reduction of complications is yet to be 
investigated. 
Troglitazone monotherapy does not induce hypoglycaemia. However, it may 
potentiate the hypoglycaemic effects of insulin and sulphonylureas and a reduction in 
dosage of one agent may be necessary. Reported side effects include diarrhoea, 
nausea, vomiting, headache, malaise and musculoskeletal pain. It is contraindicated in 
patients with severe hepatic impairment since 40 cases of serious hepatic dysfunction 
(severe hepatocellular damage, hepatic necrosis and hepatic failure) occurring during 
treatment with troglitazone have been reported worldwide since its introduction 
(Anonymous, 1997b). At present, no clear risk factors for the development of hepatic 
reactions have been identified which might allow the drug to be used safely in some 
patients. Since the risks of troglitazone therapy outweigh the potential benefits, 
troglitazone had been withdrawn in the UK from December 1997 (Anonymous, 
1997c), though it remains available in Japan and in the United States. 
Despite the serious hepatic adverse effects associated with troglitazone, the 
thiazolidinedione class of anti-hyperglycaemic agents may still be the most significant 
advance in the treatment of NIDDM since the advent of the sulphonylureas and 
biguanides in the 1950s. Other thiazolidinediones which are currently under clinical 
development include pioglitazone and BRL 49653 (Turner, 1996): The fact that 
whether the hepatic problems are a class effect remains to be answered. 
1.1.9(d) Aipha-glucosidase inhibitors 
In recent years, the alpha-glucosidase inhibitor acarbose has also been used in the 
treatment of diabetes. Acarbose, produced by fermentation of strains of Actinoplanes, 
is a pseudotetrasaccharide in which one maltose residue is replaced by a 
pseudomaltose residue, which is essential for the inhibitory effect of the compound 
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(Fig. 1.7). Acarbose acts in the intestine by inhibiting intestinal a-glucosidases 
located within the upper intestinal brush border. This results in delaying the digestion 
of carbohydrates and postponing the absorption of glucose from disaccharides, 
oligosaccharides and polysaccharides in the small intestine (Caspary and Graf, 1979), 
and hence reduces postprandial rises of blood glucose and smoothes out the 24-hour 
blood glucose profiles. Acarbose, given alone or combined with other oral 
hypoglycaemic agents, is an effective treatment for NIDDM (Chiasson et al., 1994); it 
can also be used to supplement insulin therapy in IDDM which improves glycaemic 
control and decreases insulin requirement. 
Following oral administration of acarbose, less than 2% is absorbed in its active form; 
the majority of active unchanged drug remains in the lumen of the gut to exert its 
pharmacological activity. It is metabolised by intestinal enzymes and by the microbial 
flora and is excreted in the urine and faeces. 
Acarbose may cause gastrointestinal disturbances, including flatulence due to 
bacterial action on non-absorbed carbohydrate in the colon. Bowel sounds, abdominal 
distension, diarrhoea and pain may also occur. Acarbose may potentiate the effects of 
other hypoglycaemic drugs and insulin, thus reduction in their dosage may be 
required. 
Other a-glucosidase inhibitors such as Emiglitate and Miglitol, which have similar 
actions as acarbose, are still under investigation for their use in the management of 
diabetes mellitus (Martindale, 1996). 
1.1.9(e) Other agents used in the treatment of diabetes or its 
complications 
Guar gum is used as an adjunct to treatment with diet, insulin, or other oral 
hypoglycaemics in the management of diabetes mellitus. Guar gum is obtained from 
the ground endosperms of the seeds of Cyamopsis tetragonoloba (Leguminosae) and 
is a high molecular weight hydrocolloidal polysaccharide composed of galactan and 
mannan units connected by glycosidic linkages. 
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Guar gum reduces postprandial and fasting plasma glucose concentrations as well as 
plasma insulin concentrations in diabetic patients (Blackburn et al., 1984; Hockaday, 
1990). The possible modes of action include delayed gastric emptying, decreased 
small bowel motility, decreased glucose absorption as a result of increased viscosity 
of the contents of the gastrointestinal tract, and inhibition of gastrointestinal 
hormones. 
Like acarbose, guar gum can cause gastrointestinal disturbance with flatulence, 
abdominal distension, diarrhoea and nausea. Its use is contraindicated in patients with 
gastrointestinal obstruction. Guar gum may also affect the absorption of other drugs 
such as phenoxymethylpenicillin. 
Aldose reductase inhibitors such as Epalrestat and Tolrestat inhibit the enzyme 
aldose reductase which catalyses the conversion of glucose to sorbitol. It has been 
found that accumulation of sorbitol in certain cells only occurs in hyperglycaemic 
conditions and results in a hyperosmotic effect, which may be involved in the 
pathogenesis of some diabetic complications. However, aldose reductase inhibitors 
have no influence on plasma glucose concentrations. Both Tolrestat and Epalrestat are 
used in the treatment of diabetic neuropathy (Masson and Boulton, 1990). The use of 
aldose reductase inhibitors in the treatment of other diabetic complications such as 
diabetic retinopathy and nephropathy is still under investigation. 
1.1.9(f) Potential new anti-diabetic agents 
Glucagon-like peptide 1 (GLP-1), a 37 amino acid peptide, is a gastrointestinal 
hormone capable of enhancing glucose-stimulated insulin release by ß-cells (Hauck et 
al., 1993) and decreasing blood glucose in NIDDM patients (Amiel, 1994). Because 
of the glucose-dependent effect, it is associated with a low risk of hypoglycaemia. 
However, its ability to inhibit gastric emptying leads to gastrointestinal discomfort. 
Repaglinide is a new non-sulphonylurea, insulin-stimulating drug. It appears to 
stimulate postprandial insulin response and its blood glucose-lowering effect seems to 
be similar to that of the sulphonylureas (Wolfenbuttel et al., 1993; Balfour and 
Faulds, 1998). It stimulates insulin secretion by blocking the ATP-dependent 
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potassium channel. Other non-sulphonylurea secretogogues include A4166, NN623 
and KAD-1229 (Ohnota et al., 1995; Kikuchi, 1996). 
Mecasermin (insulin-like growth factor I) has been shown to improve metabolic 
control in patients with extreme insulin resistance and improve glucose tolerance and 
decrease hyperinsulinaemia in NIDDM patients. (Kolaczynski and Caro, 1994). 
Midaglizole is under investigation as a hypoglycaemic agent. It is believed to 
stimulate insulin secretion by antagonism of a2-adrenoceptors (Kawazu et al., 1987). 
Other approaches under investigation include inhibition of fatty acid oxidation or the 
use of (33-adrenoceptor agonists (Turner, 1996). The potent anti-obesity and anti- 
diabetic properties of agonists at ß3-adrenoceptors in rodents has led to interest in 
their potential as agents for the treatment of obesity and diabetes (Arch and Kaumann, 
1993; Blin et al., 1993). In animal studies (Largis et al., 1994), 03-agonists elicited a 
reduction in weight gain in obese rodents without a concomitant decrease in food 
intake, suggesting that it was a consequence of increased thermogenesis. Thus chronic 
treatment of obese animals with ß3-agonists causes a sustained increase in metabolic 
rate, body temperature and 24h energy expenditure. The reduction in body weight is 
due to a reduction in body lipid content, consistent with the potent lipolytic activity of 
ß3-agonists. ß3-Agonists also improve glycaemic control and insulin sensitivity in 
NIDDM animals. FR149175, a p3-agonist was shown to improve hyperinsulinaemia 
and glucose tolerance in NIDDM obese rats (Yamamoto et al., 1997). (33-agonists are 
thought to interact with elements of the insulin signal transduction cascade in order to 
improve the sensitivity of target tissues to insulin (Rochet et al., 1988; Le Marchand- 
Brustel et al., 1990). However, their efficacy in man is doubtful due to species- 
specific differences between rodent and human receptors (Strosberg, 1997). Thus the 
effect of (33-agonists in man requires further investigations. 
Patients with NIDDM who cannot be controlled adequately by oral therapy and diet 
need to be given insulin either in addition to the existing treatment or in place of the 
oral therapy. 
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1.1.10 Use of plants in the treatment of diabetes 
Apart from the conventional drug therapy, it is important to mention that some plants 
have also been used as traditional remedy for the treatment of diabetes. Before the 
advent of insulin and oral hypoglycaemic drugs, plant medicines represented the 
predominant treatment for diabetes mellitus. Due to the inability of current anti- 
diabetic therapies to control all of the pathological aspects of diabetes, as well as the 
high cost and poor availability of current drug treatments for many rural populations, 
especially in developing countries, alternative drugs are clearly needed. Since people 
in rural areas of developing countries have long been and still are relying on 
traditional medicines for their primary health care, a scientific investigation of 
traditional herbal remedies for diabetes may provide valuable leads for the 
development of new anti-diabetic drugs. Such studies may lead to validation of these 
remedies and provide the basis for the development of standardised therapies for use 
in poorer countries. In fact, metformin (one of the most prescribed oral glucose- 
lowering drug) is derived from a medicinal plant, Galega officinalis, historically used 
to treat diabetes (Bailey and Day, 1989). More than 400 different plants with possible 
glucose-lowering actions are known and some of them will be discussed in detail in 
the following sections. 
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1.2 Anti-diabetic plants and their active constituents 
In recent years, there has been a renewed interest in plant-derived pharmaceuticals in 
the Western world. This is demonstrated not only by the increasing number of active 
research programmes into natural products conducted by major pharmaceutical 
companies worldwide, but also the general public who are increasingly using plant 
extracts or herbal medicine as opposed to conventional medicines in self medication. 
In fact, the trade in herbal remedies in the European Union in 1990 was valued at 
over $1000 million and rising at 13% per year (McAlpine, 1992). 
Plants are undoubtedly a potential source for new drugs or lead compounds for drug 
development (Farnsworth, 1994). In the past, many important drugs have been 
derived from natural sources and still remain the drugs of choice for particular 
medical conditions. Examples are the vinca alkaloids, vinblastine and vincristine, of 
Catharanthus roseus (Apocynaceae) used in cancer chemotherapy, the cardiac 
glycoside digoxin from Digitalis lanata (Scrophulariaceae), the analgesics morphine 
and codeine obtained from the Opium poppy Papaver somniferum (Papaveraceae), 
and more recently, the diterpene taxol from the Pacific yew Taxus brevifolia 
(Taxaceae) used for treating ovarian and breast cancer. 
As with other therapeutic areas, many plants have been used for the treatment of 
diabetes mellitus in traditional systems of medicine throughout the world. A number 
of review articles have been published on the traditional use of plants in diabetes 
(Bailey and Day, 1989; Swanston-Flatt et al., 1991) and on plants and 
phytochemicals whose reputed hypoglycaemic effects have been scientifically 
investigated (Perl, 1988; Handa et al., 1989; Day, 1990; Perez G. et al., 1998). The 
most extensive review is by Maries and Farnsworth (1995) who evaluated available 
data on more than 1200 species of plants reported either to have been used to treat 
diabetes and/or to have been investigated for anti-diabetic activity. The review 
indicated that more than 80% of those traditional plant remedies studied 
pharmacologically were demonstrated to have hypoglycaemic activity, resulting from 
a great variety of mechanisms of action. The aim of this section is to look at some 
plants which have been used traditionally for the treatment of diabetes mellitus and to 
present some natural compounds which possess anti-diabetic activity. These may 
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have the potential to act as lead compounds for the development of new anti-diabetic 
treatments. 
In this context, the discovery process (Oubre et al., 1997) that led to the use of 
metformin cannot be omitted. Galega officinalis L. (Fabaceae), also known as goat's 
rue or French lilac, was used as a treatment for diabetes in medieval Europe (Bailey 
and Day, 1989). Guanidine, the main component in Galega officinalis, was shown to 
produce hypoglycaemia in parathyroidectomized test animals by parenteral 
administration. Since this compound was too toxic for clinical use, alkyl diguanides 
were synthesized from it in the 1920s. Biguanidines (e. g. metformin and 
phenformin), a third generation of guanidine derivatives, were introduced in 1957 as 
a new class of anti-diabetic agents. To date, metformin remains an efficacious drug 
approved for treatment of NIDDM derived from a medicinal plant historically used to 
treat diabetes (Section 1.1.9(b)). 
A number of mechanisms by which phytochemicals may exert their hypoglycaemic 
activity have been described by Perl (1988). Thus herbal remedies for diabetes can be 
classified into different categories according to their mode of action as follows: 
1.2.1 Inhibition of glucose absorption from the gastrointestinal tract 
Cyamopsis tetragonolobus Taub. (Fabaceae). Guar gum (Section 1.1.9(e)) is a 
purified form of dietary fibre extracted from the seeds of Indian cluster bean C. 
tetragonolobus. It contains not less than 66% of high molecular weight 
hydrocolloidal polysaccharide galactomannan, which is known to reduce post- 
prandial hyperglycaemia (Blackburn et al., 1984; Day, 1990). Guar gum inhibits 
intestinal absorption of glucose by slowing gastric emptying and by thickening the 
unstirred water layer adjacent to the intestinal villi which acts as a barrier to diffusion 
(Hakim et al., 1995). Other traditional remedies which may work in this way include 
acacia gum (Acacia senegal Wild. ) and some other species of Acacia of the 
Fabaceae family (Maries and Farnsworth, 1995). 
Castanospermum australe A. Cunn. (Fabaceae). Castanospermine (Fig. 1.8), an 
indolizidine alkaloid isolated from C. australe, is an intestinal enzyme (a- 
glucosidase) inhibitor with hypoglycaemic activity. It blocks the hyperglycaemic 
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Figure 1.8: Hypoglycaemic intestinal enzyme inhibitors from plants 
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response to oral doses of sucrose through inhibition of disaccharidase, but does not 
improve oral glucose tolerance. (Rhinehart et al., 1987). 
Morus alba L. (Moraceae). Moranoline (Fig. 1.8), isolated from mulberry root bark 
is a potent intestinal a-glucosidase inhibitor (Yoshikuni, 1988). Miglitol (Fig. 1.8), a 
semi-synthetic derivative of moranoline, is also an a-glucosidase inhibitor which, 
unlike acarbose (Section 1.1.9(d)), is well absorbed from the gut. 
Phlorizin/phloridzin (Fig. 1.9), a phenolic glycoside present in plants of the Rosaceae 
family, especially species of the genus Malus, is a Na+-dependent sugar transport 
inhibitor (Schultz and Curran, 1970) which prevents glucose absorption from the gut 
and inhibits glucose reabsorption by the kidneys. 
1.2.2 Modification of insulin levels 
Pterocarpus marsupium Roxb. (Papilionaceae). The flavonoid, epicatechin (Fig. 
1.10), which is the active principle isolated from the heartwood of P. marsupium, has 
been shown to cause an ATP-dependent enhancement of glucose-stimulated insulin 
secretion from isolated pancreatic islets in vitro, and to cause a rise in islet insulin 
content in vivo in rats (Maries and Farnsworth, 1995). 
Allium cepa L. and A. sativum L. (Liliaceae). The hypoglycaemic principles of 
onion (A. cepa) and garlic (A. sativum) are the sulphur-containing compounds, allyl 
propyl disulphide and diallyl disulphide oxide, allicin (Fig. 1.11). Instead of direct 
stimulation of insulin release, these compounds are believed to act by competing with 
insulin, which has a disulphide linkage, for endogenous sulphydryl-rich insulin- 
inactivating compounds (Augusti et al., 1974; Maries and Farnsworth, 1995). 
Other anti-diabetic plants which may act on insulin secretion include Aloe 
arborescens Mill. (Liliaceae), Bridelia ferruginea Benth. (Euphorbiaceae), 
Clerodendron phlomidis Linn. , (Verbenaceae), Ficus bengalensis Linn. 
(Moraceae) and Poterium ancisroides Desf. (Rosaceae) (Handset al., 1989; Hakim 
et al., 1995). 
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Figure 1.10: Epicatechin, isolated from Pterocarpus marsupium 
CH2=CH-CH2-S-S-CH2CH2CH3 
Allyl propyl disulphide 
CH2=CH-CH2-S (-->O)-S-CH2-CH=CH2 
Diallyl disulphide oxide 
Figure 1.11: Hypoglycaemic sulphur-containing compounds 
present in Allium species 
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1.2.3 Increased glucose utilisation 
Blighia sapida Koen. (Sapindaceae). Two potent hypoglycaemic agents have been 
isolated from the unripe fruits of the Jamaican akee tree, B. sapida. They are 
cyclopropanoid amino acids known as hypoglycin A and its y-L-glutamyl dipeptide, 
hypoglycin B (Fig. 1.12). They act by inhibiting (3-oxidase enzymes, thus blocking 
the pathway of oxidation of long-chain fatty acids. Since fatty acids are no longer 
available as energy source, hepatic glycolysis is stimulated to provide an alternate 
energy source, and the enhanced glucose utilisation results in a fall in blood glucose 
levels. However, these hypoglycins are too toxic to be used therapeutically (Handa et 
al., 1989; Maries and Farnsworth, 1995). 
Galega officinalis L. (Fabaceae). Seeds of the traditional anti-diabetic plant, G. 
officinalis, contain a high concentration of galegine (isoamylene guanidine, Fig. 
1.13). Galegine blocks succinic dehydrogenase, thereby inhibiting the Kreb's cycle 
and increasing glucose utilisation by anaerobic respiration which leads to 
hypoglycaemia (Perl, 1988). 
1.2.4 Other plants with hypoglycaemic activity due to various modes of 
action 
Many of the plants discussed above are reported to contain a single hypoglycaemic 
component which appears to exert the hypoglycaemic activities via a particular mode 
of action. However, some anti-diabetic plants have been shown to contain more than 
one active constituent which may act via different mechanisms of action: 
Gymnema sylvestre R. Br. (Asclepiadaceae). Gymnema sylvestre, also known as 
"gurmar" due to its property of temporarily abolishing the appreciation of sweet taste 
by the tongue after chewing the leaves, is a traditional Ayurvedic remedy for the 
treatment of diabetes. G. sylvestre leaf extract was shown to increase plasma insulin 
concentrations and raise levels of insulin-sensitive enzymes such as hexokinase in 
diabetic animal models (Shanmugasundaram et al., 1983). An ethanolic extract of G. 
sylvestre containing gymnemic acids and named "GS4" was found to decrease fasting 
plasma glucose levels and increase plasma insulin levels in NIDDM patients 
(Baskaran et al., 1990); and decrease insulin requirements in IDDM patients 
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Figure 1.12: Inhibitors of fatty acid oxidation isolated from B. sapida 
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Figure 1.14: Conduritol A, isolated from Gymnema sylvestre 
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(Shanmugasundaram et al., 1990). 
A compound chemically unrelated to gymnemic acids, conduritol A (Fig. 1.14), 
isolated from G. sylvestre was also shown to modulate insulin secretion from isolated 
pancreatic islets (Billington et al., 1994). On the other hand, both conduritol A and 
the triterpenoid glycosides, gymnemic acids (also present in G. sylvestre) have been 
reported to inhibit intestinal glucose absorption (Yoshioka, 1986; Miyatake et al., 
1993). Thus the plant G. sylvestre may exhibit its hypoglycaemic effect by 
stimulating insulin secretion as well as inhibiting intestinal glucose absorption. 
Trigonella foenum-graecum Linn. (Papilionaceae). Fenugreek (T. foenum- 
graecum) seeds have long been used as a herbal remedy for the treatment of diabetes. 
The seeds are known to contain a number of hypoglycaemic principles. Early reports 
suggested that the hypoglycaemic effect of fenugreek was attributed to its major 
alkaloid, trigonelline (Fig. 1.15), the N-methyl derivative and main human metabolite 
of the vitamin nicotinic acid (Mishkinsky et al., 1967). However, administration of 
trigonelline (at a dose equivalent to that present in fenugreek) to diabetic patients did 
not show any significant hypoglycaemic activity (National Institute of Nutrition, 
1987). Hillaire-Buys et al. (1993) reported the presence of an insulin-stimulating 
substance in the seeds of fenugreek, identified as 4-hydroxyisoleucine (Fig. 1.15). 
Other proposed hypoglycaemic constituents of fenugreek are coumarin (Fig. 1.15), 
which was shown to have significant hypoglycaemic effect in normal and alloxan- 
induced diabetic rats (Shani et al., 1974) and scopoletin (Fig. 1.15), another coumarin 
constituent of fenugreek, which exerted borderline hypoglycaemic effects in normal 
and alloxan-induced diabetic rats at high doses (Shani et al., 1974). Ghosal et al. 
(1974) reported that a steroidal sapogenin-peptide ester, fenugreekine (Fig. 1.15) also 
possessed hypoglycaemic effect. In addition, Ali et al. (1995) showed that the soluble 
dietary fibre fraction of fenugreek seed (containing galactomannan as the major 
constituent) had a significant anti-hyperglycaemic effect but not hypoglycaemic 
effect in NIDDM model rats, suggesting an action at the intestinal level. 
52 















Chapter 1: Introduction 
1.2.5 Models for screening anti-diabetic plants 
Ideally, large scale clinical trials should be employed to investigate the efficacy of 
traditional herbal remedies for the treatment of diabetes. However, this is generally 
not feasible due to financial, ethical and practical reasons. Instead, various in vivo 
and in vitro techniques are used for this purpose, as discussed below. 
In vivo techniques for the study of hypoglycaemic activity employ animals with 
induced hyperglycaemia, either chemically induced i. e. treated with drugs such as 
streptozotocin or alloxan, or genetically bred (Fischer, 1985; Shafrir, 1990). In fact, 
many of the studies on anti-diabetic plants involve the use of animal models. In vivo 
bioassays are undoubtedly essential to prove the value of new hypoglycaemic 
components from plants. However, whole animal tests reveal relatively little about 
the mode of action of the extracts/compounds studied, and it can be seen from 
previous sections (Section 1.2.1-1.2.4) that there are many mechanisms by which 
blood glucose levels may be reduced. Furthermore, the use of in vivo bioassay-guided 
fractionation for isolating active constituents from plants is restricted by the cost of 
obtaining and maintaining animals, social and ethical issues on extensive use of 
animals in experimentation, and the requirement of practical training for good 
technical skills. 
Thus a number of in vitro models have been developed to elucidate the varied 
mechanisms of action of hypoglycaemic agents: 
Q Inhibition of intestinal glucose uptake. Studies on glucose uptake into intestinal 
brush border membrane vesicles (Kessler et al., 1978), Caco-2 cells (Neef et al., 
1996) or everted gut (Perl and Hikino, 1989) to detect compounds that can inhibit 
intestinal glucose absorption. 
Q Stimulation of insulin release. Isolated pancreatic islets (Jones et al., 1993) and 
insulin-secreting cell lines e. g. HIT-T15 cells (Poitout et al., 1996) are used to 
detect compounds with insulin secretagogue activity. 
Q Insulinomimetic or insulin sensitising effects. Isolated hepatocytes (Quentmeier 
et al., 1993) and hepatoma cell lines e. g. H4IIE (Valera and Bosch, 1994) are 
employed for detecting compounds with insulinomimetic effects on the liver. 
Other insulin target tissues such as skeletal muscles and adipocytes are also used 
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(Welihinda and Karunanayake, 1986). The same tissues may also be used to detect 
compounds with insulin sensitising effects. 
In vitro assays have the advantage of utilising a smaller number of animals (as a 
source of tissues or cells) and are particularly useful when screening large numbers of 
plant extracts and chromatographic fractions. However, a wide range of assays are 
required for the screening of plants for anti-diabetic activity and to elucidate the 
mode of action of the isolated phytochemicals because each assay is specific for a 
particular mechanism of action. In addition, caution must be taken when assessing in 
vitro results since compounds in plant extracts showing in vitro activity may not 
always be bioavailable in vivo. For instance, some compounds such as 
proteins/peptides may possess an effect in vitro but if administered orally in in vivo 
models, they may have been hydrolysed in the gastrointestinal tract before reaching 
the site of action. On the other hand, some precursor compounds which require 
certain metabolic activation processes in vivo would have failed to produce effect in 
in vitro models. Furthermore, the in vitro behaviour of test tissues may also differ 
from the in vivo situation. Thus any compounds/extracts which show activity in vitro 
must have their activities confirmed using appropriate in vivo models. 
1.2.6 Anti-diabetic plant research 
Many plants have been used as traditional herbal remedies for the treatment of 
diabetes. Among all these plants, selecting one which has high priority for extensive 
research study on its anti-diabetic activity is not an easy decision. However, Maries 
and Farnsworth (1995) have suggested several general criteria for choosing an 
appropriate candidate: 
The plant should - 
a) be traditionally used as an anti-diabetic remedy in one or more countries 
b) possess experimentally determined hypoglycaemic activity 
c) lack detailed information on hypoglycaemic constituents 
d) possess experimental evidence for low toxicity 
e) have botanical abundance 
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One plant which appears to fulfil all these criteria is Momordica charantia Linn., 
which forms the subject of the current thesis. This species, together with the plant 
family Cucurbitaceae to which it belongs, will be discussed in more detail in the 
following sections (Sections 1.3 and 1.4). 
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1.3 The Cucurbitaceae family 
Cucurbitaceae (Table 1.3), the single family within the order Cucurbitales, is a 
moderately large family of about 118 genera and 825 species (Jeffrey, 1990). All 
Cucurbitaceae are frost-sensitive and thus the family is confined to the warmer parts 
of the globe. The family is most abundantly found within the tropics, especially in 
tropical Africa and the neotropics (Jeffrey, 1980). Members of this family are mostly 
herbs climbing by tendrils, with abundant sap and very rapid growth. 
The family Cucurbitaceae is of great economic importance; many species of this 
family are widely cultivated for sources of vegetables and fruits (Table 1.4). For 
example, twelve genera and 18 species of cucurbits are currently under cultivation in 
China (Walters, 1989; Yang and Walters, 1992). It is interesting to note that the 
majority of cucurbit fruits sold as vegetables are immature, while the mature fruits of 
some species are grown for other uses such as for culinary and decorative purposes. 
One classic example is the species Lagenaria siceraria, the immature fruits are 
cultivated for consumption, while the mature fruits are commonly used as containers 
and musical instruments (Andres et al., 1996). 
1.3.1 The phytochemistry of the Cucurbitaceae 
Biochemically, the Cucurbitaceae are characterised by the presence of sterols, 
cucurbitacins and other triterpenoids in the vegetative parts and fruits, and by the 
occurrence in the seeds of free amino acids, seed oils and storage proteins (Jeffrey, 
1980). 
1.3.1(a) Sterols of the Cucurbitaceae 
Cucurbitaceae is a family of plants with a reputation for complex steroid chemistry. 
Studies by previous researchers (Akihisa et al., 1987a) have shown that the sterols 
found in members of the Cucurbitaceae possessed the following 7 types of skeletons 
(Fig. 1.16): 
1 saturated 5 A8(14) unsaturated 
2 O- unsaturated 6 14a-methyl-9ß, 19-cyclo skeleton 
3 i7- unsaturated 7 14a-methyl-09(11)- unsaturated 
4 A8- unsaturated 
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Table 1.4 The Cucurbitaceae family as a source of vegetables 
& fruit 
Family members Vegetables/Fruit 
Benincasa hispida 
Benincasa hispida var. chieh-qua 
Citrullus lanatus 




















squirting cucumber ` 
bottle gourd 
ridged loofah/silky gourd 
smooth loofah/water gourd 
bitter melon 
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Figure 1.16: Structures of sterols found in- the Cucurbitaceae 
All A22-double bonds are trans (E) configuration. 
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24-ethyl-z22 22-substituted (g) 
24-ethylidene-substituted (i) 
24-ethyl-A22 25_substituted (k) 
24,24-dimethyl-substituted (m) 







24,24-dimethyl-z 22-substituted (n) 
The great majority of higher plants contain predominantly sterols bearing a A5-bond 
with a 24a-alkyl substituted side chain (24R if a saturated or A25-unsaturated side 
chain, 24S if the A22 derivative) represented by sitosterol (24a-2f). However, plants 
of the family Cucurbitaceae contain mainly 24-alkyl-A7-sterols, such as 24- 
ethylcholest-7-enol (3f), 24-ethylcholesta-7,22-dienol (3g), 24-ethylcholesta-7,25- 
dienol (3j) and 24-ethylcholesta-7,22,25-trienol (3k), which constitute the 
characteristic feature of the plants of this family (Akihisa et al., 1987a). Akihisa et al. 
(1987a) also reported that among the 12 genera of the Cucurbitaceae investigated, 44 
sterols were identified. The A7-sterols (3c-3k) were found to be the major sterols 
which were accompanied by small amounts of the sterols with saturated (1c, If, lg) 
and A5- (2a-2g, 2i-2k) and A8- (4g, 4j, 4k) skeletons. The 24-ethyl-A7 22- (3g), 
A7'25(27 (3j) and A7'22,25(27)- (3k) sterols constituted the predominant sterols for the 
seed materials, whereas the 24-ethyl-07- (3f) and 07,22- (3g) sterols were the major 
ones for the mature plant tissues which consisted of leaves and stems, pericarp of the 
fruit and roots (Akihisa et al., 1986a, b). In addition, several new or uncommon 
sterols were found as minor constituents, for example, 24-methylene-25- 
methylcholest-7-enol (31) in Sicyos angulatus L. (Akihisa et al., 1987b); 24,24- 
dimethylcholest-7-enol (3m), 24,24-dimethylcholesta-7,22-dienol (3n) and 24,24- 
dimethylcholesta-7,25-dienol (3o) in Gynostemma pentaphyllum Makino (Akihisa et 
al., 1986c); 24a-ethylcholesta-8(14), 22-dienol (24(x-5g) (Akihisa et al., 1986a) and 
24-methylenepollinastanol (6e) and 14a-methyl-24a-ethylcholest-9(11)-enol (24a- 
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7f) (Akihisa et al., 1986d) in Cucumis sativus L. 
An extensive investigation on the configurations at C-24 of the 24-alkylsterols 
showed that the 24-methyl- and 24-ethylsterols lacking a A25- bond (i. e. 24-methyl-, 
24-methyl-A22-, 24-ethyl- and 24-ethyl-A22-sterols) occurred as the C-24 epimeric 
mixtures, or as a single diastereoisomer, either 24a- and 243-epimer. On the other 
hand, the 24-ethylsterols bearing a 025-bond (i. e. 24-ethyl-A25- and 24-ethyl-A22,25- 
sterols) were composed of 24ß-epimers only (Akihisa et al., 1987a). 
1.3.1(b) Triterpene alcohols of Cucurbitaceae 
Among the 13 genera of the family Cucurbitaceae examined by Akihisa et al. (1988), 
14 tetracyclic and pentacyclic triterpene alcohols were identified. Isomultiflorenol 
(Fig. 1.17) was found to be the major component in the seeds, which suggested that it 
may be a taxonomical marker of the seeds of Cucurbitaceae since only a few higher 
plants are known to contain this triterpene. The mature plant materials (aerial parts, 
pericarp of the fruits, and roots) of the Cucurbitaceae were shown to contain either 
one or more of the common triterpene alcohols such as a- and ß-amyrins, 
cycloartenol and 24-methylenecycloartanol as the major triterpene constituents (Fig. 
1.17). 
1.3.1(c) Cucurbitacins 
Cucurbitacins are predominantly found in the Cucurbitaceae family but are also 
present in several other plant families such as Begoniaceae, Cruciferae, 
Desfontainiaceae, Elaeocarpaceae and Scrophulariaceae (Mirö, 1995). 
Cucurbitacins are a group of bitter tasting, highly oxygenated, mainly tetracyclic, 
triterpenes (possessing 30 carbons), derived from the cucurbitane skeleton (19- 
(10-99f )-abeo-10u-lanost-5-en] as shown in Fig. 1.18. The C4 carries a gem- 
dimethyl group and the C24 an isopropyl group, while other methyls are present on 
C9, C13, C14 and C20. All of the cucurbitacins have an unsaturated C5 position. 
Cucurbitacins cannot be considered as steroidal since the methyl group has moved 
from C10 to C9. 
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Figure 1.17: Structures of some triterpene alcohols found in Cucurbitaceae 
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Figure 1.18: General structure of cucurbitacins 
The most common substituents are as follows: 
Cl: Sometimes unsaturated (e. g. cucurbitacins E, I, J, K and L) 
C2: Usually hydroxylated except in iso forms and in cucurbitacin C which 
has no substituents. 
C3: Hydroxylic or ketonic 
C9: Usually methylated except in cucurbitacins A and C where it is 
hydroxymethylated 
C11: Ketonic except in 11-deoxo-cucurbitacin I 
C16: Hydroxylic ((x) 
C20: Hydroxylic ((3) 
C22: Ketonic except in 22-deoxo and 22-deoxo-isocucurbitacin D 
C23: Sometimes unsaturated (e. g. cucurbitacins A, B, C, D, E, F, I, 0 and 
Q) 
C24: Not usually substituted except for a hydroxyl group on cucurbitacins 
G, H, J and K. . 
C25: Can be hydroxylated or acetoxylated 
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Cucurbitacins are widely distributed in the plant, being found in highest 
concentration in the seeds and roots. Their intense bitterness means that they are 
effectively defensive against many herbivores. However, they are not always bitter 
tasting since sweet cucurbitane glycosides, e. g. Camosiflosides V and VI, have been 
isolated from the rhizomes of Hemsleya carnosiflora (Kasai et al., 1987). 
The cucurbitacins were all named after successive letters of the alphabet from A to R, 
and at a later stage, another two cucurbitacins S and T, isolated from Bryonia dioica 
(Hylands and Salama, 1976; Hylands and Mansour, 1982), which present a new 
heptagonal ring between carbons C16 and C24 were added. Cucurbitacins are usually 
present in the plant as ß-glucosides, which are hydrolysed by the enzyme elaterase to 
give the free genins. 
Cucurbitacins represent an important phytochemical group due to their various 
pharmacological effects and their possible clinical applications (Mira, 1995), as 
listed below. 
Cytotoxic and antitumour action 
Cucurbitacins B, D, E, I, J, K, L and tetrahydro-I isolated from Bryonia alba roots all 
revealed cytotoxic activity in cell cultures. The cytotoxic action mechanism seems to 
involve a blockage in the incorporation of thymidine by the nucleic acids. 
Hepatoprotective and hepatocurative activities 
Cucumis melo, containing cucurbitacins B and E, is a remedy in Chinese traditional 
medicine for hepatitis. Cucurbitacin B has been shown to be effective in chronic 
hepatitis by normalising hepatic protein levels, stimulating cellular immunity 
functions and increasing the plasma cAMP/cGMP ratio in experimental animals. 
Cucurbitacin E also increases the cAMP/cGMP ratio. 
Antimicrobial activity 
The cucurbitacin containing species, Momordica charantia, possesses antibacterial 
activity (Fatope et al., 1990). In particular, cucurbitacin C at a concentration of 
l Omg/mL inhibits growth of the fungus, Phytophtora cactorium. 
Anti-inflammatory activity 
Cucurbitacin B, isolated from the juice of Ecballium elaterium, was shown to exhibit 
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significant anti-inflammatory action. It may work by inhibiting eicosanoid synthesis 
which modifies the production of leukotriene B4. 
Other pharmacological effects of cucurbitacins include their strong purgative 
properties and antihelminthic activity. They can also play other biological roles such 
as plant growth regulators and insect feedants (Metcalf and Lampman, 1989) or 
antifeedants. 
1.3.1(d) Seeds of the Cucurbitaceae 
Apart from the presence of sterols and cucurbitacins, eight free amino acids have 
been identified in the seeds of Cucurbitaceae, as well as a large number of other 
ninhydrin-positive compounds, the major one is citrulline which has been found in all 
genera investigated (Dunhill and Fowden, 1965). The role of these free amino acids 
and ninhydrin-positive compounds is not known, however they may possibly 
function as chemical defence mechanisms. 
The nutritive value of the seeds stems from their high oil and protein contents. The 
seed oils of Cucurbitaceae fall into 2 groups: one with palmitic-oleic-linoleic acid 
composition, the other with conjugated triene acids - punicic acid and a-eleostearic 
acid (Jeffrey, 1980). Badifu (1991) reported that among the species of Cucurbitaceae 
examined, the main fatty acids found in the seed oils were palmitic, stearic, oleic and 
linoleic. The seed proteins of Cucurbitaceae are high in nutritive value, though they 
tend to be low in lysine and sulphur-containing amino acids. They are generally rich 
in methionine (Jeffrey, 1980). 
1.3.2 Cucurbitaceae and diabetes mellitus 
A recent article by Maries and Farnsworth (1995) revealed that 30 species (belonging 
to 11 genera) of plants within the Cucurbitaceae family have either been used 
ethnomedically to treat diabetes mellitus or have been tested for therapeutic activity 
against diabetes mellitus (Table 1.5). One such example is Momordica charantia L., 
which is the subject of our present study. In the following section, an extensive and 
up to date literature review on the anti-diabetic properties and known phytochemical 
constituents of Momordica charantia L. will be presented. 
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1.4 Anti-diabetic properties and phytochemistry of Momordica 
charantia Linn. (Cucurbitaceae) 
According to Engler's scheme, the systematic position of Momordica charantia in 









Species Momordica charantia Linnaeus 
The unripe fruit of Momordica charantia Linn. has been used in Ayurvedic (Indian) 
and Chinese medicine as well as in the West Indies for the treatment of diabetes. In 
fact, the unripe fruit and seeds of Momordica charantia L. have been the subject of 
over a hundred scientific articles describing their pharmacological or phytochemical 
properties (Raman and Lau, 1996). Thus this section aims to review the scientific 
investigations conducted so far on Momordica charantia with respect to its anti- 
diabetic use in traditional remedies and to explore the possibility of future work in 
this area which may lead to the development of new anti-diabetic agents. 
1.4.1 Habitat and traditional uses 
The native country of Momordica charantia is uncertain, but the plant is cultivated 
throughout the tropics, particularly in India, China, East Africa and Central and South 
America (Walters and Decker-Walters, 1988). It is occasionally grown as an 
ornamental creeper, but more commonly cultivated for use of the unripe fruit as a 
vegetable. This has led to the existence of a wide variety of cultivars. The fruit has a 
number of different local names, being well-known as karela (India), also named 
bitter gourd, bitter-melon, balsam-pear, cundeamor (South America), ku-gua (China), 
carilla or goo-fah (Jamaica); the reported spelling of the local names is often variable. 
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The wild variety (M. charantia var. abbreviata) grows as a weed in the West Indies, 
where the plant is known as cerasee (Jamaica) or sorossie (Dominican Republic). 
This variety has smaller fruit than the Indian one. The term karela is used throughout 
this section to denote all varieties of the fruit since in the majority of studies the type 
used has not been specified. 
In addition to its major use as an anti-diabetic agent, karela has been used in India 
and Sri Lanka as a tonic, emetic and laxative (Nadkarni 1982). Both the cultivated 
and wild forms are used for this purpose (Bailey et al., 1986). In South/Central 
America, cerasee fruit or tea is used for diabetes, colds and fevers, stomach aches, 
constipation in children and the induction of abortion (West et al., 1971; Arvigo and 
Balick, 1993). Traditional Chinese uses for the fruit, seeds, vines and leaves include 
gastroenteritis, diabetes, tumours and some viral infections (Zhang, 1992a). 
When used as an anti-diabetic remedy, karela juice prepared by crushing and 
straining the unripe fruit (ca. 50m1) is taken once or twice a day. Fried karela may 
also be consumed. Cerasee on the other hand, is taken as a decoction or "tea" (hot 
water extract) of the aerial parts of the plant, free of large fruit (Bailey et al., 1986). 
1.4.2 Studies in human subjects 
Karela fruit. To date, no large scale clinical trial has been reported on the anti- 
diabetic effects of karela, but a number of studies using small groups of diabetic 
patients have been conducted. Both non-insulin-dependent diabetes mellitus 
(NIDDM, Type II, maturity onset) and insulin-dependent (IDDM, Type I, juvenile 
onset) patients have participated. 
Kirti et al. (1982) have described some early studies (1950-1974) carried out in India 
and the Caribbean, in which karela's anti-diabetic activity was observed. More recent 
interest was aroused when Aslam and Stockley (1979) reported a case of a possible 
interaction, in the form of decreased glycosuria, between the anti-diabetic drug 
chlorpropamide and a curry containing karela, taken by an Asian NIDDM patient. 
Following this, Leatherdale et al. (1981) carried out a study in 9 Asian NIDDM 
outpatients living in the United Kingdom, who were being treated with diet alone or 
diet combined with oral hypoglycaemic agents. Acute administration of karela juice 
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with a glucose load resulted in a significant improvement in glucose tolerance 
without increasing the insulin levels in the blood. Daily consumption of fried karela 
for 8 to 11 weeks had a similar, though not statistically significant, effect. 
Nevertheless, there was a significant reduction in glycosylated haemoglobin, 
indicating an improved control of blood glucose levels over this period. 
Further evidence for a beneficial chronic effect is that an improvement in both 
glucose tolerance, and fasting blood glucose levels was observed in 8 NIDDM 
patients following 7 weeks of daily consumption of powdered karela fruit (Akhtar, 
1982). Srivastava et al. (1993) reported that 3-7 weeks treatment of diabetics with 
powdered fruit, led to a mean fall of 25% (range 11-48%) in post-prandial blood 
glucose levels. There was a marked fall in both blood and urine sugar over 7 weeks 
in a group treated with an aqueous extract of the fruit. Glycosylated haemoglobin 
showed a significant reduction by the end of the trial. 
By contrast, Kirti et al. (1982) reported that whilst karela (acute or chronic 
administration) resulted in a reduction in glycosuria, there was no effect on blood 
glucose. However, in their experiments, blood glucose levels were measured two 
hours after the administration of karela extract and by this time any effects of the fruit 
may have diminished. The earlier work of Leatherdale et al. (1981) suggested that 
improved glucose tolerance is most marked within the first 90 minutes of karela 
administration. Inter-patient variation may also explain a poor response to karela; 
Welihinda et al. (1986) reported that karela juice significantly improved glucose 
tolerance in only 13 of the 18 patients tested. 
P-insulin. In 1974, Khanna et al. isolated a polypeptide (polypeptide p, p-insulin or 
v-insulin; p= plant, v= vegetable) from karela. A significant hypoglycaemic effect 
was observed in 6 IDDM, 1 NIDDM and 2 asymptomatic diabetics administered p- 
insulin subcutaneously (Baldwa et al., 1977). In a later study by Khanna et al. (1981), 
subcutaneous p-insulin led to a significant fall in blood glucose in 11 IDDM patients, 
whereas a similar effect in 8 NIDDM patients did not reach statistical significance. P- 
insulin from karela therefore appears to have insulin-like effects. One IDDM patient 
was reported to have been maintained on p-insulin for 5 months with no complaints 
of side effects. 
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Karela seeds. As well as the fruit, the potential anti-diabetic effects of the seeds have 
been examined. Oral administration of powdered karela seeds produced a significant 
reduction in post-prandial blood sugar values in 14 NIDDM and 6 IDDM patients 
(Grover and Gupta, 1990). 
1.4.3 In vivo studies in laboratory animals 
There have been numerous studies on karela in laboratory animals in vivo. Studies 
using laboratory animals have included normal animals of various species, and those 
in which diabetes mellitus has been induced by administration of alloxan or 
streptozotocin (STZ). These two drugs are known to selectively damage insulin- 
secreting beta cells of the pancreas, resulting in partial or virtual loss of insulin 
production, and their effects are irreversible (Fischer, 1985). On the other hand, the 
antihistaminic drug cyproheptadine which produces a reversible loss of pancreatic 
insulin when given in repeated doses (Fischer, 1985), is also used to induce diabetes 
in laboratory animals. No reports of the action of karela on genetically diabetic 
animals have been found to date. 
Karela juice or extracts. The three main animal species in which the effects of 
karela juice or karela solvent extracts have been investigated are the rabbit, rat and 
mouse. 
Rabbit model. One of the earliest reports of karela's activity was by Sharma et al. 
(1960) who reported that the juice caused an improvement in glucose tolerance in 
alloxan diabetic but not normal animals. Somewhat in contrast to this, Akhtar et al. 
(1981) found that dried karela fruit caused a significant dose dependent decrease in 
blood glucose and that a higher minimum dose was required for alloxan-treated 
rabbits than normal ones. The effectiveness in alloxan diabetic animals suggests that 
extra-pancreatic effects are involved; and since a higher minimum dose of karela was 
required to elicit a response in these animals, pancreatic stimulation may play some 
part in the effects of the fruit. However, Kulkarni and Gaitonde (1962) saw no 
reduction in fasting glucose levels on either acute or chronic administration of dried 
karela juice to normal rabbits. These conflicting results may be due to variations in 
blood sampling times and dosages of both karela and alloxan. 
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A number of solvent extracts of karela have -also been tested. Intravenous 
administration of a chloroform soluble extract of the juice resulted in a marked 
hypoglycaemic effect in alloxan-treated but not normal rabbits (Tiangda et al., 1987). 
This may be an indication of greater pancreatic ß-cell sensitivity to karela in alloxan- 
treated animals. Glucose tolerance in alloxan recovered rabbits (rabbits that had 
recovered normal fasting blood glucose levels but still showed inadequate glucose 
tolerance) was improved by oral administration of a benzene extract of karela, but not 
an ethanolic one (Venkanna Babu et al., 1988). Three non-sapogenic hypoglycaemic 
and one hyperglycaemic principles were reported to have been isolated from karela, 
but their identities were not given. 
Rat model. Rat models have been widely used to study the effects of karela juice and 
its extracts. Improved glucose tolerance on acute administration of the juice has been 
demonstrated in normal rats (Karunanayake et al., 1984; Chandrasekar et al., 1989) 
and in rats with anterior pituitary extract-induced hyperglycaemia (Gupta, 1963). 
Chronic administration over 30 days lowered the mean glucose tolerance in a group 
of STZ-treated rats, but this did not reach statistical significance (Karunanayake et 
al., 1990). 
Higashino et al. (1992) found that a polar solvent extract of karela improved 
tolerance of both orally and intraperitoneally administered glucose, suggesting that a 
mechanism involving an extra-intestinal action, though impaired glucose absorption 
may also be involved. Ali et al. (1993a) demonstrated that improved glucose 
tolerance only occurred in NIDDM-model STZ-treated rats and not those in which 
IDDM had been induced with a higher dose of STZ. This suggests an insulin 
secretagogue activity by karela. However, Leatherdale et al. (1981) found no 
significant increase in insulin levels in response to karela treatment in normal rats. 
In a recent study, Sarkar et al. (1996) reported that an alcoholic extract of karela 
significantly depressed plasma glucose levels by 10-15% at 1 hour in normal glucose 
primed rat model, though no increase in insulin secretion was observed. While using 
STZ-induced diabetic rat model, karela extract improved oral glucose tolerance 
causing significant reduction in plasma glucose of 26% at 3.5 hour as compared to 
metformin (reference hypoglycaemic drug) which caused 40-50% reduction at l, '2 
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and 3.5 hours. Karela extract was also shown to cause a 4-5 fold increase in the rate 
of glycogen synthesis from U-14C-glucose in the liver of normal rats. These data 
suggested that the mechanism of action of karela could be partly attributed to 
increased glucose utilisation in the liver rather than an insulin secretion effect. 
As well as improved glucose tolerance, a hypoglycaemic effect on acute 
administration of karela juice in fasted rats has been demonstrated in both normal 
(Leatherdale et al., 1981; Karunanayake et al., 1984; Chandrasekar et al., 1989) and 
STZ-treated animals (Higashino et al., 1992). However, Ali et al. (1993a) found that 
very high doses of STZ can abolish the effect of karela on basal glycaemia. In 
alloxan-induced diabetic rats, chronic administration of karela for 20 days was found 
to lower blood glucose significantly in a dose dependent manner (Srivastava et al., 
1987,1988,1993). However, Platel et al. (1993) found that 8 week administration of 
freeze-dried fruit to normal animals did not affect blood glucose levels, possibly due 
to the operation of normal homeostatic mechanisms. In a latter study by Platel and 
Srinivasan (1995), 6 weeks administration of a semi-synthetic diet containing freeze- 
dried karela powder to STZ-induced diabetic rats did not affect blood glucose levels 
and other diabetes related metabolites. In addition, karela juice administered prior to 
alloxan did not protect the animals from the induction of hyperglycaemia (Sharma et 
al., 1960). 
Other potentially beneficial effects of karela administration include lowering of 
serum cholesterol in normal rats (Platel et al., 1993), in NIDDM model rats 
(Murshed et al., 1996) and in alloxan-induced diabetic rats (Singh et al., 1989), 
delaying cataractogenesis in STZ-diabetic animals (Srivastava et al., 1987,1988, 
1993) and normalising the effects on the hepatic cytochrome P450 drug-metabolising 
enzymes in STZ-induced diabetic rats (Raza et al., 1996). 
Mouse model. In normal mice, treatment with karela extracts resulted in improved 
glucose tolerance using either orally or intraperitoneally administered glucose. There 
was no significant difference observed between insulin levels in treated and control 
animals (Day et al., 1990). A hypoglycaemic effect of the juice in STZ-treated 
animals was also demonstrated. The results of fractionation studies implied the 
presence of more than one active component, possibly alkaloidal in nature (structure 
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not given). However, Cakici et al. (1994) reported that an aqueous extract of karela 
has a hypoglycaemic activity without improving glucose tolerance in cyproheptadine- 
induced diabetic mice, suggesting that karela acts independently of intestinal glucose 
absorption and that an extrapancreatic effect may be involved. 
P-insulin. Subcutaneous administration of a polypeptide, p-insulin (isolated from 
karela) to fasted gerbils and langurs caused a significant fall in blood glucose 
(Khanna et al., 1981). In another study, Jiangxin et al. (1991) reported that both 
subcutaneous and oral administration of purified p-insulin extracted from karela had 
significant hypoglycaemic effects in diabetic rats. This is the first and only report 
found on oral hypoglycaemic activity of p-insulin. However, on closer examination 
of the results obtained, it was found that the plasma glucose levels before treatment 
were unexpectedly different between the control and treated (p-insulin) groups, with 
significantly higher values in the treated group. Thus the results appear to be 
unreliable and the reported oral hypoglycaemic activity of p-insulin requires further 
investigation. 
Charantin. Charantin (Fig. 1.19), a mixture of ß-sitosterol and stigmastadienol 
glucosides was isolated from karela by Lotlikar and Rajarama Rao (1960/61) in 
approximately 0.01% yield. A decrease in blood glucose concentration was found 
when charantin was administered to fasted normal rabbits orally or intravenously. 
However, the data were obtained using only one or two animals at each dosage level 
and no controls were carried out. The wide variations in fasting blood glucose values 
suggest that the animals may not have reached a true fasting state. Furthermore, the 
dose of charantin administered is equivalent to much higher amounts of karela than 
those required for a hypoglycaemic response in rabbits, suggesting that charantin is 
unlikely to account for all the hypoglycaemic activity of the fruit. In a more elaborate 
study (Lotlikar and Rajarama Rao, 1966), charantin (again at high dose) administered 
to normal rabbits intravenously or orally produced a gradual but significant fall in 
blood sugar. In alloxan diabetic rabbits, the - effects were more - erratic. 
Pancreatectomy of cats was reported to reduce but not abolish the hypoglycaemic 
effect of charantin (Lotlikar and Rajarama Rao, 1966), indicating a dual (pancreatic 
and extra-pancreatic) mechanism of action. 
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Figure 1.19: Sterol glucoside components of charantin 
isolated from Momordica charantia fruit 
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Karela seed. As in human subjects (Grover and Gupta, 1990), karela seed was found 
to lower blood glucose levels in STZ-induced diabetic rabbits (Kedar and 
Chakrabarti, 1982). The seed also reversed the low muscle and liver glycogen and 
elevated serum cholesterol, fatty acids and triglycerides induced by STZ. In a more 
recent study (Dubey et al., 1987), polar solvent (methanol, 50% aqueous ethanol, 
normal saline) extracts of karela seed caused a significant hypoglycaemic effect in 
fasted normal rats. The methanol and saline extracts were also able to reduce 
adrenaline-induced hyperglycaemia. In both cases, the methanol extract was the most 
potent. However, Ali et al. (1993a) reported that a methanolic extract of the seed did 
not reduce blood glucose levels in fasting or post-prandial states in normal and STZ- 
treated IDDM rats. 
Vicine. Vicine (Fig. 1.20) has been isolated from the seeds of karela in 0.6% yield 
(Handa et al., 1990). Intraperitoneal administration of vicine (dose of 100mg/kg body 
weight) caused a hypoglycaemic response in normal fasting albino rats. The dose 
used was equivalent to about 16g powder per kg body weight - about five times the 
dose administered orally by Kedar and Chakrabarti (1982) to obtain a response. This 
suggests that the activity of the seed powder may not be solely ascribable to vicine. 
Karela vines and aerial parts. Cerasee tea (prepared from the vines) was found to 
lower basal glucose concentrations and to improve glucose tolerance in normal mice 
(Bailey et al., 1985), with no significant change in the plasma insulin level. A 
hypoglycaemic response was also observed in STZ-treated mice. When cerasee tea 
was substituted for drinking water for 12 days, glucose tolerance measured on day 13 
was improved. More recently, Ali et al. (1993a) tested methanolic and saponin-free 
methanolic extracts of the whole plant of Momordica charantia in normal rats. No 
effects were seen on fasting blood glucose levels. 
1.4.4 Effects on tissues and enzymes; possible mode of action 
Attempts have been made to obtain further information on the mode of action of 
karela fruit and seeds through experiments using enzymes, tissues or cells in vitro or 
examining organs isolated from karela-treated animals. Karela fruit and seed 
preparations have a number of biological effects in vitro (Table 1.6), which may give 
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Figure 1.20: Vicine, a putative hypoglycaemic compound 







Figure 1.21: Charine, isolated from the unripe fruit of 
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an indication of their mode of action. 
Glucose absorption. A theoretical means by which glucose tolerance can be 
improved is by decreased absorption of glucose from the gut (Section 1.2). Meir and 
Yaniv (1985) reported that glucose uptake by inverted gut was inhibited in the 
presence of extracts of karela fruit. However, from the in vivo work of Day et al. 
(1990) and Higashino et al. (1992) it would appear that this may not be the 
mechanism involved in the action of karela since tolerance of intraperitoneally 
administered glucose is also improved. There have been no studies reported to date 
on effects of karela on enzymes involved in the digestion of carbohydrates, e. g. a- 
amylase. 
Insulin secretion. In a number of in vitro studies (Welihinda et al., 1982a, b; Ali et 
al., 1993b; Mosihuzzaman et al., 1994), extracts from the fruit have been found to 
stimulate insulin release from isolated pancreatic islet cells. The responsiveness of 
STZ- and alloxan- treated animals to karela, would seem to suggest that pancreatic 
stimulation is not involved. However, it must be noted that STZ and alloxan 
treatments may not result in complete destruction of pancreatic ß-cells. For instance, 
in the study by Kedar and Chakrabarti (1982), STZ-treated animals were responsive 
to glibenclamide, which acts by stimulation of insulin release from the pancreas 
(Section 1.1.9(a)). In addition, Ali et al. (1993a) found that the effects of karela could 
be abolished by treating the animals with a higher dose of STZ. In some studies 
(Sharma et al., 1960; Tiangda et al., 1987) alloxan-treated rabbits were more 
responsive to karela extracts than normal animals. This may indicate a sensitisation 
of the ß-cells to karela by alloxan. However, it, should be noted that increased insulin 
levels in vivo have not been observed in karela treated mice (Day et al., 1990), rats or 
humans (Leatherdale et al., 1981). 
Insulinomimetic effects. Karela juice shows certain insulinomimetic effects such as 
increased glucose uptake into muscle, stimulation of lipogenesis, and inhibition of 
lipolysis on tissue preparations in vitro (Table 1.6). In vitro tests on tissues taken 
from animals treated with karela have also shown a depression of hepatic 
gluconeogenetic enzymes, and increased liver and muscle glycogen. 
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There is conflicting data on effects of karela extracts on tissue respiration. Welihinda 
and Karunanayake (1986) found that karela juice did not show any effect on tissue 
respiration in diaphragm muscle in vitro. However, Meir and Yaniv (1985) reported 
that karela inhibited the oxidation of glucose by liver tissue, possibly at the first step 
in glycolysis, i. e. phosphorylation by hexokinase. These contradictory results may be 
due to differences in the tissues, methodology and type of karela preparation used. A 
more reliable indicator of effect of karela on tissue respiration may be that 
demonstrated by Shibib et al. (1993). Liver glucose-6-phosphate dehydrogenase (G- 
6-PDH) activity was elevated on in vivo administration of karela ethanolic extract by 
gastric intubation. This would enhance the utilisation of glucose by the liver leading 
to a lowering in blood glucose. 
The lipogenic and anti-lipolytic effects of karela juice in vitro are shared by seed 
extracts. A saponin (not identified) and proteins have been found to account for the in 
vitro effects of the seeds. The proteins are believed to be lectins; the abortifacient 
proteins a- and ß- momorcharins also found in the seeds are not active in this assay 
(Wong et al., 1985a, b). However, against this, Welihinda and Karunanayake (1986) 
reported that adipose tissue of karela-treated rats did not differ significantly in 
triglyceride content from that of control animals. 
Thus, inhibition of glucose absorption, insulin secretagogue activity and 
insulinomimetic effects have been attributed to karela in in vitro tests. However, not 
all of these have been fully supported by in vivo data, probably due to the compounds 
showing activity in vitro not being bioavailable in vivo (Section 1.2.5). 
1.4.5 Phytochemicals isolated from Momordica charantia and their 
relationship to its anti-diabetic effects 
Since the early 1960's, a number of phytochemicals have been isolated from 
Momordica charantia fruit, seeds and whole plants. A review of the known 
constituents was published in 1989 (Fiche Espece, 1989). These data and 
supplementary information are given in Tables 1.7-1.9. In some cases, biological 
activities, such as insulinomimetic properties, protein synthesis inhibition, or insect 























Cc N 00 
10 
vi L1ýr ýo 
C) Z 
, 
Lý Cd 0 "a 
cC 
0Ö 























ý - 00 O, 
0 00 
00 00 
u u ý ý 
C i x y 
N 
6ýi w 
(1) a cd 
0 
Cd as a) ; t:! 
.X w Cd 





















































w .. a ".:. ä 






.b vý i 
U 





















ei v I 
Q 
.ý 
















































C7 ýä Obi 
e 
82 







































































































































































































































































































































Chap ter 1: Introduction 
11 o 



























































































































v-, 0 - 0 , ý 0 o h 
. - 
- 





















bO 00 C CU A 0 
O M e C 














r- > O 0 'v 
'b (U 00 N 

























K- .. w 
.r cs cs N 
-e N 
r Ü ;; ö 
y 
E ö 
































c a N 
r 












aý >, C) C) v o o E o ö 











































Q' -- p0 
ON N d w "--ý 
Q 00 - 0 ^. 
p p 
r Q Oý ON y Q pq v "ý 
Q CI 
'ý e c 
y 
a` 
Q m ý, o ca 
o i 
3 cl Ü 0 7 Cl) w° 
o 
















U t) L) as 0 U p 
b 
p 













a) z C. ) .5 a 0 
> r. n 
E 
ä 










ß" n ö C 2 ti? .0 
`ý - C) C 
41z J-5 5% 
'O 0 ö 




0 c -ö .c 
ed c Ä c ä 0 
Cts Q ö ý 
o 
ý as 0 cd 0 
o 
° 






, .; ~ 
vý 
. p o 00 = 0 
Q U 
"- 









'+"' Z3 Q- N co 
"'I'- 5 






















































































4) u . 
85 
















ý Q aä x 
o 
ºý ý aä ä 
m 
v ý x 
U) 
C O b N 
N 

























































































































































































































Cd 6 -0 C A I- 





O i 0\ a\ ii ä Ü w t .ý 















CA () >1 













ä v > Q. Cd 





5 3 c ö > 
O 
on cN n 0 
' 



































to 0 - a) 
cn 
V E C 
co 
y W a 
a 
































E 1. > 
ö ö Ü 
ö ö -m -E 
E 
C! ý U C/D coi 
2 
























Chapter 1: Introduction 
in a particular type of compound e. g. saponins or proteins. Possible identities which 
emerge for the hypoglycaemic principle in Momordica charantia are steroidal 
glycosides, insulinomimetic lectins and alkaloids; the evidence relating to each of 
these is discussed below. 
Steroidal/cucurbitacin glycosides, steroids and terpenoids. The earliest reported 
active constituent of karela fruit was "Charantin" (Fig. 1.19), a mixture of glucosides 
of ß-sitosterol and 5,25 stigmastadien-3ß-ol (Lotlikar and Rajarama Rao, 1960/61, 
1966). However, it is important to note that the dose of charantin required to elicit a 
hypoglycaemic response in rabbits was equivalent to 180 to 315g of fruit orally and 
81g fruit intravenously, whereas a hypoglycaemic effect can be seen in rabbits with 
about 10 to 15g of the fruit per kg body weight. 
In 1975, Olaniyi isolated a substance "foetidin", from the whole plant of Momordica 
foetida, which was found to be identical in composition to charantin. Marquis et al. 
(1977) claimed that at 18 hours from administration, foetidin lowered blood glucose 
in fasting rats in an effect comparable to insulin. This claim is often quoted in the 
literature as support that the steroidal mixture is the active principle of Momordica 
charantia. However, a closer examination of the original data presented in the paper 
shows that foetidin was not significantly different from control at time points other 
than the 18 hour sample. 
It is now known that Momordica charantia fruit, seeds and vines contain other 
cucurbitacin glycosides i. e. momordicosides and momordicines (Fig. 1.22,1.23); 
Tables 1.7-1.9). Recently, three pentacyclic triterpenes (momordicin, momordicinin 
and momordicilin) and a sterol (momordenol) have been isolated from karela fruits 
(Begum et al., 1997; Fig. 1.24) but no pharmacological studies have been reported so 
far on these compounds. A saponin fraction from the seeds of karela showed 
insulinomimetic effects in vitro (Wong et al., 1985b; Ng et al., 1986b). The 
contribution of steroidal constituents other than charantin to the in vivo anti-diabetic 
effects of Momordica charantia has not been evaluated. 
Insulinomimetic proteins. In vitro insulinomimetic effects have been observed with 
fruit proteins (Table 1.7) and seed proteins (Table 1.8). The active seed protein is 
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Figure 1.22 (continued): Momordicosides isolated from Momordica charantia 
fruit and seeds. 
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Figure 1.23: Momordicines isolated from Momordica charantia leaves 
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Figure 1.24: New compounds isolated from M. charantia fruit 
(Begum et al., 1997) 
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believed to be a galactose binding lectin (Table 1.8). Khanna et al. (1981) reported 
that an 1 lk Dalton protein (p-insulin or v-insulin) caused hypoglycaemia in man and 
laboratory animals on parenteral administration. 
Proteins are generally considered to be inactive when administered by the oral route, 
as they would undergo extensive digestion by proteolytic enzymes. Thus the 
possibility of a polypeptide being responsible for the hypoglycaemic effects of the 
fruit or seeds when given orally must be viewed with some scepticism. However, 
against this, there is some evidence (Pusztai, 1986) that lectins may be absorbed into 
the bloodstream from the gastro-intestinal tract. Khanna (1985) has stated without 
any supporting data that p-insulin is also effective orally. In fact, the oral 
hypoglycaemic effect of p-insulin in diabetic rats has been reported by Jiangxin et al. 
(1991), and further investigations are required to confirm the results (Section 1.4.3). 
Alkaloids. Day et al. (1990) reported that hypoglycaemic activity of fractionated 
karela fruit juice resided in an alkaloid-rich fraction. The alkaloids have not been 
isolated or characterised. The pyrimidine nucleoside vicine (Fig. 1.20) has been 
isolated from the seeds (Dutta et al., 1981; Barron et al., 1982). This "alkaloid" has 
been found to induce hypoglycaemia in rats at an intraperitoneal dose equivalent to 
16g of seeds per kg body weight (Handa et al., 1990). Kedar and Chakrabarti (1982) 
found the seed powder to be orally effective in rabbits at 1-3g per kg body weight. 
Thus vicine may not account for all the activity of the seeds. 
A pyrimidine arabinopyranoside named charine (Fig. 1.21) was isolated from the 
unripe fruits of Momordica charantia by El-Gengaihi et al. (1995). Since charine has 
a very similar chemical structure to vicine, it is therefore a potential hypoglycaemic 
compound in karela fruits and its hypoglycaemic activity remains to be investigated. 
Kakra compounds. Srivastava et al. (1993) isolated three non-steroidal 
hypoglycaemic compounds (Kakra 1 b, 111 a and 111 b) from the fruit which differ 
from earlier reported principles, i. e. p-insulin or charantin. The structure of these 
compounds had not been elucidated. 
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1.4.6 Other pharmacological and toxicological properties 
A number of effects of Momordica charantia unrelated to diabetes have been 
investigated. No data are available on standard toxicity parameters e. g. LD50 values of 
the juice, seeds or plants. However some information on toxicity is available from 
observations made during experimental or clinical use of Momordica charantia 
extracts in animals or humans. 
Anti-cancer. Protein fractions obtained from the fruit and seed of Momordica 
charantia have the ability to inhibit cell growth, guanylate cyclase activity and 
ribosomal activity (Tables 1.7 and 1.8). West et al. (1971) demonstrated inhibitory 
effects of whole plant extracts on seedling root growth, division of fertilised sea 
urchin eggs, rat foetal growth (if injected on day of mating) and the growth of Hep2 
cells in culture. They also reported a single case study of a leukaemia patient in 
whom regular intake of the extract led to a fall in white blood cell count, and an 
increase in blood haemoglobin. 
Antiviral. The growth of herpes simplex virus I (Foa-Tomasi et al., 1982) and 
human immunodeficiency virus I (Lifson et al., 1988; Lee-Huang et al., 1990) is 
inhibited by karela extracts. Increased T-cell count and a normalisation of the 
CD4/CD8 ratio seemed to occur in three HIV positive patients given regular doses of 
karela juice (Zhang, 1992b). The juice was administered as a retained enema i. e. 
rectally. This may explain its apparent effectiveness since the active anti-viral 
components of Momordica charantia are believed (Zhang, 1992b) to be the proteins 
a- and (3-momorcharins and MAP 30 (Table 1.8), which would be expected to 
undergo hydrolysis by pancreatic enzymes if administered by the oral route. 
Furthermore, Bourinbaiar and Lee-Huang (1995) reported the enhancement of weak 
HIV antagonists, dexamethasone and indomethacin, by MAP 30, which suggested 
that use of MAP 30 in combination with low doses of dexamethasone and 
indomethacin may improve the efficacy of anti-HIV therapy. 
Analgesic effects. A methanolic extract of the seeds from unripe fruit has been 
shown to produce a marked dose-dependent analgesic effect in mice and a much 
weaker effect in rats (Biswas et al., 1991), but using different test systems for the two 
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species. Naloxone pretreatment failed to modify the analgesic response, suggesting 
that opioid receptors were not involved. 
Anti-inflammatory effects. A dose related anti-inflammatory effect has been 
demonstrated using carageenin-induced rat hind-paw oedema (Lal et al., 1990). Free 
radical scavenging activity of the juice in vitro (Rao, 1991) may be involved. 
Gastroprotective and ulcer healing activity. Karela fruit extract was shown to 
significantly inhibit the development of absolute ethanol and aspirin induced acute 
ulcers in laboratory rats (Fernandopulle et al., 1996). 
Hypotensive action. "Cerasee" (aerial parts of Momordica charantia) extract 
showed a marked transient depressor effect on injection to the anaesthetised dog 
(Feng et al., 1962). Gamma amino butyric acid has been suggested to be responsible 
for this effect (Durand et al., 1962). 
Antifertility effects. Oral administration of karela fruit extract (1.75g/day for 60 
days) to male dogs resulted in testicular lesions and mass atrophy of spermatogenic 
elements (Dixit et al., 1978). Serum enzymes were normal implying that an infertility 
state was induced without altering general metabolic activity in the animal. 
A study by Stepka et al. (1974) found that daily oral administration of the fresh juice 
of Momordica (species not stated) leaves to a group of female mice, reduced the 
fertility rate. This was reversed on withdrawal of the treatment. No pathological 
changes were seen in any of the maternal organs, but in some cases, concepti were 
seen as necrotic masses. In more recent work, proteins capable of inducing abortions 
((x- and ß-momorcharins) and necrosis of placental trophoblasts have been isolated 
from Momordica charantia seeds (Table 1.8). It is possible that similar proteins 
occur in the leaves. Uterine bleeding has been induced in pregnant rats given karela 
juice (6ml/kg) orally (Zhang, 1992b), while 2 pregnant rabbits given karela juice 
(6ml/kg) suffered uterine haemorrhage and death within a few hours (Sharma et al., 
1960). No such effect was noted in non-pregnant females. 
Effects on growth, blood and serum lipids. Chronic administration of karela 
extract (1.75g orally per day for 20-60 days) to dogs resulted in elevated levels of 
serum cholesterol and non-esterified fatty acids, but no significant changes in body 
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weight or serum enzymes (Dixit et al., 1978). Rats maintained on a diet containing 
freeze-dried karela for 8 weeks showed no change in food consumption rate or 
growth rate (Platel et al., 1993). At the end of this period, organ weights (liver, 
kidney, testes, spleen, adrenals and heart) were similar to those of control animals. 
Blood cell counts, cell volume and haemoglobin parameters showed no significant 
difference to controls and remained within the normal range. However in this study, 
there was a significant decrease in blood cholesterol. 
Hepatotoxicity. Following the administration of karela juice and seed extract to rats 
(lOml/kg body weight daily for 30 days), serum y-glutamyl transferase and alkaline 
phosphatase was significantly elevated, but consistent histopathological defects were 
not observed in the liver (Tennekoon et al., 1994). Therefore the elevated enzymes 
could either be due to mechanisms not obvious at the histological level or to enzyme 
induction. The prevalence of dilatation and/or congestion in the hepatic central veins 
and associated sinusoids was twice as high in the juice treated -group as in the seed 
extract treated and control groups. Ng et al. (1994) have found that a- and ß- 
momorcharins can induce cytoplasmic blebs and other morphological changes in rat 
hepatocytes in vitro. Secretion of various enzyme markers of cell damage is also 
raised. 
Fatal doses in animals. Continuous single or twice daily oral administration of 
karela juice (6m1/kg body weight) to 6 rabbits resulted in 5 animals dying within 5-25 
days (Sharma et al., 1960). In an acute effect, pregnant but not normal rabbits, died 
within a few hours of receiving this dose (Sharma et al., 1960). Rats given karela 
juice (18-40ml/kg body weight, by intraperitoneal route) became sluggish and died 
within 6-18 hours. Zhang (1992b) reported that pregnant rats died within a few hours 
of receiving karela juice (6m1/kg body weight) orally. In normal and alloxan diabetic 
rats given the same dose daily, 80-90% died within 5-23 days. Abdominal injection 
of the juice at (15m1/kg body weight) caused death in 6-18 hours. In rabbits receiving 
10mlIkg orally per day, the majority were reported to have shown toxic effects, 
although the nature of these effects was not elaborated. 
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Toxicity in humans. Although toxicity has been observed in some animal studies, if 
extrapolated to humans, the relevance of the dose and route of administration must be 
considered. A dose of 6-10ml/kg would represent a dose of 400m1-1000ml for an 
adult. The normal adult dose is closer to 50ml, given orally. There are no published 
reports of fatal or serious effects in adults at this dose. 
Patel et al. (1968) reported that administration of the juice or dried juice powder 
(equivalent to 250-500g of the fruit) to diabetic patients led to abdominal pain and 
diarrhoea. Zhang (1 992b) has used orally or rectally administered fruit juice to treat 
HIV-positive patients. He reported that there was very low clinical toxicity. A patient 
who had been given the juice daily for over three years did not show any, change in 
blood chemistry or any other untoward effect. Liver, kidney, heart or blood 
abnormalities have not been reported in any of Zhang's patients despite long term use 
of Momordica charantia fruit juice. 
The only report of a potentially fatal reaction in humans is hypoglycaemic coma 
induced in two small children (Hulin et al., 1988a, b). The children aged three and 
four required urgent medical attention following ingestion of a water extract of 
Momordica charantia leaves and vines. In both cases, the Sorrosi (cerasee) tea had 
been administered by their mothers early in the morning before any other food was 
consumed. Between 1-2 hours after ingestion, the children experienced convulsions 
followed by coma. Blood glucose was in the region of 1mM (normal range 3.8- 
5.5mM). Both patients recovered following hospital treatment. 
1.4.7 Conclusion 
The unripe fruit, seeds and aerial parts of Momordica charantia Linn. have been used 
as an anti-diabetic remedy in a number of areas of the world notably India, Sri Lanka, 
China and the West Indies. Limited studies on humans have shown that karela fruit 
juice reduces fasting blood glucose and improves glucose tolerance on acute 
administration. Prolonged administration causes 'a lowering of glycosylated 
haemoglobin in the blood, and decreases glycosuria and basal glycaemia. The 
hypoglycaemic and anti-hyperglycaemic effects of karela fruit and seeds have also 
been demonstrated in animal models. Through evidence from animal and in vitro 
studies, there is support for insulin secretagogue activity of the fruit. However, 
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enhanced insulin levels in vivo in response to administration of karela have not been 
observed. Insulinomimetic effects have also been observed in vitro, and there is 
evidence (Sarkar et al., 1996) that hepatic glucose utilisation is increased in vivo. 
It is interesting to note that variation in results occurred among studies on karela by 
different research groups. For example, some researchers reported the reduction in 
basal glycaemia after karela administration in normal and diabetic animal models 
(Akhtar et al., 1981; Leatherdale et al., 1981; Higashino et al., 1992), while others 
did not observe this effect (Kulkarni and Gaitonde, 1962; Platel et al., 1993; Platel 
and Srinivasan, 1995). These conflicting results may be due to variations in karela 
used, i. e. karela fruits from different geographical sources may vary in their chemical 
constituents and anti-diabetic activity (Lau et al., 1996), due to subject variability, 
variations in dosages of karela administered, as well as differences in extraction 
methods employed in preparing karela extracts. 
A wide range of compounds have been isolated from Momordica charantia fruit, 
seeds and vines, mainly steroidal or triterpenoid compounds and proteins. Suggested 
hypoglycaemic compounds include a polypeptide (p-insulin), a steroid mixture 
(charantin) and a pyrimidine nucleoside (vicine). However, none of these is fully 
supported as a sole active constituent by the scientific data available. It is possible 
that a number of active constituents with a range of biological effects beneficial to 
diabetes are present in the fruit. 
Principal toxic properties of karela juice noted in animals are anti-fertility effects and 
hepatotoxicity, with death occurring on chronic oral treatment with doses of the order 
of 6m1/kg body weight. Pregnant females were particularly susceptible. 
Encouragingly, similar effects have not been reported in humans despite widespread 
use of the fruit juice both as a medicinal plant and as a vegetable. 
Thus karela fruit or seeds may provide a new extract, compound or lead compound 
with anti-diabetic effects for the oral treatment of both IDDM and NIDDM patients. 
There is clearly a need for a thorough investigation of the orally active 
hypoglycaemic principles of Momordica charantia, in which due consideration is 
given to the dose and route of administration. The most logical approach would in the 
first instance be using a whole animal model (in vivo), with further studies carried out 
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on in vitro models to determine mode of action. Much scientific research has been 
conducted on Momordica charantia which supports its use in the treatment of 
diabetes. The next step would be to carry out a systematic study to isolate and 
identify the active component(s) of the plant, and elucidate their mode of action. 
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1.5 Aim of present study 
"To use a systematic, relevant approach to isolate and identify orally active anti- 
diabetic phytochemicals in the unripe fruit of Momordica charantia, and to 
elucidate its mode of action. " 
As discussed in Section 1.4, numerous studies in humans, animals and in vitro 
models have demonstrated a potential beneficial effect of karela juice or extracts in 
diabetes. Although a number of hypoglycaemic principles have been proposed, either 
they have only been tested at relatively high doses compared to their concentrations 
in the fruit, or their effects on oral administration have never been fully investigated. 
In addition, the mode of action of karela has never been satisfactorily explained. Thus 
there is a need for further investigation of the oral hypoglycaemic activity of the 
unripe fruit of Momordica charantia to address these issues. 
The aims of the present study are as follows: 
Q Despite the fact that a number of hypoglycaemic compounds have been proposed, 
none of these appear to totally satisfy the enquiry. Thus a systematic approach, an 
in vivo (Streptozotocin-induced diabetic [NIDDM] rat model) bioassay guided 
fractionation will be employed in the present investigation. 
Q The unripe fruit of Momordica charantia (karela) are found (either cultivated or 
wildly grown) in different parts of the world. Thus variations in physical 
appearance, chemical constituents and biological activity among different varieties 
of karela obtained from various geographical sources will be examined. 
Q Inconsistent results have been obtained from previous studies as to whether karela 
improves either glucose tolerance or basal glycaemia or both. Thus the effect of 
karela on glucose tolerance, as well as its effect on fasting glucose levels will be 
examined using a diabetic animal model. 
Q Information on the site of action of karela will be investigated using different 
routes of administration of glucose in glucose tolerance studies. 
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Q So far, only in vitro but not in vivo insulin secretagogue activity of karela had been 
observed. Thus further investigation on plasma insulin levels in vivo in response 
to karela administration will be carried out. 
Q Some previous studies used parenteral route of administration of karela extracts or 
isolates. However, karela juice is known to exert an effect on oral administration. 
Due to the present project's main interest in isolating orally active anti-diabetic 
compounds from karela, only the oral route of administration of karela will be 
used in this study. 
Q In vitro models will be used, where appropriate, to examine the effect of karela 
extracts and isolates on particular mechanisms of action. 
This research project was financially supported by an EPSRC Case Award (Lipha, 
France). The collaboration with the pharmaceutical company Lipha enabled all the in 
vivo studies (using a diabetic animal model) to be carried out (by the author, with the 
help of some technicians) in the Pharmacology research laboratory at Lipha, while all 
the phytochemistry work was carried out in the Pharmacognosy research laboratory at 
King's College London. Spectral analysis was provided by ULIRS AMX 400 Nuclear 
Magnetic Resonance Spectroscopy Service and ULIRS Mass Spectrometry Service at 
the Chemistry Department of King's College London. 




Chapter 2: Phytochemical studies 
Chapter 2: Botanical and Photochemical studies 
2.1 Introduction 
Many plants are found in various parts of the world as they grow equally well in 
numerous localities having similar climates and soils. In the case where the plant is 
of importance as food crop or medicinal use, it may even be largely cultivated rather 
than collected from the wild (happens in many countries). For example, the 
cinchonas, indigenous to the Andes of South America, were successfully introduced 
to Indonesia and India which at one time became the principal geographical sources 
for the bark and its quinoline alkaloids (quinine and quinidine for the treatment of 
malaria). However, it must be remembered that a plant may grow well in different 
situations but fail to produce the same chemical constituents. In the case of Cinchona 
succirubra, the plant only produces alkaloids if they are grown at altitude and not at 
low levels (Evans, 1989). Thus it is important to note that natural variation in 
chemical constituents may occur within the same plant species. 
In this context, the plant Momordica charantia 'L. is found throughout the tropical 
countries. The plant either grows wild or is cultivated for use of the unripe fruit as a 
vegetable. This has led to the existence of a wide variety of cultivars. However, 
previous studies on Momordica charantia fruit (Section 1.4) seldom specified the 
geographical source or cultivar used. 
No previous reports were found of comparisons between varieties. Thus the aim of 
the present study is to investigate both physical and chemical variations among 
different varieties of Momordica charantia (karela) fruit. 
2.2 Plant materials 
Seven varieties of fresh unripe karela fruit from different geographical sources were 
studied: 
a) Karela fruit from Thailand (Fig. 2.1) - purchased from "Loon Fung Supermarket" 
in Chinatown, London, UK. 
b) Karela fruit from Kenya, Africa (Fig. 2.2) - purchased from "The Food Centre", 
70 Turnpike Lane, London, UK. 
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c) Karela fruit from Jaipur, India (Fig. 2.3) - purchased from market "Lal Kothi 
Sabji Mandi", Jaipur, by Dr Raka Kamal, Associate Professor of Botany at 
University of Rajasthan, Jaipur, India. The fruit were sent by courier and arrived 
slightly "off'. 
d) Karela fruit from Bombay, India (Fig. 2.4) - purchased from a street vegetable 
vendor in Bombay by Dr Amala Raman, Lecturer in Pharmacognosy, King's 
College London, UK. 
e) Karela fruit from Nigeria, Africa (Fig. 2.5) - supplied by Dr Kemi Odukoya, 
Faculty of Pharmacy at University of Benin City, Benin, Nigeria. 
f) Karela fruit from Bangladesh (Fig. 2.6) - purchased from a grocery store in 
Brixton market, London, UK. 
g) Karela fruit grown in UK (Fig. 2.7) - purchased from a grocery store in 
Chinatown, London, UK. 
All varieties were examined and authenticated by Dr Charles Jeffrey (Cucurbitaceae 
expert, Royal Botanic Gardens, Kew, UK). 
2.3 Methods 
2.3.1 Botanical studies 
Among all different varieties of karela fruit obtained, the physical appearances such 
as colour, size (length and maximum width) and shape of the fruit were carefully 
examined and compared. 
Seeds obtained from three varieties of karela fruit (Thai, Indian (Jaipur) and Kenyan) 
were planted in a greenhouse in Chelsea Physic Garden, UK. The seeds were sown in 
April and the plants were examined in' September, after 5 months of growth. In 
addition, specimens of all three different varieties of M charantia plants were 
collected and mounted as herbarium sheets. Herbarium voucher specimens (no. 
MolOHbl (Thai), MolOHb2 (Kenyan) and MolOHb3 (Indian)) are deposited at the 
Pharmacognosy Section, Department of Pharmacy, King's College London. 
2.12 Phytochemical studies 
All different varieties of karela fruit, except those from India (Jaipur) and Nigeria 
(due to shortage of supply), were used for phytochemical studies. 
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Figure 2.1: Momordica charantia fruit from Thailand 
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Figure 2.2: Momordica charantia fruit from Kenya, Africa 
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Preparation of karela iuice 
Fresh karela fruit were thoroughly washed and seeds removed. The fruit flesh was cut 
into small pieces, crushed in a kitchen blender, and the juice collected after filtering 
through muslin cloth (Fig. 2.8). 
Figure 2.8: Fruit juice obtained from karela of different geographical origins. 
(Left to right: Thai, Bangladesh, UK, Indian (Bombay) and Kenyan) 
Thin layer chromatography (TLC) 
lOµ1 of karela juice of different varieties were spotted on silica gel GF254 plate 
(Merck Darmstadt, Germany). The plate was developed using solvent system - ethyl 
acetate: methanol: water (77: 15: 8). The zones were detected by examination under 
UV light (X= 254nm) and in daylight after spraying with 0.5% anisaldehyde in 
methanol: glacial acetic acid: concentrated sulphuric acid (85: 10: 5) and subsequent 
heating at 100°C for 10 minutes. 
2.4 Results 
2.4.1 Different varieties of unripe fruit of Momordica charantia L. 
Since this research study commenced, a number of varieties of Momordica charantia 
(karela) fruit from different geographical origins were obtained. They were either 
home grown (UK) or imported from countries such as Thailand, Kenya, India, 
Nigeria and Bangladesh (Fig. 2.1-2.7). Surprisingly, karela fruit from different 
geographical sources were found to be different in size, shape and colour (Table 2.1). 
For example, karela fruit from India (Jaipur and Bombay), Africa (Kenya and 
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Nigeria) and Bangladesh had similar appearances; all were dark green in colour, 
pointed at both ends, covered in small warts with spiky irregular ridges running along 
their length. The major differences among them was the size. The Indian karela fruit 
(Fig. 2.3 and 2.4) were much smaller than the ones from Kenya (Fig. 2.2) and 
Bangladesh (Fig. 2.6), while the Nigerian karela fruit (Fig. 2.5) were the smallest 
among all different varieties. In contrast, Thai karela fruit (Fig. 2.1) were large in 
size, light green in colour, pointed only at the apical end, with smooth irregular ridges 
running along its surface. The home grown (UK) karela fruit (Fig. 2.7) were similar 
to those from Thailand, though they were green in colour and smaller in size. Despite 
the differences in appearance, their identities as Momordica charantia L. were 
confirmed by Dr Charles Jeffrey, a Cucurbitaceae expert at Royal Botanic Gardens, 
Kew, UK. A possible explanation for the physical differences among all these 
varieties is that they were different cultivars of Momordica charantia, i. e. they were 
grown in different parts of the world and the different weather conditions and 
agricultural techniques may account for the differences observed. Dr Jeffrey also 
commented that the Thai, Kenyan, Bangladesh and British varieties were likely to be 
cultivated, while the Indian and Nigerian varieties (being small in size) appeared to 
have grown in the wild. Furthermore, the author later came across (from a Chinese 
magazine) a new variety of karela fruit cultivated in the greenhouse in Taiwan. The 
fruit were very similar in shape to those from Kenya, however they were white in 
colour (Fig. 2.9). 
L. 0 
J 
Figure 2.9: White karela fruit cultivated in Taiwan 
(Photo reproduced from a Chinese magazine) 
Dr Jeffrey emphasised that when classifying plants, the whole plant (leaves, flowers, 
fruit, seeds, stems, etc. ) should be taken into account (Jeffrey, 1967). To investigate 
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this point, seeds obtained from three varieties of karela fruit (Thai, Indian (Jaipur) 
and Kenyan) were planted in a greenhouse in Chelsea Physic Garden, UK. The plants 
reached a height of about 7-8 feets after 5 months of growth, bearing flowers but no 
fruit. All three varieties of Momordica charantia plants were almost identical in 
appearance: climbing vines with bright green lobed leaves, long spirally twisted 
tendrils and small yellow flowers (Fig. 2.10-2.12). This again confirmed their 
identities as M charantia L. despite the differences in physical appearances among 
the karela fruit. 
2.4.2 Comparison of chemical constituents among different varieties of 
karela fruit 
A simple assessment of the variation in chemical constituents among different 
varieties of karela fruit (Bangladesh, Kenyan, Thai, UK grown and Indian (Bombay)) 
was made using thin layer chromatography. From the results shown in Fig. 2.13, both 
qualitative and quantitative differences were observed. The pattern of the zone 
profiles were generally similar among the five varieties, however, some notable 
variations were seen. For example, the UV light absorbing zone a was present in all 
varieties except Indian karela, whereas the UV absorbing zones b, c and d were only 
present in UK, Indian and Bangladesh karela respectively. The UV absorbing zones e 
and f were present in all varieties except UK karela. Anisaldehyde is a spray reagent 
for detection of sugars, steroids and terpenes (Krebs et al, 1969). From the zone 
profiles shown in Fig. 2.13, two purple zones w and x (likely to be steroids or 
terpenoids) were present in Thai karela, also present (only in small quantities) in 
Indian karela, but absent in the other varieties. On the other hand, a bright yellow 
zone y was present in all varieties except Thai and UK karela, whereas a pink zone z 
(may be steroid or terpenoid) was only found in Indian karela. Where common 
constituents were present, the intensity of the zone differed among varieties, e. g. 
zones s and t. These results suggest that significant variations in chemical 
constituents occurred in karela fruit from different geographical origins. 
2.5 Discussion and conclusion 
Although its native country is uncertain, Momordica charantia is commonly 
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Figure 2.11: Momordica charantia plant of Indian origin 
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Keys: A= Bangladesh; B= Kenyan; C= Thai; D= UK; E= Indian (Bombay) 
Adsorbent: Silica gel GF254,250µm thick 
Mobile phase: Ethyl acetate: methanol: water - 77: 15: 8 
Visualisation: i) UV light at 254nm before spraying (zones marked by pencil) 
ii) Daylight after spraying with anisaldehyde spraying agent 
Figure 2.13: The zone profiles of the juice from 5 different varieties 
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cultivated throughout the tropics for the unripe fruit as food crop. We observed that 
karela fruit from different geographical origins were different in size, shape, colour 
and even had different constituent profiles. The existence of several varieties of 
Momordica charantia may be due to different weather conditions and cultivation 
techniques. In addition, it is interesting to note that within one variety, different 
batches purchased at different time of the year may also vary in constituents, though 
the difference was small (Fig. 2.14). 
Previous studies on Momordica charantia fruit have seldom specified the 
geographical source or cultivar of karela used. However, our results demonstrated 
variations in both physical appearances and chemical constituents among different 
varieties of karela fruit which may, in part, account for differences between 
researchers' results. Variation in content of specific sterols in a number of varieties of 
karela will be discussed in Section 5.7. Furthermore, an investigation on differences 
in biological activities between two varieties of karela fruit (Thai and Kenyan) will 
be presented in Chapter 3. This study confirms that it is important to record the origin 
of karela fruit when used for research studies. 
Figure 2.14: The zone profiles of fruit juice of two different batches of Kenyan 
karela. (Same TLC system used as in Fig. 2.13) 
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3.1 Introduction 
The main aim of the present study was to investigate the potential efficacy of karela 
fruit and its components in the treatment of Type II diabetes; the hypoglycaemic and 
anti-hyperglycaemic activities of karela. The ideal way of doing this would be using 
large scale double-blinded clinical trials. However, this is infeasible in the present 
work; the reasons have been discussed earlier on in Chapter 1. Thus the use of animal 
models of non-insulin-dependent diabetes would be an alternative for examining the 
effects of karela fruit on NIDDM. 
3.1.1 Animal models of non-insulin-dependent diabetes 
There are various animal models of non-insulin-dependent diabetes available (Bailey 
and Flatt, 1990; Shafrir, 1992). Selection of models for studying anti-diabetic 
compounds depends upon the particular features of NIDDM required. 
According to Bailey and Flatt (1990), the models can be categorised into 3 main 
types: 
a) Experimentally induced NIDDM models - they are produced by surgical (< 
about 95% pancreatectomy) or chemical (low-dose alloxan or 
streptozotocin, or neonatal streptozotocin) reduction of the ß-cell mass. 
b) Spontaneous syndromes of severe hyperglycaemia with possible ketosis - 
for example, Chinese hamster, the C57BL/KsJ db/db mouse and the 
Keeshond dog. These models usually show an early phase of obesity and 
hyperinsulinaemia with ß-cell hyperplasia and insulin resistance. The 
hyperglycaemia usually exceeds 20 mmol/L. 
c) Spontaneous syndromes of non-severe hyperglycaemia without ketosis - 
examples such as Zucker fatty fa/fa rat, Japanese KK mouse and Goto- 
Kakizaki rat. The first 2 of these models generally exhibit obesity, islet ß- 
cell hyperplasia, hyperphagia, hyperinsulinaemia and insulin resistance. 
The hyperglycaemia is usually below 20 mmolfL. 
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3.1.2 The no STZ diabetic rat model 
In the present study, the non-insulin-dependent diabetic animal model employed for 
examining the anti-diabetic activity of karela fruit is known as nO STZ, i. e. an animal 
model of NIDDM induced by neonatal administration of streptozotocin (STZ). 
Streptozotocin, a 2-deoxymethyl-nitrosourea-glucopyranose molecule (Fig. 3.1), 
produces a selective toxic effect on pancreatic ß-cells and induces diabetes mellitus 
in laboratory animals (Fischer, 1985). STZ is believed to act on nuclear DNA. During 
decomposition of STZ, highly reactive carbonium ions are formed which cause 
alkylation of DNA bases. In the following phase of excision DNA repair, the nuclear 
enzyme poly (ADP-ribose) synthetase becomes activated to such an extent that 
cellular levels of its substrates NAD become critically depleted, resulting in cell 




NH- CO N CH3 
NO 
Figure 3.1: Structure of streptozotocin 
The diabetic syndrome in the nO STZ model was generated by injecting Wistar rats 
on the day of birth (n0 = birth) intravenously (saphenous vein) with 100mg/kg body 
weight of streptozotocin (Portha et al., 1979). This model is based on the fact that a 
capacity of regeneration of beta cells is still present in Wistar rats in the first week of 
life. In nO STZ model, 50% of ß-cell mass regenerates, and thus results in rats which 
are mildly hyperglycaemic with many characteristic features close to human NIDDM 
(Portha et al., 1989; Fig. 3.2). This pattern of NIDDM is chronic and stable (up to 20 
weeks). 
This particular nO STZ diabetic rat model was chosen in our study because this is a 
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standard diabetic model used at Lipha (the industrial sponsor of this research project) 
for screening anti-diabetic compounds. The advantage of this model is that the 
regeneration of 50% ß-cell mass results in a mildly hyperglycaemic model, with 
specific failure of insulin release in response to glucose. In addition, the running costs 
for experiments which involve rats are relatively cheap as compared to other animal 
species such as rabbits or gerbils. However, the limitation of this model is that the 
rats do not have the complete characteristic features of NIDDM, for instance, the rats 
have no insulin resistance. 
3.2 Effect of oral karela juice on basal glycaemia and oral 
glucose tolerance 
3.2.1 Materials and methods 
Plant material 
Two different varieties of fresh unripe karela fruit, imported from Thailand (Fig. 2.1) 
and Kenya (Fig. 2.2), were purchased from local grocery stores (Section 2.2). Both 
varieties were authenticated by Dr Charles Jeffrey (Cucurbitaceae expert, Royal 
Botanic Gardens, Kew, UK). Herbarium voucher specimens (no. MolOLl & 
MoIOL2) were deposited at the Pharmacognosy Section, Department of Pharmacy, 
King's College London. 
Preparation of karela juice 
Fresh fruit were thoroughly washed and seeds removed. The fruit flesh was cut into 
small pieces, crushed in a kitchen blender, and the juice collected after filtering 
through muslin cloth. Karela juice was kept refrigerated (2-8 °C) and used within 5 
days. For 200m1 juice, approximately 0.4kg fresh fruit of Thai karela or 0.9kg fresh 
fruit of Kenyan karela (without seeds) was required. 
Animals 
Adult Wistar non-insulin-dependent diabetic (NIDD) rats, 3-4 months old, weighing 
245-335g and bred at the animal house at Lipha were used. They were maintained on 
standard rat pellets (UAR, Villemoisson sur Orge, France; diet no. UAR 113) and tap 
water ad libitum. The rats were made diabetic by injecting streptozotocin (STZ; 
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Sigma, see Appendix A) intravenously (100mg/kg body weight) on the day of birth 
(n0 STZ; Section 3.1.2). The induction of STZ-diabetes was confirmed by the 
determination of fasting hyperglycaemia (>_ 25% above normal value which is around 
140mg/dl) on Control Day. 
Effects on basal glycaemia 
On Control Day, water (10ml/kg) was orally administered (force-feed with a syringe) 
to lh fasted nO STZ rats at 0 min, and blood samples (0.3m1) were drawn from the 
tail tip at 60,90,120,180,240 and 360 minutes. The rats were kept unfed throughout 
this period. 
Rats with plasma glucose >_ 140mg/dll at 1 hour sampling time were chosen for the 
test, and randomly divided into various groups. 
On Test Day 1 (4 days after Control Day), rats (n=5) were orally dosed with one of 
the following: water (10ml/kg body weight) as a negative control; metformin 
(200mg/kg; Lipha), a well-known anti-diabetic agent (Section 1.1.9(b)), as a positive 
control; Thai karela juice (5ml or IOmlfkg) or Kenyan karela juice (5m1 or 1Oml/kg). 
Blood sampling was carried out at the same time points as on Control Day. 
Apart from studying the acute effect of karela juice by single dose administration on 
Test Day 1, the cumulative effect of karela juice was also examined. In order to 
investigate the effect of cumulative administration of karela juice, the different 
treatments were given for four consecutive days and the experimental procedures 
were repeated on Test Day 4. 
Effects on oral glucose tolerance test (OGTT) 
On Control Day, water (10ml/kg) was orally administered to 2h fasted nO STZ rats, 
30 min before an oral glucose challenge (2g/kg body weight; 2g in 5ml water; 
Merck). Blood samples (0.3m1) were drawn from the tail tip at 0 min (just before 
glucose was given) and at 10,20,30,45,60 and 90 min after glucose administration. 
The rats were kept unfed throughout this period. 
Rats with high OG values (>_ 400mg/dl; OG = the sum of the increase in plasma 
1 Units for glucose measurements: mg/dl = mmol/L x 18 
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glucose at all time points compared with time 0) were chosen for the experiment, and 
randomly divided into various groups. 
On Test Day 1 (3 days after Control Day), rats (n=6) were orally dosed (force-feed 
with a syringe) with one of the following: water (10ml/kg body weight) as a negative 
control, metformin (200mg/kg; Lipha) as a positive control, Thai karela juice 
(1Oml/kg) or Kenyan karela juice (5ml/kg)*. As on Control Day, oral glucose was 
given 30 min after the test substances and blood sampling was carried out at the same 
time points. 
To investigate the effect of cumulative administration of karela juice, the four 
different treatments were given for four consecutive days and the experimental 
procedures for OGTT repeated on Test Day 4. 
* From the preparation of karela juice, it was found that in order to obtain the same 
volume of juice, the ratio of weight of fruit flesh of Kenyan to Thai karela was 
approximately 2: 1. Thus the dosage of karela juice used in our testing was 5ml/kg 
(Kenyan) and 1 Oml/kg (Thai), so that a similar original weight of karela of the two 
different varieties were tested. 
Analysis of plasma glucose and insulin 
Blood samples were subjected to centrifugation (9000rpm; 5 min) and plasma 
separated from blood cells. Plasma glucose was measured with a glucose analyser 
(EBIO Analyser 6666 or Beckman Glucose Analyser 2) using a glucose oxidase 
method. Plasma insulin was measured by radioimmunoassay using a commercial kit 
(Sorin-Insik 5) with rat insulin (Novo Nordisk) as standard. 
In both studies (effects on basal glycaemia and oral glucose tolerance), results 
obtained for each treatment group on Control Day were compared with the results of 
that group on Test Days 1 or 4. Data obtained were evaluated using Student's paired 
t-tests so that each individual animal's results on Test and Control days were 
compared. Values were considered to be significantly different if p<0.05. 
3.2.2 Results 
3.2.2 (a) Effects of karela juice on basal glycaemia 
The effects of water and metformin on basal glycaemia in nO STZ diabetic rats are 
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shown in Table 3.1. Water (negative control) did not significantly decrease the mean 
plasma glucose at any time point on either Test Days 1 or 4. On the other hand, with 
metformin (an anti-diabetic drug which acts as a positive control in this study), there 
was a significant decrease at most time points on both Test Days 1 and 4. These 
results validate our experimental model. 
From the results (Table 3.2), for Thai karela juice 5ml/kg, there was no significant 
decrease in mean plasma glucose on Day 1. On Day 4, there was a decrease in mean 
plasma glucose at 60,90 and 120 min but none of these decreases were statistically 
significant (p > 0.05). When the dosage was increased to 10ml/kg, very similar 
results were obtained on Day 1. However, on Day 4, there was a larger decrease in 
mean plasma glucose at 60,90 and 120 min (p = 0.15,0.10 and 0.25 respectively) but 
none of them reached statistical significance at the accepted level of p<0.05. These 
results indicated that Thai karela may have a cumulative effect on basal blood 
glucose and a higher dose may result in a statistically significant effect. It is also 
interesting to note that at both dosages, there was an unexpected significant increase 
in mean plasma glucose at 360 min on Day 1, for which there was no clear 
explanation. 
In the case of Kenyan karela juice (Table 3.3), at doses of both 5 and 1Oml/kg, there 
was no significant difference in mean plasma glucose at any time points on either 
Test Days 1 or 4. 
From the negative results of both varieties of karela on basal glycaemia, it is not 
surprising to find that both varieties (at both dosages) had no statistically significant 
(p > 0.05) effect on the basal insulin levels (Tables 3.4 and 3.5). However, the fact 
that there was an increase (though not statistical significant; 0.05 <p<0.1) in mean 
plasma insulin level for Thai karela juice at dose of 5m1/kg (Test Day 1) and Kenyan 
karela juice at dose of 5m1/kg (both Days 1 and 4) at some time points suggests that 
insulin may have been released. 
3.2.2 (b) Effects of karela juice on oral glucose tolerance 
The effects of water and metformin on plasma glucose in the oral glucose tolerance 
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not significantly affect glucose tolerance at any time point on either Days 1 or 4. On 
the other hand, with metformin, there was a significant decrease of mean plasma 
glucose at most time points on both Day 1 and Day 4. These results validate our 
experimental model. 
Figure 3.3 shows the anti-hyperglycaemic effects of juice from both varieties of 
karela in nO STZ diabetic rats-For Thai karela (Fig. 3.3a), the reduction in plasma 
glucose at individual time points on Test Day 1 did not reach statistical significance 
although mean values were lower than control. However, mean OG was significantly 
reduced by 29% (p < 0.05). Cumulative treatment resulted in a better improvement in 
oral glucose tolerance (Test Day 4); with a significant decrease in plasma glucose at 
20,30,45 and 60 min and a reduction of mean AG by 38% (p < 0.05). 
For Kenyan karela (Fig. 3.3b), single day treatment significantly decreased plasma 
glucose levels at 20,30 and 45 min. Although mean plasma glucose values for the 
cumulative treatment were similar to the single treatment, these were not 
significantly different from control, probably due to greater variation in values. 
Neither acute nor cumulative administration of Kenyan karela produced a statistically 
significant reduction in mean OG. 
The effects of both varieties of karela on plasma insulin levels are shown in Figure 
3.4. For Thai karela (Fig. 3.4a), acute administration of the juice (Day 1) resulted in a 
large increase in mean plasma insulin at 10 min, though it did not reach statistical 
significance. However, cumulative administration caused a significant increase in 
phase I insulin secretion (0,10 min). 
For Kenyan karela (Fig. 3.4b), an increase in the overall area under the plasma 
insulin curve was observed on both Days 1 and 4 but differences from control did not 
reach statistical significance apart from at the 20 min time point on Day 4. 
No significant effect on plasma insulin levels was observed with either acute or 
cumulative administration of water (Appendix 1) which validates our results. 
3.2.3 Discussion 
In most (if not all) previous animal studies on karela (Raman and Lau, 1996), 
experiments were designed so that separate control and treatment groups were used. 
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Chapter 3: In vivo studies on karela fruit 
In contrast, in our present study, experimental design and the method of interpreting 
the results was to compare the results obtained within each treatment group on 
Control Day with Test Days 1 and 4. Since each rat may react differently despite the 
same experimental conditions, the advantage of this method was to compare the 
results of individual rats on Control Day with Test Days 1 and 4. Here, assumption 
was made that the same rat will react in the same way on different days provided the 
experimental conditions were kept constant. To demonstrate this, the mean plasma 
glucose of the 6 rats in which water was given on Control Day, Test Days 1 and 4 (in 
the oral glucose tolerance test) is given in Table 3.6. There was no significant 
difference either between the mean plasma glucose on Control Day and Test Day 1 or 
between the values on Control Day and Test Day 4. Furthermore, this method of 
interpretation only requires a small number of rats for each treatment group as there 
is no need to account for inter-individual variation. 
From the results, both Thai and Kenyan karela did not produce a statistically 
significant effect on basal glycaemia on NIDDM model rats at the tested doses (5 or 
10ml/kg body weight). In this context, our results were contradictory to some 
previous researchers who had demonstrated a hypoglycaemic effect on acute 
administration of karela juice/extracts in both normal animals (Leatherdale et al., 
1981; Karunanayake et al., 1984; Chandrasekar et al., 1989) and diabetic animals 
(Sharma et al., 1960; Higashino et al., 1992; Ali et al., 1993a). However, our results 
indicated that Thai karela, but not Kenyan karela, showed an apparent cumulative 
decreasing effect on basal blood glucose and a statistically significant effect may be 
seen if higher dosages are used. Kulkarni and Gaitonde (1962) reported no reduction 
in fasting glucose levels on either acute or cumulative administration of dried karela 
juice to normal animals. These conflicting results may be due to variations in blood 
sampling times and the variety, dosages and preparations of karela used, as well as 
the diabetic status (IDDM, NIDDM or normal) of the animals. 
In contrast, our results from the oral glucose tolerance test confirmed that both 
varieties exhibited anti-hyperglycaemic activities though not to the same extent. Both 
varieties of karela juice produced a significant improvement in OGTT, of which the 
effect of Thai karela was more pronounced. The results of plasma insulin 
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measurement showed that this improvement in OGTT was due, at least in part, to an 
increase in insulin secretion in response to glucose, mainly in the first phase. 
In healthy (non-diabetic) humans, glucose administration is known to promote an 
initial (phase I) stimulation of insulin within the first 5-10 min (Section 1.1.7). In 
NIDDM patients however, there is an impairment in this first phase of insulin 
secretion (Cerasi et al., 1972; Robertson, 1992). A similar deficiency is observed in 
the nO STZ model used in the present study (Portha et al., 1979; Giroix et al., 1983), 
as shown in Fig. 3.4 (control graphs). In fact, these rats are mildly hyperglycaemic 
with many characteristics features close to human NIDDM (Fig. 3.2). Thus the 
improvement of both glucose tolerance and phase I insulin response in these animals 
may be of significance to the treatment of NIDDM patients using karela. 
Based on an extensive literature search (Raman and Lau, 1996), it appears this is the 
first demonstration of an in vivo insulin secretagogue effect by karela despite reports 
of an effect in vitro (Welihinda et al., 1982a, b; Ali et al., 1993b; Mosihuzzaman et 
al., 1994). The stimulation of phase I insulin secretion reported here, may have been 
missed in earlier studies on humans (Leatherdale et al., 1981) or animals 
(Leatherdale et al., 1981; Day et al., 1990; Sarkar et al., 1996), due to the later initial 
blood sampling times (30 min or more) employed previously. In addition, it is 
possible that stimulation of insulin secretion may not have been apparent in the 
particular models used. For instance, it may be masked in normal animals where a 
good phase I response already exists, or absent in models where almost complete 
destruction of ß-cells has occurred (Day et al., 1990; Sarkar et al., 1996). The doses 
of STZ employed in these latter studies would be expected to have an insulinopenic 
effect (Bailey and Flatt, 1990). Further studies on insulin stimulation by karela will 
be discussed in the following section (Section 3.3). No statistically significant 
alterations to plasma insulin level were observed in studies on basal glycaemia 
(Section 3.2.2(a)) but this may be due to the late sampling time for the first blood 
sample (60 min after the administration of karela juice). 
Since Thai karela (10ml/kg) gave a more significant improvement on oral glucose 
tolerance than Kenyan karela (5ml/kg), our further research studies (as discussed in 
the following chapters) were focused solely on Thai karela. 
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3.3 Investigation on the dose-response effect of karela on 
oral glucose tolerance 
In the previous section (3.2.2(b)), both varieties (Thai and Kenyan) of karela were 
shown to improve oral glucose tolerance and stimulate phase I insulin secretion, 
though to a different extent. Thus, the dose-response effect of the two varieties of 
karela on oral glucose tolerance was examined. 
3.3.1 Materials and methods 
Freshly prepared karela juices(both varieties) were used in the study. The same nO 
STZ NIDDM rat model was employed and an oral glucose tolerance test was carried 
out (same experimental procedures as described in Section 3.2.1). The dosages of 
karela juice (for both varieties) used were 5,10 and 15m1/kg of body weight. As 
before, treatment was administered for 4 days and both acute (after single dose 
treatment) and cumulative (after 4 days of treatment) effects of karela on oral glucose 
tolerance were studied. Plasma glucose and insulin were measured. Water and 
metformin controls were performed as before (results not shown). 
3.3.2 Results 
Plasma glucose 
From the results (Fig. 3.5; Table 3.7), for Thai karela juice, 5m1/kg dose improved 
oral glucose tolerance after single treatment but only reached statistical significance 
at 2 time points, with mean AG reduced by 28% (p = 0.171). However, cumulative 
treatment with 5m1 dose improved oral glucose tolerance significantly at most time 
points, with mean AG reduced by 33% (p = 0.065) as compared with control. As the 
dose was increased to 10ml/kg, a similar result was obtained with the single dose 
where plasma glucose was only significantly reduced at 2 time points, with a mean 
AG reduction of 22% (p = 0.153). However the cumulative treatment had a more 
pronounced improvement in oral glucose tolerance, with a significant decrease in 
plasma glucose at all time points, where the mean AG was reduced by 17% (p = 
0.051). As the dose was further increased to 15m1/kg, even a single dose produced a 
significant improvement in oral glucose tolerance at 4 time points, with a mean AG 
reduction of 27% (p = 0.114). The cumulative treatment reduced mean plasma 
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Figure 3.5: The dose-response effect of orally administered Thai/Kenyan karela juice 
(5,10 or 15 ml/kg body weight) on oral glucose tolerance (2g/kg) in 2h 
fasted nO STZ diabetic rats (n=5 or 6). Glucose challenge was given at time 
0; karela juice was given 30 min before glucose. Values of plasma glucose 
are mean ± SEM. 
*p<0.05, ** p<0.02, *** p<0.01 as compared with control, by Student's paired t-tests. 
142 
Figure 3.5 (continued): Chapter 3: In vivo studies on karela fruit 











----0-- BEFORE TREATMENT (CONTROL) 
-- *- - AFTER TREATMENT (DAY 1) 
I AFTER TREATMENT (DAY 4) 
TIME (MIN. ) 
143 
0 20 40 60 80 100 














Chapter 3: In vivo studies on karela fruit 
KENYAN KARELA JUICE 5mI/kg 
--0--- BEFORE TREATMENT (CONTROL) 
- AFTER TREATMENT (DAY 1) 




20 40 60 80 100 




KENYAN KARELA JUICE 10mi/kg 
---0- BEFORE TREATMENT (CONTROL) 
-- h-- AFTERTREATMENT(DAY1) 









__ ý ýý ;ý- __ 
_''ý 
100 
0 20 40 60 
TIME (MIN. ) 
80 100 
144 
Figure 3.5 (continued): 
Chapter 3: In vivo studies on karela fruit 









-0-- BEFORE TREATMENT (CONTROL) 
400 
-- -A- - AFTER TREATMENT (DAY 1) 







20 40 60 80 100 
TIME (MIN. ) 
a 
145 
Chapter 3: In vivo studies on karela fruit 
Table 3.7: Effect of orally administered karela (Thai or Kenyan; 5,10 
or 15m1/kg body weight) on oral glucose tolerance (2g/kg) 
in 2h fasted nO STZ diabetic rats. Glucose was given at 
time 0; karela was given 30 min before glucose. 
*p < 0.1, **p < 0.05, ***p < 0.02. ****p < 0.01 compared with control, by Student's paired t- 
tests. OG = the sum of the increase in plasma glucose at all time points compared with time 0. 
Treatment OG 
mean ± SEM % reduction 
Thai karela 
Dose: 5mlJkg 
Control Day (n=6) 783.2 ± 81.4 --- 
Day 1 (n=6) 564.2 ± 75.8 28.0 
Day 4 (n=6) 523.5 ± 89.5 * 33.2 * 
Dose: 10ml/kg 
Control Day (n=6) 614.8 ± 102.3 ----- 
Day 1 (n=6) 481.8 ± 82.8 21.6 
Day 4 (n=6) 512.3 ± 68.0 * 16.7 * 
Dose: 15nil/kg 
Control Day (n=5) 611.6 ± 75.4 
Day 1 (n=5) 446.4 ± 92.7 27.0 
Day 4 (n=5) 460.8 ± 81.8 ** 24.7 ** 
Kenyan karela 
Dose: 5ml/kg 
Control Day (n=6) 624.0 ± 87.0 
Day 1 (n=6) 499.3 ± 166.2 20.0 
Day 4 (n=6) 414.3 ± 44.5 * 33.6 * 
Dose: lOml/kg 
Control Day (n=6) 740.3 ± 45.8 ----- 
Day 1 (n=6) 493.0 ± 73.5 *** 33.4 *** 
Day 4 (n=6) 516.3 ± 62.8 **** 30.3 **** 
Dose: 15ml/kg 
Control Day (n=6) 658.5 ± 109.5 ----- 
Day 1 (n=6) 545.2 ± 97.0 ** 17.2 ** 
Day 4 (n=6) 654.3 ± 93.1 0.6 
4 
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glucose but this was significant at only one time point, probably due to greater 
variation in values; however it resulted in a significant reduction in mean AG by 25% 
(p = 0.041). In addition, with all three dosages, the mean plasma glucose levels at 0 
min on Day 4 were all lower than control and for two of them (at doses of 5 and 
10ml/kg) the differences reached statistical significance. 
For Kenyan karela juice, a single 5m1/kg dose improved mean values in the oral 
glucose tolerance curve but none of the time points reached statistical significance. 
However, the cumulative treatment with the same dosage resulted in significant 
reduction in plasma glucose at all time points and a reduction of mean AG by 34% (p 
= 0.087). When the dose was increased to 10ml/kg, the improvement in oral glucose 
tolerance was more pronounced in both acute and cumulative treatments, with a 
significant reduction in mean AG by 33% (p = 0.016) and 30% (p = 0.006) 
respectively. As the dose was further increased to 15ml/kg, instead of having a more 
pronounced improvement in oral glucose tolerance than that observed with the dose 
of 10ml/kg, both the acute and cumulative treatments improved oral glucose 
tolerance to a much smaller extent, and only the acute and not the cumulative 
treatment produced a significant reduction in mean AG (Table 3.7). However, the 
mean plasma glucose levels at 0 min on Day 4 were lower than control with all three 
dosages, with significant reduction at doses of 5 and 15ml/kg. 
Plasma insulin 
The effects of both Thai and Kenyan karela juice (at different dosages) on plasma 
insulin in nO STZ diabetic rats, in response to an oral glucose load (2g/kg) are shown 
in Table 3.8. From the results obtained, a 5m1/kg single dose of Thai karela juice 
caused a decrease in plasma insulin at all time points, where the reduction in plasma 
insulin reached statistical significance at some time points. The cumulative 
administration of Thai karela juice (at the same dosage) resulted in a larger decrease 
in plasma insulin at most time points. As the dosage of Thai karela juice increased to 
10 or 15ml/kg, similar results were obtained: both acute and cumulative 
administration resulted in reduction in plasma insulin at all time points, where 
cumulative administration had a more pronounced effect. However, the increase in 
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dosages of Thai karela juice did not produce a larger reduction in plasma insulin. 
Very similar results were obtained with different dosages of Kenyan karela juice. 
3.3.3 Discussion 
In this experiment, the dose-response effect of karela (both varieties) on oral glucose 
tolerance was examined. If the dosage and response are in a linear relationship, then 
one will expect that as the dose increases, a greater effect will be obtained. However, 
this seems not to be the case in this study. From the results, we observed that for both 
Thai and Kenyan karela, as the oral dose increased from 5m1/kg to 10ml/kg, the 
improvement on oral glucose tolerance became more significant. But as the dosage 
was further increased to 15m1/kg, the improvement on oral glucose tolerance 
appeared to be of a smaller extent than that of 1Oml/kg. This suggests that IOml/kg 
may be the optimum dose which can be used in this particular nO STZ diabetic rat 
model. There are a few possible explanations for the reduced effect with the high 
dose of 15ml/kg. One explanation is that the volume used might be too large for the 
rats which caused diarrhoea and resulted in incomplete absorption. of the dose 
(Kergoat, 1997). If this was the case, then we might have seen a loss in weight for the 
rats that were treated with the high dose of 15m1/kg during the four days of treatment. 
However, from the results (Appendix 2), weight reduction in rats treated with high 
dose (15mlIkg) of karela (both varieties) juice was not seen during the four days 
treatment period. Instead, there was a weight gain in both cases, though the weight 
gain was not statistically significant with high dose of Thai karela juice. Another 
possible explanation is that the amount of glucose (if present) in karela juice might 
have been absorbed, and so as the dose increased, more glucose (from karela juice) 
was absorbed which might have affected the results. By using quantitative HPLC 
(High Performance Liquid Chromatography), glucose was found to be present in both 
varieties of karela juice and the concentrations were ranged between 8-11mM and 7- 
8mM in Thai and Kenyan karela juice respectively (Appendix 6). From the 
calculations (Appendix 3), at a dose of 15m1/kg of karela juice, about 0.0095g extra 
glucose will be available for absorption. This is only a small quantity (about 1%w/w) 
as compared to the amount of glucose given in the oral glucose tolerance test (2g/kg, 
i. e. 0.7g for a rat weighing 350g). Therefore even if the glucose present in karela 
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juice was absorbed, it is unlikely to have affected the results of the oral glucose 
tolerance tests. However, on a closer examination of the results, the tailing effect 
with the high dose (15m1/kg) may not be a genuine effect. For instance, in the case of 
Thai karela juice, 
Dose: 10mUkg % reduction in mean OG = 21.6 (Day 1); 16.7 (Day 4) 
Dose: 15m1/kg % reduction in mean OG = 27.0 (Day 1); 24.7 (Day 4) 
a larger increase in % reduction in mean OG was observed between 10 and 15m1/kg 
dosages. However, in the case of Kenyan karela juice, 
Dose: 10ml/kg % reduction in mean OG = 33.4 (Day 1); 30.3 (Day 4) 
Dose: 15m1/kg % reduction in mean OG = 17.2 (Day 1); 0.6 (Day 4) 
a sharp decrease in % reduction in mean OG was obtained between 10 and 15m1/kg 
dosages. In addition, tolerance might have developed which explained the Day 4 
result at dose of 15m1/kg. Thus the dose/response may differ with the variety of 
karela tested. 
Apart from the above, the basal glycaemia (plasma glucose at time 0, just before the 
glucose challenge) was always lowered on Day 4, and in some cases, it reached 
statistical significance (Fig. 3.5). This suggests that both varieties of karela had an 
overall improvement in hyperglycaemia. This was postulated earlier (Section 3.2.3). 
It is surprising to note that the initial (phase I) stimulation of insulin by karela (which 
was reported earlier in Section 3.2) was not observed here (Table 3.8), despite the 
fact that same experimental conditions were used. Instead of a rise in plasma insulin, 
both varieties of karela, at all different dosages, caused a decrease in insulin levels at 
all time points. These results are contradictory to what we observed earlier (Fig. 3.4). 
However, a detailed examination of the data obtained suggested that the insulin 
results may be unreliable, due to the fact that acute and cumulative treatment with 
both water and metformin (as controls) also resulted in a decrease in plasma insulin 
at most time points (Table 3.9). Another possible explanation is that different batches 
of karela were used in these experiments which may account for the variations in 
results. 
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Further experiments are required in order to confirm the insulin-stimulating effect of 
karela. However, the present results suggested that the anti-hyperglycaemic effect of 
karela was most likely caused by mechanisms other than insulin stimulation. 
This study indicates that the dose and the variety of karela tested may affect the 
results of the oral glucose tolerance obtained. In addition, the dose-response 
relationship for karela was not linear, i. e. increase in dosage did not always result in 
an increase in response. This study is believed to be one of the first detailed 
investigation on the dose-response effect of two varieties (Thai and Kenyan) of karela 
on oral glucose tolerance using a diabetic animal model, though various dosages of 
karela had been tested with regard to its anti-diabetic effect by previous researchers 
on separate occasions in diabetic animals (Raman and Lau, 1996). For example, 
Karunanayake et al. (1984) studied the effect of karela juice (0.25,0.5 and 1ml/l00g 
body weight of Sprague-Dawley rat) on glucose tolerance and the variation of effect 
with dose was noted. 
3.4 Effect of whole karela juice, the supernatant and the 
sediment on oral glucose tolerance 
It was found that solids in fresh Thai karela juice (prepared as described in Section 
3.2.1) sedimented out on standing to give a clear liquid on top and fine residue at 
bottom. As a result, an oral glucose tolerance test was carried out to see if the anti- 
hyperglycaemic activity resided in the supernatant or the sediment. 
3.4.1 Method 
The experimental procedures for the oral glucose tolerance test were the same as before. 
The four different treatment, groups were: water (10ml/kg body weight) as a control, 
whole karela juice (IOml/kg), supernatant (IOml/kg) and sediment (IOml/kg). The 
supernatant and sediment were separated by centrifuging the whole juice. The 
sediment was resuspended in water before administration. The dosages of both 
supernatant and sediment used in the test were equivalent to 10ml/kg of whole karela 
juice. The different treatments were given for four consecutive days and the blood 
sampling was carried out on Test Day 4. 
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3.4.2 Result and discussion 
From the results (Fig. 3.6), the cumulative effects (after four days of treatment) of 
both the supernatant and the sediment improved oral glucose tolerance to a very 
similar extent, though in both cases, the plasma glucose level at all individual time 
points did not reach statistical significance. However, the effects of the supernatant 
and the sediment were only half of that produced by the whole juice, in which there 
was a significant decrease in plasma glucose at most time points. These results 
suggested that the anti-diabetic compound(s) was present in both the supernatant and 
sediment (may be in very similar concentration) and therefore the whole juice was 
used for future testing. 
3.5 Investigation of karela juice solvent extracts on oral 
glucose tolerance 
From the results obtained so far, it was shown that whole karela juice of Thai variety, 
at dosage of 10mUkg, had the most promising improvement on oral glucose tolerance 
in nO STZ NIDDM model. Thus attempt was made to fractionate the whole juice in 
order to further study the active ingredient(s) and the mode of action. 
3.5.1 Materials and methods 
Preparation of karela extracts 
Freshly prepared karela juice (Thai variety only) was frozen immediately (after 
preparation as in Section 3.2.1) and later freeze-dried. The freeze-dried juice 
(approximately 30g dry weight equivalent to 1 litre juice) was sequentially extracted 
(using Soxhlet extraction) with solvents (of increasing polarity) in the following 
order: hexane, chloroform, methanol and water, for 6 hours each time. Each extract 
was evaporated to dryness using a rotary vacuum evaporator. Figure 3.7 showed the 
TLC zone profiles of the constituents of the different extracts, apart from the water 
extract in which no suitable solvent system was yet found to move the extract up the 
baseline. As shown on the TLC plates, the three different extracts contained different 
constituents. From the sequential solvent extraction, one would expect the most non- 
polar compounds to be extracted in the hexane extract, whereas the most polar 
compounds would be retained in the water extract. 
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For in vivo studies, residues were made up to the equivalent volume of juice from 
which they were extracted. Hexane and chloroform extracts were each reconstituted 
in 0.3% v/v Tween 80 in water (since these extracts are insoluble in water and Tween 
80 acts as a solublising agent (Martindale, 1996)). Methanol and water extracts were 
each reconstituted and made up to volume using water since they were water soluble. 
Animals 
Adult Wistar nO STZ induced NIDD rats were used as before. 
Effects on oral glucose tolerance test (OGTT) 
The same experimental procedures were used as before (Section 3.2.1). In addition to 
the four different test extracts, water (10m1/kg), 0.3% v/v Tween 80 in water 
(10ml/kg) and metformin (200mg/kg; 200mg in 10ml water) were used as controls 
for validating the experiment. Since hexane and chloroform extracts were 
reconstituted in 0.3% v/v Tween 80, those rats were given Tween instead of water on 
Control Day (Appendix 4). The dosages of extracts used in the test were equivalent 
to l Oml/kg of whole karela juice: 





Both acute (single treatment) and cumulative (4 days treatment) effects of the four 
extracts on oral glucose tolerance were investigated. Both plasma glucose and plasma 
insulin were measured as before (Section 3.2.1). 
3.5.2 Results 
Since Tween 80 was introduced in this experiment as a solublising agent for the non- 
polar extracts (hexane and chloroform extracts), it was necessary to check if Tween 
itself had any effect on oral glucose tolerance. Table 3.10 shows the results with the 
three controls: water, metformin and 0.3% v/v Tween 80. As expected, water (as a 
negative control) had no significant effect on oral glucose tolerance, whereas 
metformin (a positive control) exhibited a significant improvement in oral glucose 
tolerance on both acute and cumulative treatment. In the case of 0.3% v/v Tween 80, 
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which acts as a negative control, a slight improvement in oral glucose tolerance was 
observed, though the reduction of plasma glucose at all time points did not reach 
statistical significance on both Days 1 and 4. These results validated our 
experimental model. 
From the results of the test extracts (Fig. 3.8), among the four different karela 
extracts, only the hexane and water extracts significantly improved oral glucose 
tolerance, where a more pronounced effect was found on Day 4 (as compared to Day 
1) in both cases. Both acute and cumulative treatment with chloroform extract did not 
improve oral glucose tolerance. In addition, it is interesting to note that the methanol 
extract had a tendency of increasing plasma glucose at most time points on Day 1, 
though the differences did not reach statistical significance. On Day 4, there was a 
slight decrease in mean plasma glucose at most time points, though again this did not 
reach statistical significance. 
The effect of all four extracts on plasma insulin in response to the oral glucose load 
was shown in Fig. 3.9. The results showed that both hexane and water extracts, after 
acute or cumulative administration, caused a rise in mean plasma insulin at 10 min 
time point (phase I release, Section 1.1.7), though the rise in all cases did not reached 
statistical significance. However, this phase I insulin release was not observed with 
both the chloroform and methanol extracts, though the plasma insulin level at time 0 
on both Days 1 and 4 was significantly raised with the chloroform extracts. 
3.5.3 Discussion 
In the previous chapter, the TLC zone profile (Fig. 2.13) of the whole Thai karela 
juice revealed that it contained many compounds. In order to find out which 
compound(s) is responsible for the anti-hyperglycaemic effect, it was necessary to 
fractionate the whole juice. Here, a sequential soxhlet extraction using solvents of 
different polarities was employed for the initial fractionation of the whole juice. This 
method aims to extract different groups of compounds into different solvents, 
according to their polarities (as shown in Fig. 3.7). In this case, one expected the 
most non-polar compounds would have been extracted by hexane, then slightly more 
polar compounds would have been extracted by chloroform, followed by methanol, 
and finally the most polar compounds would go into the water extract. However, it is 
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important to note that there is always a possibility for some compounds to have 
appeared in more than one solvent, due to incomplete extraction. 
Among the four different karela extracts, only hexane and water extracts were found 
to be active in improving oral glucose tolerance in our NIDD model rats. This 
suggests that Thai karela contains at least two active components: a non-polar 
compound and a very polar compound. The slight improvement (though not 
significant) on oral glucose tolerance by the methanol extract (only after cumulative 
treatment) may be due to the presence of traces of the very polar component which 
was predominantly present in the water extract. 
Our results generally supported the findings by previous researchers. For example, 
Venkanna Babu et al. (1988) reported that glucose tolerance in alloxan recovered 
rabbits was improved by oral administration of a benzene extract of karela, but not an 
ethanolic extract. In this instance, ethanol, with a similar polarity as methanol, might 
not be polar enough to extract the very polar active component(s). In addition, 
Higashino et al. (1992) reported that a polar solvent extract of karela improved 
tolerance of orally administered glucose. 
One possible identity of the active component present in the water extract might be 
steroidal glycosides, such as charantin, a mixture of sitosterol and stigmastadienol 
glucosides, which had been previously reported as the active compound by Lotlikar 
and Rajarama Rao (1966). If this is the case, then the aglycone of the glycoside might 
be extracted in the hexane extract which is responsible for the activity. This is further 
investigated in a latter chapter (Section 5.8). 
In addition, it is interesting to look at the dosages of hexane and water extracts which 
gave a significant improvement in oral glucose tolerance. About 2mg/kg of hexane 
extract was enough to elicit a response, whereas about 1 00mg/kg of water extract was 
required for a similar response. Though the improvement of oral glucose tolerance by 
both extracts was much less than that produced by metformin, a much higher dose of 
metformin was employed in the tests (200mg/kg). 
The possible stimulation of phase I insulin release by both hexane and water extracts 
corresponds to the insulin stimulation by whole karela juice reported earlier (Section 
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3.2.2(b)) although this was not observed in Section 3.3. These results again suggested 
that there may be a connection between the anti-hyperglycaemic effect of karela and 
the stimulation of phase I insulin release. This is based on the fact that only the 
hexane and water extracts which exhibited an initial rise in plasma insulin resulted in 
a significant improvement in oral glucose tolerance, whereas both chloroform and 
methanol extracts did not stimulate phase I insulin release and also had no significant 
effect on oral glucose tolerance. 
3.6 Investigation of the mode of action of karela extracts 
The previous experiment illustrated that both hexane and water extracts had 
significant effect on oral glucose tolerance. In order to further understand the mode of 
action of these extracts, their effects on intravenous and intraperitoneal glucose 
tolerance were studied. 
3.6.1 Effects on intravenous glucose tolerance test (IVGTT) 
Method 
On Control Day, either water (10ml/kg) or 0.3% v/v Tween 80 (10ml/kg) was orally 
administered to 2h fasted rats, i. e. 45 min before an intravenous glucose (0.5g/kg) 
challenge. The rats were then immediately anaesthetised by intraperitoneal injection 
of sodium pentobarbitone (Sanofi; 5mg/100g body weight (see Appendix B)). Blood 
samples (0.3m1) were drawn from the tail tip at 0 min (just before glucose was 
administered intravenously via the saphenous vein) and at 5,10,15,20 and 30 min 
after glucose administration. The rats were unconscious throughout this period. 
Three days later, 5 groups of rats (n=6) were orally dosed with one of the following 
for 4 consecutive days: either water (10ml/kg) or 0.3% v/v Tween 80 (10ml/kg) as 
negative controls, metformin (200mg/kg; 200mg in 10ml) as a positive control, or 
hexane extract (10ml/kg) or water extract (10ml/kg) as test substances. The dosages 
of extracts used in the testing were the same as in OGTT (Section 3.5.1). On Test 
Day 4, (as on Control Day), the rats were anaesthetised and intravenous glucose was 
given 45 min after the test substances and blood sampling was carried out at the same 
time points. Plasma glucose and insulin were measured. 
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Results 
The experimental model was validated with the results obtained with the negative 
controls (water and 0.3% v/v Tween 80) and the positive control (metformin). From 
the results shown in Fig. 3.10, both extracts, after cumulative administration, did not 
improve intravenous glucose tolerance, and neither did they have any stimulatory 
effects on plasma insulin (Table 3.11). In fact, the water extract had a tendency of 
reducing plasma insulin level, in which the level at two of the time points reached 
statistical significance. 
3.6.2 Effects on intraperitoneal glucose tolerance test (IPGTT) 
Method 
On Control Day, either water (10ml/kg) or 0.3% v/v Tween 80 (10ml/kg) was orally 
administered to 2h fasted rats, 30 min before an intraperitoneal (using a needle) 
glucose (2g/kg; 2g in 5m1) challenge. Blood samples (0.3m1) were drawn from the 
tail tip at 0 min (just before glucose was administered intraperitoneally) and at 5,10, 
15,20,30,45,60 and 90 min after glucose administration. The rats were kept unfed 
throughout this period and no anaesthetic was required. 
Three days later, 5 groups of rats (n=6) were orally dosed with one of the following 
for 4 consecutive days: either water (10ml/kg) or 0.3% v/v Tween 80 (10ml/kg) as 
negative controls, metformin (200mg/kg; 200mg in 10ml) as a positive control, 
hexane extract (10ml/kg) or water extract (10ml/kg) as test substances. The dosages 
of extracts used in the experiment were the same as in OGTT (Section 3.5.1). On 
Test Day 4, as on Control Day, intraperitoneal glucose was given 30 min after the test 
substances and blood sampling was carried out at the same time points. Plasma 
glucose and insulin were measured. 
Results 
The experimental model was validated with the results obtained with the negative 
controls (water and 0.3% v/v Tween 80) and the positive control (metformin). From 
the results (Fig. 3.11), hexane extract, but not water extract, improved intraperitoneal 
glucose tolerance after 4 days of treatment. The plasma glucose at most time points 
were significantly reduced. As shown on Fig. 3.12, the hexane extract appeared to show 
some stimulation of insulin release compared to control at 10 and 15 min time points, 
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though this was not statistically significant (p = 0.081 and 0.282 respectively). The 
water extract also resulted in an initial rise in mean plasma insulin compared to 
control (at 5 min time point), which again did not reach statistical significance (p = 
0.188). 
3.6.3 Discussion 
In the previous section (Section 3.5), both hexane and water extracts of karela juice 
were shown to improve oral glucose tolerance. By further studying their effects on 
intravenous and intraperitoneal glucose tolerance, one would expect a clearer picture 
on the mode of action of the two extracts to be revealed. From the results obtained, 
both hexane and water extracts significantly improved oral glucose tolerance but not 
intravenous glucose tolerance implying that Thai karela may inhibit glucose 
absorption from the gastrointestinal tract. Our result supports the finding by previous 
researchers (Meir and Yaniv, 1985) where in vitro glucose uptake by inverted gut 
was shown to be inhibited in the presence of extracts of karela fruit. However, no 
previous data could be found on the effect of karela juice/extracts on intravenous 
glucose tolerance. To the best of our knowledge, this is possibly the first IVGTT 
study carried out on karela. 
It is also interesting to note that only hexane extract and not water extract improved 
intraperitoneal glucose tolerance. This is contradictory to the results reported by Day 
et al. (1990) and Higashino et al. (1992) where in both cases, a polar solvent extract 
(aqueous extract used by Day et al. ) of karela was found to improve tolerance of both 
orally and intraperitoneally administered glucose. Regarding the mode of action, our 
results suggest that the hexane extract may also have some effects on the liver, since 
it seems to work when glucose passes through the hepatic portal vein (oral and 
intraperitoneal administration), whereas the water extract works primarily on the gut. 
In fact, the hepatic insulinomimetic effect of karela have been reported in previous 
studies. For example, in a recent study by Shibib et al. (1993), liver glucose-6- 
phosphate dehydrogenase (G-6-PDH) activity was elevated on in vivo administration 
of karela ethanolic extract by gastric intubation. This would enhance the utilisation of 
glucose by the liver leading to a lowering in blood glucose. In addition, the karela 
ethanolic extract was also reported to cause a depression in gluconeogenic enzymes 
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(glucose-6-phosphatase and fructose-l, 6-biphosphatase) which may again account for 
the hypoglycaemic effect. However, it is unlikely that the active compound(s) present 
in the polar ethanolic extract would also be present in our non-polar hexane extract. 
Thus from the results obtained so far, it is very likely that karela exhibits its anti- 
hyperglycaemic activity via a combination of modes of action. 
3.7 Conclusion 
In the following chapters, research work will be focused entirely on the hexane 
extract of karela (since this was the most active extract among those tested), in which 
its mode of action and its phytochemistry will be further investigated. 
In order to further investigate the effect of karela on glucose absorption in the gut, an 
in vitro model of intestinal glucose absorption using brush border membrane vesicles 
was employed. Detailed experimental procedures regarding the use of the in vitro 
model and the results obtained will be discussed in the next chapter (see Chapter 4). 
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4.1 Introduction 
4.1.1 Glucose transport 
Glucose is the major metabolic fuel for all mammalian cells. Glucose is transported 
across the small intestine by a two stage process: firstly, the entry of glucose into the 
epithelium across the brush border membrane; secondly, the efflux of glucose out of 
the cell across the basolateral membrane into the extracellular fluid near the blood 
capillaries, ready for absorption. Distinctly different glucose transport systems have 
been shown to be present in the two types of plasma membranes isolated from the 
small intestine (Murer et al., 1974). The major transport mechanism in the brush 
border membrane is the Na/glucose co-transport system, SGLT1, where glucose is 
transported across the membrane into the cells against its concentration gradient 
through a coupling to the sodium electrochemical potential gradient across the 
membrane (Semenza et al., 1984; Hediger et al., 1987). A low intracellular 
concentration of Na+ is maintained by the Na /K+-ATPase localised in the basolateral 
membrane (Stirling, 1972). Phlorizin (Fig. 1.9) binds specifically to the Na /glucose 
transporter, inhibiting glucose uptake from the gut (Sigrist-Nelson and Hopfer, 1974). 
The glucose accumulated into the intestinal epithelial cells is then transported across 
the basolateral membrane by a Nä -independent facilitated diffusion system 
(facilitative glucose transporter, GLUT-2) located on the basolateral membrane 
(Wright et al., 1980; Thorens, 1992; Mueckler and Holman, 1995). 
4.1.2 Fructose transport 
Sigrist-Nelson and Hopfer (1974) had suggested the existence of a distinct Na - 
independent transport system in the brush border membrane for D-fructose, which is 
different from that of D-glucose. The fructose transporter was later found to be 
facilitative transporter GLUT-5 (Mahraoui et al., 1992; Hyun and Martello, 1995). 
4.1.3 Use of an in vitro brush border membrane vesicle model 
As discussed in Section 1.2, for a compound to be anti-diabetic, one of the modes of 
action is to inhibit glucose absorption from the gastrointestinal tract. In the last 
chapter, both hexane and water extracts of karela were shown to improve oral 
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glucose tolerance (Fig. 3.8) but not intravenous glucose tolerance (Fig. 3.10) in nO 
STZ NIDDM model rats, suggesting that they may in fact work by inhibiting glucose 
uptake from the gut. In order to investigate this particular mode of action, an in vitro 
model using intestinal brush border membrane vesicles was employed. 
4.2 Brush border membrane vesicles (BBMI/) 
4.2.1 Introduction 
Brush border membrane vesicles are made from the tips of the microvilli of small 
intestine. BBMV are enclosed in a double-layer unit membrane, the interior 
representing the serosal side. They are spherical, with an average diameter of 350nm, 
, as shown in Fig. 4.1 (Wood, 1991). The vesicles are tightly sealed (Semenza et al., 
1984), thus they can accumulate solutes against a concentration gradient. More than 
90% of vesicles have the correct orientation to allow solute flux in vitro which 
coriectly models that in vivo (Haase et al., 1978). 
Advantages of the BBMV absorption model: 
a) BBMV are a microvillar membrane preparation free of organelles and 
endogenous substrates, and virtually free of metabolising enzymes. They enable 
the membrane events associated with absorption to be examined in isolation, in 
the absence of any metabolic effects (Kessler et al., 1978). 
b) BBMV are one of the most stable intestinal preparations available for studying 
transport. 
c) BBMV require only small amount of substrates (µl volumes). 
d) BBMV are a -very well-characterised model in terms of glucose uptake (Hopfer 
et al., 1973; Semenza et al., 1984; Wood, 1991). 
Here, BBMV were used as an in vitro model for studying the effect of karela 
juice/extracts on glucose uptake. 
4.2.2 Materials and method 
Brush border membrane vesicles were made from the tips of the microvilli of frozen 
rabbit small intestine. Frozen rabbit intestines were prepared as in Fig. 4.2. BBMV 
were prepared using the Mg 2+ precipitation method proposed by Schmitz et al. 
(1973), with the modifications of Kessler et al. (1978), summarised in Fig. 4.3. All 
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Freshly killed white New Zealand rabbit 
(by intravenous injection of pentobarbitone, 60mg/kg body weight) 
I 
Small intestine was dissected from the pyloric sphincter to ileo- 
caecal junction, and the mesentery was separated from the 
intestine 
Small intestine was placed in 200m1 ice-cold 154mM KCl 
The remaining mesentery and fat were removed, contents of the 
intestine were gently squeezed out 
The small intestine was cleaned in 200m1 fresh ice-cold KCl 
I 
Small intestine was cut longitudinally, washed thoroughly in 
KCI, and blotted dry between tissues 
I 
Small intestine was weighed and snap frozen in a plastic bag in 
liquid nitrogen 
Frozen small intestine was stored at -70°C 
Figure 4.2: Flow chart for the preparation of frozen rabbit small 
intestine 
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Frozen small intestine was thawed in 200m1 Buffer 1 and was cut into 
small pieces 
Mechanically vibrated for 1 minute using a Vibro-mixer (Vibromax) 
Solution was filtered under vacuum and the supernatant was made up to 
300m1 with Buffer 1 
(Connective tissues and muscles were removed) 
I 
0.61g MgC12 was added and stirred 
(Magnesium precipitation of nuclei, mitochondria, most of basolateral membranes 
and other cell debris) 
Solution was centrifuged at 4°C, 5000rpm, for 15 minutes 
The pellet was discarded, the supernatant was centrifuged at 4°C, 
17000rpm, for 30 minutes 
The supernatant was discarded, the pellet was resuspended in Buffer 2 
1 
The solution was centrifuged at 4°C, 17000rpm, for 40 minutes 
1 
The supernatant was discarded, the pellet was resuspended in lml Buffer 3 
The pelleted volume was measured and it was doubled using Buffer 3 
1 
The solution was passed 5 times through a 25 gauge needle 
(BBMV vesicles were formed) 
I 
The solution was divided into 0.26m1 aliquots and snap frozen in liquid 
nitrogen 
Buffer 1: 1 0mM mannitol, 2mM HEPES-Tris*, pH 7.1 
Buffer 2: 100mM mannitol, 0.1mM MgSO4i 2mM HEPES-Tris, pH 7.4 
Buffer 3: 300mM mannitol, 10mM HEPES-Tris, 0.1mM MgSO4, pH 7.4 
* HEPES = N-2-Hydroxyethylpiperazine-N'-2-ethanesulphonic acid 
Tris = 2-amino-(hydroxymethyl)propane-1,3-diol 
Figure 4.3: Flow chart for the preparation of BBMV 
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chemicals and reagents used were purchased from Sigma. 
4.3 Studies on glucose uptake using brush border membrane 
vesicles 
4.3.1 Materials and method 
The uptake of D-glucose into BBMV was performed according to the rapid filtration 
technique of Hopfer et al., 1973. 
One aliquot (0.26m1) of frozen BBMV was resuspended in 0.44m1 of Buffer 3 
(300mM mannitol, 10mM HEPES-Tris, 0.1mM MgSO4, pH 7.4). BBMV (20µl) 
were mixed with 40µl of 0.1mM D-glucose (Sigma) solution {0.1mM D-glucose in 
glucose incubation buffer (100mM NaSCN, 100mM mannitol, 10mM HEPES-Tris 
(Sigma), pH 7.4) containing D-[2-3H]glucose (Amersham) to a specific activity 
approximately 25000cpm} and placed in a water bath at 25°C. In order to obtain a 
time profile of glucose uptake into BBMV, glucose uptake was stopped after certain 
incubation times (0,10,20,40,60,120,300 and 3600 seconds) by addition of lml 
ice-cold stop-wash buffer (200mM NaCl, 10mM HEPES-Tris (pH 7.4), 250µM 
phlorizin (Fig. 1.9; Sigma)) to the incubated mixture, followed by rapid filtration 
through a pre-wetted 0.45µm cellulose acetate/nitrate Millipore filter. The filter was 
washed 5 times with 1ml of the same ice-cold stop-wash buffer. The filters, which 
retained the BBMV, were each placed in a minivial together with 3.5m1 scintillation 
fluid (Ready-protein scintillation cocktail; Beckman-RHC Ltd. ) and were counted for 
5 minutes in the appropriate [3H] channel of the liquid scintillation counter (LKB 
Wallac Instruments Ltd. ). All reactions were performed with 3 repeats and the mean 
values were calculated. Control incubations containing 40µ1 of 0.1mM [3H]-labelled 
D-glucose solution (without the addition of BBMV) were also filtered as above in 
order to measure non-specific binding of D-glucose to the filters, and corrections 
were applied to the glucose uptake values. 
Glucose uptake was expressed as picomoles (pmoles, 10-12) of glucose/mg protein 
using the following equation: 
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Glucose uptake = 
corrected cpm amount of glucose added (pmoles) 
---------------------------------- x ------------------------------------------------------------------- 
mean cpm for control samples protein concentration of BBMV x volume of BBMV (ml) 
Corrected cpm (counts per minute) _ 
actual measured value - value for non-specific binding to filter. 
Mean control cpm = 
total activity (in this case, the activity of 40µl 0.1mM radiolabelled D-glucose). 
Amount of glucose added in pmoles: 
in this case, 40µ1 of 0.1mM D-glucose, 
0.1mM =_ O. 1mM/L = 0.1µM /ml - 0.1nM4tl 100pmoles/µl, 
i. e. for 40p1, there were 4000pmoles. 
volume of BBMV added: in this case, 20µl = 0.02ml. 
The protein concentration of BBMV suspension was determined according to the 
method of Bradford (1976), with modifications by Read and Northcote (1981). This 
protein determination method involved the binding of the dye, Coomassie Brilliant 
Blue G-250 (C47H48N3O7S2Na), to the protein sample, followed by measurement of 
the change in absorbance at 595nm due to the formation of a blue dye-protein 
complex. Protein concentration was expressed in mg/ml. 
Preparation of dye reagent 
10mg of Coomassie Brilliant Blue G-250 (Sigma) was dissolved in 5m1 of 95% 
ethanol. To this solution, 10ml of 85%w/v phosphoric acid (BDH chemicals Ltd. ) 
was added. The resulting solution was diluted to a final volume of 100ml. The final 
concentrations in the reagent were 0.01%w/v Coomassie Brilliant Blue G-250, 
4.7%w/v ethanol and 8.5%w/v phosphoric acid. 
Preparation of BBMV test samples 
One aliquot (0.26m1) of frozen BBMV was resuspended in 0.44ml of water (instead 
of Buffer 3). Three dilutions (using water) were made for the assay: 1 in 10; 1 in 50 
and 1 in 100 dilutions. 
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Protein assay 
Bovine serum albumin (Fraction V, 98-99% albumin; Sigma) was used. A standard 
protein solution lmg/ml was prepared. The preparation of standard solutions for the 
calibration curve was shown in Table 4.1. 
Table 4.1: Preparation of standard solutions for the calibration curve for 
protein assay 

















For the calibration curve, dye reagent (950gl) was added to 50µl of protein solutions 
A-F containing 0-50µg of protein. Absorbance at 595nm (A595) was measured (using 
a UV/VIS spectrophotometer; Perkin Elmer UV/VIS Spectrometer Lambda 2) 
against a water blank within the first hour, since the dye binding process completed 
in approximately 2 min with good colour stability for 1 hour (Bradford, 1976). All 
measured As9s were corrected by subtraction of the A595 obtained using solution A. 
Samples were assayed in duplicate and mean results were obtained. The same assay 
procedures were used for the BBMV test samples, i. e. 950µl of dye reagent was 
added to 50µ1 of each of the three dilutions of BBMV samples. Thus the protein 
concentration of BBMV can be calculated by taking the mean of the three results 
obtained from the 3 dilutions. The protein assay was carried out for each batch of 
BBMV. 
4.3.2 Results 
The results of the protein assay for a particular batch of BBMV are presented in 
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Appendix 5. In this case (Appendix 5), the protein concentration was 3.5mg/ml. 
Using the equation, mean glucose uptake (expressed as pmoles/mg protein) at each 
time point was calculated. A typical glucose uptake profile in BBMV is drawn and 
shown in Fig. 4.4. From the graph, a rapid initial glucose uptake was observed which 
reached the peak at 20 seconds (696.8 pmoles/mg protein), and then gradually 
declined to below 100 pmoles/mg protein at 3600s. 
4.3.3 Discussion 
According to Hopfer et al. (1973), glucose uptake by BBMV represents entry into an 
intravesicular aqueous space rather than binding to the membrane. In addition, the 
presence of sodium in the medium (but not in the intravesicular spaces) stimulates D- 
glucose transport. In our study, the presence of sodium thiocyanate in the glucose 
incubation buffer (outside BBMV) provides the Na+ required for the co-transport of 
D-glucose. The glucose uptake profile showed a large overshoot which is transient 
since no ion pumps are present in BBMV as required to maintain the inwardly 
directed sodium gradient. Thus a transient accumulation of D-glucose was seen to 
occur initially, however, once the driving ion gradient was dissipated, the 
accumulated glucose declined by diffusion out of the vesicles towards equilibrium. 
4.4 Effects of karela juice on glucose uptake using BBMV 
model 
The effect of Thai karela juice on glucose uptake was studied using BBMV model. 
4.4.1 Materials and method 
Freshly prepared Thai karela juice was used in the study (method as described in 
Section 3.2.1). 
One aliquot (0.26m1) of frozen BBMV was resuspended in 0.44m1 of Buffer 3 
(300mM mannitol, 10mM HEPES-Tris, 0.1mM MgSO4, pH 7.4). For the control, 
20µl BBMV was mixed with 40µ1 of 0.1mM D-glucose solution {0. lmM D-glucose 
in glucose incubation buffer (100mM NaSCN, 100mM mannitol, 10mM HEPES- 
Tris, pH 7.4) containing D-[2 3H]glucose to a specific activity approximately 
25000cpm} and placed in a water bath at 25°C. For the test, 20µ1 BBMV was mixed 
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with 20µ1 of 0.2mM D-glucose solution {0.2mM D-glucose in glucose incubation 
buffer of double concentration (200mM NaSCN, 200mM mannitol, 20mM HEPES- 
Tris, pH 7.4) containing D-[2-3H]glucose} and 20µ1 karela juice (at different 
concentrations, see below). Glucose uptake was stopped after 20s incubation time 
(peak uptake, as shown in Fig. 4.4) by addition of lml ice-cold stop-wash buffer and 
the rest of the procedures were carried out as before (Section 4.3.1). All reactions 
were performed with 3 repeats and the mean values were calculated. Control 
incubations containing 20gl of 0.2mM [3H]-labelled D-glucose solution and 2Oµ1 
karela juice (at different concentrations), without the addition of BBMV, were used 
to measure non-specific binding of D-glucose to the filters. Glucose uptake was 
expressed as pmoles/mg protein as described before (Section 4.3.1). The test 
solutions used were: karela juice (neat), diluted karela juice --- 1 in 10,1 in 100 and 1 
in 1000 dilutions with water. In a separate experiment, instead of using water as the 
diluent, glucose solution (having the same concentration of glucose as in karela 
juice(l OmM, Appendix 6)) was used to' dilute karela juice to give 1 in 10,1 in 100 
and 1 in 1000 dilutions. 
4.4.2 Results 
4.4.2(a) Effect of karela juice (at different concentrations by dilutions with water) 
on glucose uptake 
Results are shown in Fig. 4.5. As a control, the absence of karela juice resulted in no 
inhibition of glucose uptake into the vesicles. However, karela juice (neat) caused an 
approximately 91% inhibition of glucose uptake. As the juice was diluted (with 
water), the inhibitory effect was also reduced. Thus the more diluted the juice, the less 
inhibitory effect on glucose uptake. 
4.4.2(b) Effect of karela juice (at different concentrations by dilutions with glucose 
solution) on glucose uptake 
Results obtained are shown in Table 4.2. From the results, the dilution of karela juice 
(using glucose solution as diluent) did not affect the percentage of inhibition of 
glucose uptake into BBMV. All four different concentrations of karela juice gave very 
similar percentage of inhibition of glucose uptake into BBMV. 
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Table 4.2: Effect of various concentrations of karela juice (diluted with 10mM 
glucose solution) on glucose uptake into BBMV 
Concentration of karela juice % of inhibition of glucose uptake into BBMV 
neat 92.0 
1 in 10 dilution 90.1 
1 in 100 dilution 91.3 
1 in 1000 dilution 90.6 
4.4.3 Discussion 
The results (4.4.2(a)) obtained seem to confirm that karela juice inhibited glucose 
absorption from the gut. A clear dose-response effect was observed; the more diluted 
the juice, the less inhibition of glucose uptake into the vesicles. However, on closer 
examination of the experimental protocol, the inhibitory effect seen might not be 
totally related to karela juice. This is because karela juice contains D-glucose, as 
shown in the HPLC assay (Appendix 6). The analysis showed that Thai karela juice 
contained about 8-11mM glucose, which is much higher than the concentration of 
glucose used in this in vitro testing (O. ImM). Thus the glucose that is present in 
karela juice might have competed with the radiolabelled D-glucose and resulted in an 
apparent inhibitory effect of glucose uptake into the vesicles. In addition, the fact that 
D-fructose is present in the juice (Appendix 6) may also need to be considered. 
However, the results are unlikely to have been affected by the presence of D-fructose 
in the juice since the fructose transporter in the brush border membrane is known to 
be different from that for the transport of D-glucose (Section 4.1.2). In fact, other 
results obtained in our laboratory (Srijayanta et al., 1997) have shown that fructose 
has no effect on glucose uptake by BBMV. 
As a result, further investigations have to be carried out in order to confirm the 
results. To overcome this problem, one possible solution is to remove all glucose 
from karela juice by techniques such as dialysis or size exclusion chromatography, 
and then repeat the experiment, but this could prove to be time consuming. An 
alternative is to dilute karela juice in glucose solution (having same concentration of 
glucose as in the juice) instead of water. This would maintain the same glucose 
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concentration throughout the dilutions of karela juice, whilst any active compounds 
would be diluted, thus allowing a possible dose-response effect to be seen. The latter 
was carried out and from the results (Section 4.4.2(b)), the dilution of karela juice did 
not affect the percentage of inhibition of glucose uptake into BBMV. Thus we can 
confirm that the presence of D-glucose in karela juice (in a relatively high 
concentration (around 10mM) as compared to that of D-glucose used in this 
experiment (0.1mM)) competed with the radiolabelled D-glucose and resulted in an 
apparent inhibitory effect of glucose uptake into the vesicles. Thus the inhibitory 
effect of glucose uptake (if any) caused by the active components in karela juice 
would have been masked. 
4.5 Effects of hexane extract of karela on glucose uptake 
using BBMV model 
Hexane extract of karela was chosen for further study using the BBMV model 
because: 
i) The positive result of hexane extract on OGTT and its lack of effect on IVGTT 
suggests that it may work by inhibiting glucose absorption from intestine. 
ii) Hexane, a non-polar solvent, is not expected to extract any glucose present in 
karela juice. Thus the hexane extract should have the advantage of containing no 
glucose (confirmed by the HPLC assay (Appendix 6)), as opposed to whole 
karela juice, methanol and water extracts of karela which contain glucose. 
4.5.1 Materials and method 
Preparation of hexane extract 
Hexane extract of karela was prepared and reconstituted in 0.3% v/v Tween 80 in 
water prior to testing as described before (Section 3.5.1). 
In vitro testin using BBMV model 
The same experimental procedures were used as above (Section 4.4.1). In this case, 
for the control, 20µ1 BBMV was mixed with 20µl of 0.2mM D-glucose solution 
{0.2mM D-glucose in glucose incubation buffer of double concentration (200mM 
NaSCN, 200mM mannitol, 20mM HEPES-Tris, pH 7.4) containing D-[2- 
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3H]glucose} and either 2Oµ1 of water or 20µ1 of 0.3% v/v Tween 80. Here, water is 
used as an extra control to check if Tween 80 (the solubilising agent for redissolving 
hexane extract) itself had any inhibitory effect on glucose uptake into BBMV. For the 
test, 20µ1 BBMV was mixed with 20gl of 0.2mM radiolabelled D-glucose solution 
and 20µ1 of hexane extract of karela juice (redissolved in 0.3% v/v Tween 80). 
Glucose uptake was measured at 20s (peak uptake) and 3600s (equilibrium point). 
4.5.2 Results 
The results of the glucose uptake studies with hexane extract are shown in Table 4.3. 
From the results, 0.3% v/v Tween 80 had no significant effect on glucose uptake in 
BBMV when compared to control (water). However, the hexane extract at 
concentrations of 0.073µg/µ1 and 0.73µg/µ1 resulted in percentage inhibitions of 
glucose uptake of 10.8 ± 1.6% (p = 0.075, compared to control (0.3% v/v Tween 80) 
by unpaired t-test) and 33.5 ± 2.1% (p < 0.0001) respectively. There was no 
significant change in equilibrium glucose uptake at 3600s between Tween 80 and 
hexane extract at 10 times concentration, indicating that the BBMV probably 
remained intact. 
4.5.3 Discussion 
Our in vitro results supported the possibility that the hexane extract of karela inhibits 
intestinal glucose uptake. This explains the fact that hexane extract significantly 
improved oral but not intravenous glucose tolerance as we observed earlier in 
Chapter 3. However, since hexane extract was shown to improve intraperitoneal 
glucose tolerance (Section 3.6.2) as well, it may also have some effects on the liver 
(as already discussed in Section 3.6.3), in addition to the inhibitory effect on 
intestinal glucose absorption. 
Our results also supported the previous findings by Meir and Yaniv (1985) in which 
glucose uptake by inverted gut was inhibited by acetone extract of karela. However, 
on closer examination of the experimental procedures, the author would question the 
accuracy of the reported inhibitory effect. This is because acetone extract is likely to 
contain glucose which is extracted from karela (our HPLC assay has shown the 
presence of glucose in karela, see Appendix 6) and the presence of unlabelled 
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glucose might have competed with radiolabelled [14C] glucose used in the 
experiment and thus the observed inhibitory effect remains questionable. 
The present study suggested that hexane extract may contain active compounds 
which act like phlorizin that inhibits Na+-dependent/glucose transport in the brush 
border membrane. Although the IC50 (median inhibitory concentration) value of the 
hexane extract was not determined, by extrapolation, it would possibly be in the 
region of 1-5 µg/µl, i. e. 1-5 mg/ml. According to Johansen et al. (1998), phlorizin 
has an IC50 value of 0.1mM, i. e. about 0.05mg/ml in this model. Thus phlorizin may 
be 20-100 fold stronger than the hexane extract of karela as a Na+-dependent glucose 
transport inhibitor. 
Na+-dependent glucose co-transporters are found in the small intestine as well as in 
the proximal tubule in the kidneys. If hexane extract contains phlorizin-like 
compound(s), the anti-hyperglycaemic effect may be a result not only of the 
inhibition of glucose uptake by the intestine, but also due to its inhibitory effect on 
the reabsorption of glucose by the kidneys resulting in glycosuria. To the best of our 
knowledge, the latter has never been fully examined. However, the absence of 
lowering effect of the hexane extract on intravenous glucose tolerance may indicate 
an absence of any effect on the kidneys. 
4.6 Conclusion 
Despite the fact that BBMV have been well-characterised in terms of glucose uptake, 
the author believes that this is the first time where BBMV were used as an in vitro 
model for studying natural products with intestinal glucose uptake inhibitory effect. 
In fact, with the advantages of low experimental cost and simple procedures, as well 
as the beauty of requiring only small amount of substrates for testing, BBMV are a 
good in vitro model for screening anti-diabetic plants for potential inhibitory effects 
on glucose uptake from the intestine. 
The only drawback of the BBMV model is that the substrates used for testing should 
ideally be glucose free in order to have valid results. Thus in our present study, only 
the hexane, but not water, extract was tested since the water extract is likely to 
contain glucose which is present in karela fruit. Sugars can be removed from the 
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extract by different techniques (Houghton and Raman, 1998). One such method is 
size exclusion chromatography using standard hydrophilic exclusion gels such as 
Sephadex0. Here, sugars, being small molecules, are retained by the column and are 
eluted last, whereas the larger molecules in the extract pass through and are eluted 
first. In this way, sugars can be separated from other components in the extract. 
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Chapter 5: Bioassay-guided fractionation of karela juice 
5.1 Introduction 
The investigations described in Chapter 3 had revealed that both hexane and water 
extracts of Thai karela improved oral glucose tolerance in nO STZ NIDDM rats, with 
the hexane extract being more potent. In in vitro experiments, we observed an 
inhibitory effect of hexane extract on glucose uptake in a BBMV model (Chapter 4). 
In this chapter, further studies carried out on the hexane extract with respect to 
isolating its active components will be described. Here, bioassay-guided fractionation 
using the in vivo nO STZ NIDDM model was employed. The whole hexane extract 
was further fractionated by column chromatography, the sub-fractions obtained were 
used in oral glucose tolerance tests using the nO STZ model. The active sub-fractions 
were further fractionated by column chromatography or preparative thin layer 
chromatography (PTLC) until pure compounds were obtained, whereas the inactive 
fractions were not studied further. The structures of the isolated compounds were 
elucidated using nuclear magnetic resonance spectroscopy (NMR), mass 
spectrometry (MS) and gas chromatography-mass spectrometry (GC-MS). 
All the NMR, MS and GC-MS spectra were run by the ULIRS NMR spectroscopy 
service, ULIRS mass spectrometry service and ULIRS GC-MS unit respectively in 
the Chemistry Department of King's College London. 
1H NMR, 13C NMR and DEPT spectra were recorded on a Bruker AMX-400 
(400MHz) instrument. Additionally, two-dimentional Correlation Spectroscopy 
(COSY), Nuclear Overhauser Enhancement Spectroscopy (NOESY) and 13C_ 111 one 
bond correlation spectroscopy were obtained, wherever possible, for reference. 
Deuterated solvent, CDC13 was used in all cases, with Tetramethylsilane (TMS) as 
internal reference. Chemical shifts are expressed as S values (ppm) downfield from 
TMS. 
Electron Impact Mass Spectrometry (SIMS) measurements were recorded on high 
resolution instrument with resolution of 3500 using processing software DS90 
against Kratos MS 890 instrument. A direct insertion probe was used for 
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measurement of the sample. 
High resolution Fast Atom Bombardment (FAB) MS were recorded on a VG ZAB- 
SE using a xenon FAB gun. The sample was introduced by a matrix 
(nitrobenzylalcohol + sodium chloride) on a probe. Accurate mass measurements 
were recorded using peak matching at a resolution of 8-10000. 
5.2 Fractionation of hexane extract by column chromatography 
5.2.1 Materials and method 
Solvents 
Hexane (C6H14), methanol (MeOH), acetonitrile (CH3CN) and chloroform (CHC13) 
were obtained from BDH Chemicals, UK. 
Preparation of hexane extract 
Fresh Thai karela fruit (15kg, Batch M) was bought and karela juice was prepared as 
described in Section 3.2.1. Karela juice (7.8L) was immediately freeze-dried into 
powder (232.15g). The freeze-dried powder was then extracted (using Soxhlet 
extraction) with hexane for 18 hours. Hexane extract was evaporated to dryness using 
a rotary vacuum evaporator and 2.2302g of residue was produced. 
Column chromatography 
Approximately 100g reverse-phase silica powder (LiChroprep0 RP-18, particle size 
40-63µm, Merck) was used to pack a column (30cm in length x 26mm internal 
diameter, with space in column of 28ml). The adsorbent was first made into a slurry 
with MeOH and loaded on the column, then pressure was applied and the adsorbent 
was compressed to a hard layer. Flash chromatography was used whereby the flow of 
solvent is increased by a positive pressure applied to the column, in this case, 
nitrogen gas was used. The dried hexane extract M2 (2.001g), premixed with 
minimum amount of hexane solvent, was applied to the top of the column of 
adsorbent. The column was then eluted by gradient elution of decreasing polarity, 
starting with MeOH, then MeOH: CH3CN (2: 1), followed by CH3CN, CHC13 and 
finally C6Hl4. 
N. B. This procedure is not suitable for further work since a non-polar solvent should not be present at 
the start of reverse-phase chromatography. It is recommended that the hexane solution is mixed with 
stationary phase and the solvent (hexane) removed by evaporation before the adsorbed sample is 
applied to the top of the column. 
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Thin laver chromatography (TLC) 
Commercial pre-coated reverse-phase (RP-18 F254s, Merck) plates were used for 
preliminary screening of crude extracts and to monitor fractions of extracts obtained 
from the column chromatography. In this case, the solvent system used was MeOH: 
CH3CN (2: 1). 
5.2.2 Results 
Figure 5.1 presents the schematic diagram for the extraction process of Thai karela 
fruit. 94 x 5m1 fractions were initially collected from the column chromatography. 
Fractions with similar constituents were pooled together and eventually eleven sub- 
fractions (M2A-M2K) were obtained (Fig. 5.1). From the TLC zone profile (Fig. 
5.2), each sub-fraction contains at least 2 components. 
5.3 Effect of sub-fractions of hexane extract on oral glucose 
tolerance in nO STZ model 
In the previous section (5.2), the crude hexane extract was fractionated into 11 sub- 
fractions. Ideally, all these sub-fractions should be tested for their effects on oral 
glucose tolerance in the nO STZ diabetic model. However, this would be too time- 
consuming and uneconomical. Thus only four sub-fractions (which together covered 
the whole range of compounds present in the hexane extract) were chosen for OGTT. 
5.3.1 Materials and method 
TLC of plant extracts 
The four sub-fractions of hexane extract chosen for the study were M2C, M2D, M2E 
and M21 as these contained, between them, all the components of the hexane extract. 
In order to determine the dose of each sub-fraction used for the in vivo testing, an 
estimation of the concentration of each extract as compared to that of the whole 
crude hexane extract was carried out. Since 2.2302g of dried hexane extract was 
obtained from 7.8L karela juice, 100ml of karela juice should give 28.6mg dried 
hexane residue. The crude hexane extract residue was reconstituted in hexane solvent 
to give a concentration of 50µg/µ1. Each of the four sub-fractions was reconstituted 
in hexane solvent to give a concentration of 10µg/µ1. On a RP-18 plate (20cm x 
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Chapter 5: Bioassay-guided fractionation of karela juice 
20cm), 10µl of crude hexane extract and 2,5,10 and 20 t1 of each of the four sub- 
fractions of hexane extract were applied. The plate was developed using a solvent 
system of MeOH: CH3CN (2: 1) and after development, it was sprayed with 0.5% 
anisaldehyde in methanol: glacial acetic acid: concentrated sulphuric acid (85: 10: 5) 
with subsequent heating at 100°C for 10 minutes. The colour intensity of the zone 
profile of the four sub-fractions (at different concentrations) was compared with that 
of the whole crude hexane extract and thus an estimation of the concentrations of the 
four sub-fractions in the total extract could be determined. 
Animals 
Adult Wistar nO STZ induced NIDD rats were employed as before (Section 3.2.1). 
Oral glucose tolerance test 
The same experimental procedures were used as before (Section 3.2.1). In addition to 
the four different test extracts (see below for dosages tested) and the whole crude 
hexane extract (M2; 1Oml(11.4mg)/kg), 0.3% v/v Tween 80 in water (IOml/kg) and 
metformin (200mg/kg; 200mg in l Oml water) were used as controls for validating the 
experiment. The dried extract residues of the four sub-fractions were each 
reconstituted in 100ml of 0.3% v/v Tween 80 prior to testing. The cumulative (4 days 
treatment) effects of the four extracts on oral glucose tolerance were investigated. 
Both plasma glucose and plasma insulin were measured as before (Section 3.2.1). 
5.3.2 Results and discussion 
By comparing the colour intensity of the zone profiles between the whole hexane 
crude extract and the four sub-fractions of hexane extract, the equivalent 
concentrations of each sub-fraction were estimated as follows (Table 5.1). 
Table 5.1: Estimation of concentrations of the sub-fractions of hexane extract 
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Instead of testing the above five extracts at concentrations equivalent to that of the 
whole karela juice, in the OGTT, they were tested at four times more concentrated 
dosages (Table 5.2). This was to make sure that any active constituents present would 
be concentrated enough to produce positive effect on oral glucose tolerance, taking 
into account that there might be more than one active constituent in the hexane 
extract, and the fractions would be weaker than the total extract. 
Table 5.2: Dosages of sub-fractions of hexane extract tested in OGTT 






The negative result for 0.3% v/v Tween 80 and the positive effect of metformin on 
oral glucose tolerance validated the experimental model (results not shown). The 
activity of the whole crude hexane extract (M2) on oral glucose tolerance was also 
confirmed (Appendix 7). From the results of the OGTT (Fig. 5.3), both extracts M2C 
and M21 significantly improved oral glucose tolerance after four days of treatment, 
with mean AG' reduced by 22% (p = 0.049) and 17% (p = 0.082) respectively. 
However, extract M2D had no effect on oral glucose tolerance, whereas extract M2E 
increased mean plasma glucose at all time points after four days of treatment, though 
none of them reached statistical significance. Despite the positive effect of both 
extracts M2C and M21 on oral glucose tolerance, neither of them had any significant 
effect on plasma insulin (Table 5.3). 
It is important to note that the effects of the two active fractions M2C and M21 (Fig. 
5.3) were much weaker than that of the whole crude hexane extract (Appendix 7). 
This is possibly due to synergistic or additive effect of the active components. In fact, 
this weakening effect was also observed with the hexane and water extracts (Fig. 
1 AG = the sum of the increase in plasma glucose at all time points compared with time 0 
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Chapter 5: Bioassay-guided fractionation of karela juice 
3.8) as compared to the whole karela juice (Fig. 3.3). 
5.4 Fractionation of extract M21 
5.4.1 First stage of fractionation 
5.4.1(a) Materials and methods 
In order to further fractionate the extract M21, a suitable chromatographic system had 
to be sought. Since hexane extract should contain relatively non-polar compounds, 
separation using a lipophilic Sephadex® LH-20 (particle size 25-100µ, Sigma) 
column was initially employed. A small sample of extract M21 (16.7mg) was applied 
to a LH-20 column (19cm in length x 17mm internal diameter) with the mobile 
system of MeOH : CHC13 (1: 1). However, good separation of components was not 
achieved using this system. 
Then further trials were run using silica as the adsorbent, with various non-polar 
solvents such as C6H14, CHC13 at different concentrations. It was found that better 
separations of components were achieved using silica than LH-20 as adsorbent. Thus 
a silica column was finally used to further fractionate hexane extract M21. 
Approximately 150g silica powder C60-H (particle size 40-60µ. m, Rhone-Poulenc) 
was used to pack a column (35cm in length x 26mm internal diameter, with space in 
column of 30m1). The column was conditioned with C6H14 and flash chromatography 
was used where nitrogen gas was employed. The dried extract M21 (600mg), 
premixed with minimum amount of hexane solvent, was applied to the top of the 
silica column. The column was then eluted by gradient elution of increasing polarity: 
i) C6H14 (300m1) *f1-30 
ii) C6H14 : CHC13 = 80: 20 (300m1) f31-57 
iii) C6H14 : CHC13 = 60: 40 (200m1) f58-74 
iv) C6H14 : CHC13 = 40: 60 (200m1) f75-91 
v) C6H14 : CHC13 = 20: 80 (300m1) J92-112 
vi) CHC13 (1000ml) f713-183 
vii) CHC13 : MeOH = 1: 1 (200m1) f184-197 
viii) MeOH (100ml) f198-200 
*f= fractions collected 
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5.4.1(b) Results and discussion 
From the silica flash column, 200 sub-fractions were collected. TLC zone profile of 
various sub-fractions are shown on Fig. 5.4 and the sub-fractions were pooled 
together as in Table 5.4. From the results, one of the main component (red-brown 
spot with Rf 0.13-0.14; Fig. 5.4) in extract M21 resided in fractions 169-193 (M21t; 
Table 5.4). Further fractionation of hexane extract M21t was carried out in order to 
isolate this compound. Since this compound did not quench UV light, it is unlikely to 
have an aromatic structure. An early prediction of this compound was that it was 
likely to be either steroidal or triterpenoid, as it reacted with anisaldehyde (a spraying 
agent for detection of sugars, steroids or triterpenes) to give a red/dark pink colour. 
5.4.2 Second stage of fractionation (fractionation of extract M21t) 
5.4.2(a) Materials and method 
Hexane extract M21t (210mg) was further fractionated by putting through another 
silica column (particle size 18-32µm, ICN Biomedicals; 23cm in length x 17mm 
internal diameter) and the column was eluted with the following solvents of 
increasing polarity: 
i) CHC13 fl-14 
ii) CHC13 : EtOAc (ethyl acetate) = 3: 1 f75-17 
iii) CHC13 : EtOAc = 2: 1 f18 
iv) CHC13 : EtOAc =1: 1 f19 
v) EtOAc J20-24 
vi) EtOAc : MeOH =1: 1 f25-27 
vii) MeOH J28-29 
5.4.2(b) Results 
Figure 5.5 shows the TLC zone profile of sub-fractions of extract M21t. The main 
component of interest (dark red spot; Rf 0.58) resided in fractions 9-11 (123.9mg). 
5.4.3 Third stage of fractionation (further fractionation of extract M2lt) 
5.4.3(a) Materials and method 
Fractions 9-11 (123.9mg) were further fractionated by putting through another silica 
column (particle size 18-32µm, ICN Biomedicals; 23cm in length x 17mm internal 
206 
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Chapter 5: Bioassay-guided fractionation of karela juice 
Table 5.4 Sub-fractions of hexane extract M21 
Fractions Codes Weight (mg) 
1-24 a 10.1 
25-32 b 3.0 
33-42 c 0.4 
43-48 d 3.3 
49-67 e 0.7 
68-81 f 5.0 
82-86 g 5.5 
87-89 h 3.9 
90-93 - i 3.5 
94 j 0.6 
95-99 k 2.2 
100-123 1 9.1 
124-130 m 10.0 
131-132 n 9.6 
133-147 o 53.5 
148-153 p 3.5 
154-163 q 3.8 
164-167 r 1.8 
168 s 2.8 
169-193 t 217.3* 
194 u 140.1 
195-197 v 77.4 
198-200 w 1.6 
Total: 568.7mg 
* Fraction M21t was taken for further fractionation (Section 5.4.2) 
4 
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Chapter 5: Bioassay-guided fractionation of karela juice 
diameter) and the column was eluted with the following solvents of increasing 
polarity: 
i) CHC13 fl-14 
ii) CHC13 : EtOAc =1: 1 f15-18 
iii) EtOAc f19 
iv) MeOH J20-21 
5.4.3(b) Results and discussion 
Figure 5.6 shows the TLC zone profile of further sub-fractions of extract M21t. The 
compound of interest (Rf 0.58) resided mainly in fraction 8 (46.9mg), though also 
present in small amount in fractions 7 (33.7mg), 9 (11.0mg), 10 (10.8mg) and 11 
(2.1mg). The tailing appearance of the zone in fraction 8 suggests that it may be a 
mixture of 2 compounds. 
5.4.4 Isolation of compounds by preparative thin layer chromatography 
5.4.4(a) Materials and method 
Preparative thin layer chromatography (PTLC) was used to isolate individual 
compounds from fraction 8 (46.9mg) and from the combined fractions of 9 and 10 
(21.8mg in total). Silica plates (lmm in thickness) were prepared for PTLC. 
Fractions 8 and 9+10 were separately loaded onto silica plates and developed using 
mobile phase CHC13 : EtOAc = 3: 1. Since the compound(s) of interest did not 
quench UV light, anisaldehyde spraying agent was used as an indicator (by spraying 
only on one edge of the silica plate) for locating the compound on the plate after 
development. Compound(s) was isolated by scraping off the silica powder at zones 
indicated by anisaldehyde and eluted with MeOH : CHC13 = 1: 1. 
5.4.4(b) Results and discussion 
Figure 5.7 shows the TLC zone profile for compounds isolated from fractions 8,9 
and 10. Eight sub-fractions (A-H) were obtained from fraction 8, while the combined 
fractions 9+10 gave five sub-fractions (I-M . From the results (Fig. 5.7), the 
compound of interest resided in fractions B (27.1mg), C (15.4mg), I (2.4mg) and M 
(6.7mg). The zone profiles of two reference steroidal compounds which are 
commonly found in plants, stigmasterol (Fig 5.8) and ß-sitosterol (Fig 5.8) were also 
210 
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C, Hs 
HO 
Stigmasterol (C29H480; m. wt. 412) 
C? HS 
HO 
ß-Sitosterol (C29H500; m. wt. 414) 
Figure 5.8: Two steroidal compounds commonly found in plants 
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used for comparison. However, due to the fact that both stigmasterol and (3-sitosterol 
presented similar coloured zones at very similar Rf value (Fig. 5.7), it is difficult at 
this stage to state whether compound(s) isolated in fractions B, C, I and M were 
either of these compounds or some other closely related steroidal compounds. 
However, using another adsorbent and solvent system (Fig. 5.9), compound in 
fraction C (M2ItC) was found not to be either stigmasterol or ß-sitosterol. 
5.4.5 Identification of compounds isolated from extract M21 
In the previous section (5.4.4), compounds were isolated in fractions B, C, I and M. 
Due to the minute quantity in fractions I and M, only compounds in fractions B and C 
(known as M2ItB and M2ItC respectively) were subjected to structure elucidation by 
NMR and MS. However, from the similarity in Rf value and the colour of the zones, 
the two compounds in fractions I and M were likely to be the same ones as in 
fractions B and C. 
5.4.5(a) Compound M2ItC 
TLC zone profile (Fig. 5.7) shows that a single compound was present in fraction C. 
Results so far also suggested that the compound (M2ItC) is likely to be steroidal. 
Thus the NMR and MS spectra of stigmasterol were used for reference and 
comparison to those obtained from the compound M2ItC. 
Method 
11-1 NMR spectra (400MHz) and 13C NMR spectra (100MHz) were obtained. The 
reference compound, stigmasterol (32mg, Sigma) and compound M2ItC (15mg) were 
individually dissolved in CDC13, with an internal reference compound TMS 
(tetramethylsilane) added to the solution. 
In order to find out the molecular weight, both electron impact (EI) and high 
resolution fast atom bombardment (FAB) mass spectra were obtained for both 
samples. 
Results 
The 'H NMR spectrum for compound M2ItC showed a pattern characteristic of 
steroids whilst a proton signal at -3.5ppm signified the possibility of a sterol. Thus 
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Mý. IfC REFS, REFI 
RP- 18 F254 plate 
Application : 10µl 
Solvent system - MeOH : CH3CN (2: 1) 
Detection - 
i) UV shortwave 254nm (zones marked by pencil) 
ii) Anisaldehyde spraying agent 
REF1 - stigmasterol; REF2 - (3-sitosterol 
Figure 5.9: TLC zone profiles of compound M2ItC and two reference 
steroidal compounds 
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the 1H and 13C NMR spectra of a known sterol, stigmasterol, were obtained for 
reference. NMR and MS spectra for the commercially obtained stigmasterol are 
included in Appendix 8. The main proton assignments of stigmasterol are: C3-H, 1H, 
63.52, multiplet; C6-H, 1H, 55.35, doublet, J(coupling constants) = 5.3 Hz; C22-H, 
1 H, 55.14, double doublet, J= 15.1 Hz & 8.6 Hz; C23-H, 1H, 85.01, double doublet, 
J= 15.2 Hz & 8.7 Hz. By reference to literature values (Ikan, 1991), the chemical 
shifts of all the carbons in the NMR were assigned as shown in Table 5.5. The EI 
mass spectrum showed the molecular ion peak at m/z 412, and the molecular formula 
C29H48O was established. by high resolution FAB mass spectrum (Appendix 8). 
Appendix 9 includes full NMR and MS spectra for compound M2ItC. The EI mass 
spectrum showed the molecular ion peak at m/z 412, and the molecular formula 
C29H480 was established by high resolution FAB mass spectrum. Despite having the 
same molecular weight and formula as stigmasterol, differences were exhibited in 1H 
and 13C NMR spectra of the two compounds. For example, 1H signals corresponding 
to the side chain double bond were different between the 2 compounds. In 
stigmasterol, we observed at S 4.98-5.18, two double doublets due to transcoupling (J 
= 15.1 Hz) and coupling from protons at adjacent carbons, C-20, C-24. In M2ItC, a 
different pattern was observed. The pattern indicated a terminal double bond on the 
side chain. A doublet (J= 2.5 Hz) at 54.64 corresponding to one of the protons at C- 
26, and a double doublet at 54.73 (J = 1.4 Hz & 2.5 Hz) corresponding to the second 
proton. The J value of 2.5 Hz is most probably due to geminal coupling of the 2 
protons on C-26, while the J value of 1.4 Hz may represent long-range coupling of 
one of these protons to that on C-24. In 13C NMR spectrum, the chemical shifts are 
virtually identical between the 2 compounds, apart from those in the double bond 
region. The signals correspond to C-5 (6141.2) and C-6 (5122.1) in stigmasterol are 
also found in M2ItC (5140.8 and 5121.8), indicating that a double bond exists 
between C-5 & C-6, same as stigmasterol. However, the other 2 signals in 
stigmasterol (S 138.8 and 129.7) were very different from those in M2ItC (6147.6 
and 6111.4). This suggests that compound M21tC was not stigmasterol, but very 
likely to be a closely related steroidal compound, possibly with the side chain double 
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Chapter 5: Bioassay-guided fractionation of karela juice 
bond at a different position in agreement with the 1H spectrum. In fact, the 13C NMR 
spectrum for M2ItC showed the presence of 29 carbon signals in the molecule. The 
DEPT spectrum exhibited 5 methyls, 12 methylene and 8 methine signals, while the 
remaining four signals were due to the quaternary carbon atoms. On the basis of all 
the spectral evidences, the structure of M2ItC was formulated as 5,25- 
stigmastadienol, as confirmed with previous reported data (Ahmad et al., 1993; Table 
5.6). The main proton assignments are: C3-H, 1H, 53.53, multiplet; C6-H, 1H, 85.35, 
double doublet (J = 3.2 Hz & 2.1 Hz); C26-H, 2H, 64.64, doublet (J = 2.5 Hz) and 
64.73, double doublet (J= 2.5 Hz & 1.4 Hz); C27-H, 3H, 61.56, singlet. 
5.4.5(b) Compound M2ItB 
From the TLC zone profile (Fig. 5.7), there is only one spot in fraction B (27.1mg). 
However, the slightly tailing effect of the spot suggests that it may contain more than 
one compound, which would be confirmed by NMR. 
S. 4.5(bl) NMR 
Method 
IH NMR spectra (400MHz) and 13C NMR spectra (100MHz) were obtained. 
Compound M2ItB (27mg) was dissolved in CDC13, with an internal reference 
compound TMS added to the solution. 
Results and discussion 
1H and 13C NMR spectra of compound M2ItB are presented in Appendix 10. Results 
suggest that compound M21tB is likely to be steroidal since both 1H and 13C spectral 
pattern matches those of sterols, like stigmasterol and 5,25-stigmastadienol. M2ItB is 
likely to be a mixture of two sterols because the 13C spectrum gave a large number of 
carbons (>40). In fact, the 1H spectrum for M2ItB appeared like the spectrum of 5,25- 
stigmastadienol overlaid with a second spectrum, e. g. extra signal at 65.15 and a 
broader C3-H signal (63.48-3.62). By examining the relative intensity of the double 
bond signals at 65.15 and 65.34, it appears that the mixture is about 1: 1. Therefore, 
the spectral data suggests that M2ItB is likely to be a 1: 1 mixture of two steroidal 
components. Hence attempts were made to separate the two components by TLC. 
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Table 5.6: 13C NMR (CDC13) spectral data for compound M2ItC 
HO 5,25-stigmastadienol 
Carbon no. ppm (own results)* ppm (literature)** 
C-1 37.3 37.4 
C-2 31.7 31.5 
C-3 71.8 71.7 
C-4 42.3 42.2 
C-5 140.8 141.0 
C-6 121.8 121.8 
C-7 31.9 33.6 
C-8 31.9 31.8 
C-9 50.1 50.3 
C-10 36.5 36.4 
C-11 21.1 21.3 
C-12 39.8 39.7 
C-13 42.3 42.3 
C-14 56.8 56.9 
C-15 24.3 24.3 
C-16 28.2 28.2 
C-17 56.1 56.2 
C-18 11.9 11.8 
C-19 19.4 19.4 
C-20 35.6 35.4 
C-21 18.7 18.6 
C-22 33.7 33.7 
C-23 29.4 29.6 
C-24 49.6 49.5 
C-25 147.6 147.6 
C-26 111.4 111.4 
C-27 17.8 17.8 
C-28 26.6 26.4 
C-29 12.1 12.1 
* Corrected ppm (the actual value on spectrum - 2.7ppm) as the CDC13 
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5.4.5(b2) TLC 
The following TLC systems were tried in order to separate the 2 steroidal compounds 
present in M2ItB, though none of them succeeded in separation of the mixture: 
A) Using silica gel 60 F254 plate; with solvent systems: 
i) CHC13 
ii) CHC13 : EtOAc = 4: 1 
iii) CHC13 : EtOAc = 3: 1 
iv) multiple development with firstly CHC13, then CHC13 : EtOAc (4: 1), 
followed by CHC13 : EtOAc (3: 1) 
B) Using RP-18 F254s plate; with solvent system - MeOH: CH3CN (2: 1), a multiple 
development was tried (3 times and 4 times development). 
Due to the failure in separating the mixture by TLC, attempt was made using GC-MS. 
5.4.5(b3) GC-MS analysis 
Materials and method 
The instrument is JEOL AX5O5W. 
Column : BP1 (supplied by SGE) 
Phase Bonded phase methyl siloxane 
Phase thickness 0.251tm 
Length 25m 
Internal diameter 0.22mm 
Carrier gas: Helium 
Pressure l2psi 
Flow 1 cm3miri 1 
Temperature programme 
Initial temperature 120°C 
Initial time 2 min 
Ramp rate 6°C min" 
Final temperature 320°C 
Final time 5 min 
Injection: 0.2 µl on column 
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Three reference compounds were used: ß-sitosterol, 5,25-stigmastadienol (M2ItC) 
and stigmasterol. Each of the samples (the reference compounds and M2ItB) was 
dissolved in 200µl CHC13 before analysis. 
Results and discussion 
The electron impact mass spectra for the three reference compounds are included in 
Appendix 11. Using this GC system, separation of sterols was achieved and the 
elution order of the three reference sterols (identified by their MS) was stigmasterol 
(34.4min after injection), followed by 5,25-stigmastadienol (34.8min), and finally ß- 
sitosterol (35.1 min), as shown in Appendix 11. 
From the analysis, M21tB was found to contain (3-sitosterol and 5,25-stigmastadienol, 
i. e. a mixture of two sterols as predicted. 
5.5 Effect of 5,25-stigmastadienol and ß-sitosterol on oral 
glucose tolerance in nO STZ NIDDM model 
5.5.1 Introduction 
In the previous section (5.4), extract M21 was shown to contain both 5,25- 
stigmastadienol and ß-sitosterol as the main constituents. Thus the effects of both 
compounds on oral glucose tolerance were investigated in order to see if they are 
responsible for the anti-hyperglycaemic activity of the whole extract M21. 
5.5.2 Materials and method 
Compounds tested 
5,25-stigmastadienol (M2ItC, at doses of 10ml(1.3mg)/kg and 10ml(4.6mg)/kg) and 
ß-sitosterol (10ml(3. lmg)/kg) were tested. Each compound was reconstituted in 
100m10.3%v/v Tween 80 prior to testing. 
Animals 
Adult Wistar nO STZ induced NIDD rats were employed as before (Section 3.2.1). 
Oral glucose tolerance test 
The same experimental procedures were used as before (Section 3.2.1). 0.3% v/v 
Tween 80 (10ml/kg) and metformin (200mg/kg; 200mg in 10m1 water) were used as 
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controls for validating the experiment. 
5.5.3 Results and discussion 
From the results (Table 5.7), compound 5,25-stigmastadienol at dose of 1.3mg/kg 
improved oral glucose tolerance but none of the time points reached statistical 
significance. The dose tested was equivalent to the dose tested for the whole fraction 
M21 (Table 5.2) determined by quantitative TLC as described in Section 5.3. The 
lack of significant improvement in oral glucose tolerance may be due to the fact that 
the dose tested was too low. Thus both compounds, 5,25-stigmastadienol and 3- 
sitosterol, were tested at about 3-4 times more concentrated dosages. From the results 
(Fig. 5.10), both 5,25-stigmastadienol and D-sitosterol significantly improved oral 
glucose tolerance (a reduction in OG by 51% (p = 0.0015) and 50% (p = 0.0030) 
respectively). It is interesting to note that in both cases, there was a significant 
increase in plasma glucose at time 0. No significant effect on plasma insulin was 
observed with either of the compounds (Table 5.8). 
Here is another example of the synergistic or additive effect of the active components 
in karela (as previously discussed in Section 5.3.2). When 5,25-stigmastadienol was 
tested at an equivalent dose to that of whole hexane extract, it had no significant 
effect on oral glucose tolerance. It was necessary to increase the dose by about 3-4 
times in order to see the positive effect. 
It is interesting to note that both 5,25-stigmastadienol and (3-sitosterol are aglycones 
of charantin (Fig. 1.19; a 1: 1 mixture of 5,25-stigmastadienol and ß-sitosterol 
glucosides), a compound which was believed to be the active constituent in 
Momordica charantia (Section 1.4.3). 
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5.6 Fractionation of extract M2C 
5.6.1 Preparative thin layer chromatography 
Apart from extract M21, extract M2C also improved oral glucose tolerance in nO STZ 
NIDDM rats (Section 5.3). Thus further fractionation on extract M2C was carried out 
in order to isolate the main component. From the TLC zone profile (Fig. 5.2), the 
main component in M2C is the red spot with Rf0.67. 
5.6.1(a) Materials and method 
The main component (red spot with Rf 0.67) was isolated by preparative thin layer 
chromatography using silica gel 60 F254 plate (lmm in thickness), with mobile phase 
of CHC13 : EtOAc = 1: 2. Using this system, the compound had a Rf value of 0.23. 
Repeated PTLC procedures were carried out until a pure compound was obtained. 
5.6.1(b) Results 
The compound of interest (M2Ciii), 8mg, was isolated from fraction M2C by PTLC. 
5.6.2 Identification of compound M2Ciii 
5.6.2(a) Method 
1H NMR spectra (400MHz) and 13C NMR spectra (100MHz) were obtained. In order 
to find out the molecular weight, electron impact and high resolution fast atom 
bombardment mass spectra were also obtained. 
5.6.2(b) Results and discussion 
All spectral data for compound M2Ciii are included in Appendix 12. From the IH 
NMR spectrum, the absence of signals in the region of 7-9ppm indicates that it is not 
an aromatic compound. The complexity of signals around 0.8-2ppm was very similar 
to that of 5,25-stigmastadienol or stigmasterol, suggesting that it may be a steroidal 
compound. The proton signal at 9.7ppm means that the compound has an aldehyde 
group. The signal at 207.9ppm in the 13C NMR spectrum again indicates the presence 
of an aldehyde. The 13C NMR spectrum showed the presence of 30 carbon signals in 
the molecule. The DEPT spectrum exhibited 7 methyls, 7 methylene and 10 methine 
signals, while the remaining 6 signals were due to the. quaternary carbon atoms. 
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On the basis of all the NMR spectral data, the compound is likely to be a teträcyclic 
triterpenoid, with an aldehyde group. From an extensive literature search on all 
compounds previously isolated from Momordica charantia, one possible identity is 
momordicine I (Fig. 5.11), which was previously isolated from the leaves and vine by 
Yasuda et al. (1984). This paper reported only partial NMR ('H and 13C) spectral 
data for momordicine I and the compound was dissolved in deuterated pyridine rather 
than CDC13 (in our case). 
Figure 5.11: Structure of momordicine I 
Thus a reference sample of momordicine I (5mg) was obtained from the 
corresponding author of the paper, Dr Hikaru Okabe, Faculty of Pharmaceutical 
Sciences, Fukuoka University, Japan. The 1H and 13C NMR spectra of reference 
momordicine I (Appendix 13) were run at King's College under the same conditions 
(i. e. dissolved in solvent CDC13) as our compound M2Ciii. Due to instrumental 
problem, the13C spectrum for reference momordicine I only covered 0-180ppm, thus 
the signal corresponding to the aldehyde group was not seen on the spectrum. 
However, from the results, the 1H spectra for both reference compound and M2Ciii 
are virtually identical. In both cases, the 'H NMR spectra showed the presence of an 
aldehyde group at 59.72 (1H, singlet, C19-H). Although the expected splitting 
patterns were not always observed, the following tentative proton assignments were 
made. We observed 3 signals in S 3.57-4.49 region, due to protons on carbons with a 
hydroxy group, i. e. C3-H, C7-H, and C23-H. The signal 64.46 (multiplet) was 
assigned to C23-H, a proton being close to a double bond and coupled to protons on 
C-22 and C-24. The signal 83.97 (doublet; J= 5.3 Hz) probably corresponds to C7-H, 
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though a double doublet splitting pattern is expected. The remaining signal 53.57 
possibly corresponds to C3-H, similar to that in stigmasterol and 5,25- 
stigmastadienol. We again observed 3 signals in 8 5.18-5.90 region, of which the 
peaks at 55.19 and 55.89 were doublets. These may correspond to protons on C-6 and 
C-24 since both of which would give doublets due to coupling with protons on C-7 
and C-23 respectively. Comparing to stigmasterol where the C6-H signal was at 
55.35, the C6-H signal of momordicine I will be predicted to be at 55.19 (J = 8.5), 
therefore the signal at 55.89 (J = 4.2) is assigned to C24-H. 13C assignments for 
compound M2Ciii and reference momordicine I (Table 5.9) were made by 
comparison with literature values for closely related cucurbitane triterpenoids (Fatope 
et al., 1990). By comparing both 13C NMR spectra (Table 5.9), it was shown that 
M2Ciii contained mainly momordicine I, though with some possible impurities 
present as extra carbon peaks were seen. Despite some minor differences observed in 
the double bond region between the two 13C spectra, both 1H spectra matched well in 
this region. The fast atom bombardment mass spectrum also confirmed the molecular 
weight of the compound as 472 (495-23(Na)). Thus we confirmed that the compound 
M2Ciii is mainly momordicine I. 
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Table 5.9: 13C NMR (CDCl3) spectral data for compound M2Ciii 
Momordicine I 
Carbon no. ppm (M2Ciii) ppm (reference compound*) 
C-1 21.2 21.2 
C-2 29.1 29.1 
C-3 76.1 76.1 
C-4 41.4 41.4 
C-5 145.5 N/A 
C-6 123.9 123.9 
C-7 65.9 65.9 
C-8 50.8 50.8 
C-9 49.9 49.9 
C-10 36.6 36.6 
C-11 23.6 23.5 
C-12 28.4 28.4 
C-13 45.4 45.4 
C-14 47.6 47.4 
C-15 34.6 34.6 
C-16 29.0 29.0 
C-17 47.5 47.6 
C-18 14.9 14.9 
C-19 207.9 N/A 
C-20 32.6 32.6 
C-21 18.8 18.8 
C-22 44.4 44.4 
C-23 66.3 66.3 
C-24 128.9 128.9 
C-25 134.0 N/A 
C-26 25.8 25.7 
C-27 18.2" 18.1' 
C-28 25.4 25.4 
C-29 27.2 27.2 
C-30 17.9' 17.9a 
* obtained from Dr Hikaru Okabe, Fukuoka University, Japan. 
N/A - not available; 'The assignments in the same vertical column may be reversed. 
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5.7 Investigation on the presence of sterols and momordicine I 
in different varieties of karela fruit and seed 
5.7.1 Introduction 
From the previous sections (5.4 and 5.6), two steroidal compounds (5,25- 
stigmastadienol and ß-sitosterol) and a tetracyclic triterpenoid (momordicine I) were 
found in the hexane extract of Thai karela. Thus in this section, the presence of these 
three compounds, together with another common steroidal compound, stigmasterol, 
in different varieties of karela fruit and seed will be investigated. Two methods were 
used, TLC and GC-MS. 
5.7.2 Materials and method 
Hexane extract of different varieties of karela fruit (Thai, Kenyan, Indian- (Bombay), 
UK grown) and Thai karela seeds were prepared for investigation. Different varieties 
of karela juice (100ml each) were freeze-dried and the freeze-dried powder was each 
refluxed with hexane solvent (200m1) for 30 min. Thai karela seeds (54 seeds =- 
5.02g) were crushed into powder using pestle and mortar and refluxed with hexane 
solvent (200m1) for 30 min. All the hexane extracts obtained were evaporated to 
dryness using a rotary evaporator. 
5.7.2(a) TLC 
The entire dried hexane extracts were redissolved in Iml hexane solvent and 5p1 (- 
0.5m1 original karela juice) each were applied on the plate (RP-18 F254s), with 
solvent system - McOH : CH3CN (2: 1). The four reference compounds, ß-sitosterol, 
stigmasterol, 5,25-stigmastadienol and momordicine I were each dissolved in CHC13 
(5mg in 0.5m1 CHC13) and 5p1 each (=50µg) were applied on the plate. After 
development, the zones were detected under UV shortwave and also under daylight 
after spraying with anisaldehyde spraying agent and subsequent heating at 100°C for 
10 min. 
5.7.2(b) GC-MS 
In section 5.4.5(b3), a GC-MS system was derived for the separation of sterols. By 
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using this system, further investigations were carried out on the sterol content in 
different varieties of karela fruit and seed. 
Following TLC, the remaining extract of different varieties of karela fruit and seed 
(approx. lml) were re-dried and re-dissolved in 200µl hexane prior to the analysis. 
The GC-MS system and the procedures were the same as before (Section 5.4.5(b3)). 
The reference compounds used were: (3-sitosterol, 5,25-stigmastadienol and 
stigmasterol. A few mg (unmeasured) of the reference compounds were dissolved in 
200µ1 CHC13 before analysis. 
5.7.3 Results and discussion 
The TLC zone profiles of hexane extracts of different varieties of karela fruit are 
shown in Fig. 5.12. From the results, the zone profiles of all hexane extracts were 
very similar, though minor differences (intensity of the coloured zones) were 
observed among different varieties and also within the same variety. By comparison 
with the reference compounds, 5,25-stigmastadienol was present in all varieties, 
whereas momordicine I was only detectable in Thai and UK karela. Due to the 
relatively similar Rf values and zones colour for compounds ß-sitosterol and 
stigmasterol, it is difficult to comment on their individual presence in different 
varieties of karela fruit. However, the presence or absence of one or both compounds 
in different varieties of karela fruit was further confirmed by the GC-MS analysis. 
Figure 5.13 shows the zone profile of hexane extracts of Thai karela fruit and seed. 
The zone profiles between the fruit and the seed are very different, a few components 
present in the seed were not found in the fruit (e. g. zones x and y) and vice versa. It is 
interesting to note that momordicine I was not present in the seed, and the compound 
5,25-stigmastadienol was also likely to be absent. Again, the presence or absence of 
this compound as well as ß-sitosterol and stigmasterol in the seed was further 
investigated by the GC-MS analysis. 
Results obtained from the GC-MS analysis are shown in Table 5.10. From the 
results, Thai, Kenyan and UK grown karela fruit all contained ß-sitosterol and 5,25- 
stigmastadienol, but not stigmasterol, and the results are consistent among different 
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batches of the same variety. However, the Indian karela only contained 5,25- 
stigmastadienol, and not the other 2 sterols. Thai karela seed, unlike the fruit, only 
contained ß-sitosterol, and not 5,25-stigmastadienol or stigmasterol. 
TLC and GC-MS results showed that both momordicine I and 5,25-stigmastadienol 
were absent in Thai karela seed. If these compounds are the active constituents 
responsible for the anti-hyperglycaemic effect of karela fruit (5,25-stigmastadienol 
was shown to improve oral glucose tolerance; section 5.5 and momordicine I was 
isolated from an active fraction), then the effectiveness of karela seed (Section 1.4.2- 
1.4.3) for the treatment of diabetes remains questionable, though it is important to 
remember that there may be other active compounds present in the seed, such as 
sitosterol. 
Table 5.10: The sterol content in different varieties of karela fruit and seed 
Hexane extracts of -sitosterol 5,25-stigmastadienol stigmasterol 
Thai karela fruit (batch 1) yes yes no 
Thai karela fruit (batch 2) yes yes no 
Thai karela fruit (batch 3) yes yes no 
Kenyan karela fruit (batch 1) yes yes no 
Kenyan karela fruit (batch 2) yes yes no 
Indian (Bombay) karela fruit no yes no 
UK grown karela fruit yes yes no 
Thai karela seed yes no no 
Furthermore, it would be interesting to make accurate quantitative analysis of the 
sterol content in different varieties of karela fruit and seed. Although accurate 
quantitative analysis was not performed in our study, a rough estimation of the 
amount of 5,25-stigmastadienol in Thai karela juice was made as follows. With 
regards to the TLC zone profile (Fig. 5.12), 50µg of 5,25-stigmastadienol was 
applied on the TLC plate. By comparing the colour intensity of the zone (which 
corresponds to 5,25-stigmastadienol) in Thai karela hexane extract (=-0.5m1 karela 
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juice), a rough estimate of 25µg of 5,25-stigmastadienol is being present. Thus about 
0.5mg of 5,25-stigmastadienol was present in 10ml of karela juice. However, the 
OGTT study (Section 5.5) showed that about 5mg/kg of 5,25-stigmastadienol was 
required to produce a effect, which is equivalent to a dose of 100ml of karela juice/kg 
body weight of rat. Therefore, we can conclude that 5,25-stigmastadienol is not the 
sole active component in karela. 
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5.8 Acid hydrolysis of the karela water extract 
5.8.1 Introduction 
In Chapter 3, both hexane and water extracts of Thai karela were shown to have anti- 
hyperglycaemic activity. In the present chapter, the compounds identified in the 
active fractions of the hexane extract are 5,25-stigmastadienol, momordicine I and ß- 
sitosterol. There is a possibility that their corresponding glucosides may be present in 
the water extract and are responsible for the observed anti-hyperglycaemic activity. 
Since acid can hydrolyse 0-glycosides to give their corresponding aglycones and 
sugars, acid hydrolysis of the water extract will be carried out to see if glycosides of 
the three steroidal/triterpenoid aglycones are present. 
5.8.2 Materials and method 
Sulphuric acid (20%v/v; 50m1) was added to karela water extract (50m1). The 
mixture was refluxed for 1 hour, then extracted with solvents hexane (3 x 50m1), 
followed by chloroform (3 x 50m1). The extracts were concentrated down by rotary 
evaporator. For comparison, the water extract, 50m1, (without undergoing acid- 
hydrolysis), was also extracted with hexane and CHC13. 
All extracts (the crude water extract, the hexane and CHC13 extracts obtained from 
the water extract with or without acid-hydrolysis, the remaining aqueous mixtures) 
were evaporated to dryness and then redissolved in 1ml appropriate solvent before 
application. All extracts, together with the reference compounds, 5,25- 
stigmastadienol, momordicine I, ß-sitosterol and stigmasterol (5mg each individually 
dissolved in 1ml CHC13), were all applied (10µi each) on the TLC plate (RP-18 
F254 S), with solvent system - MeOH : CH3CN (2: 1). After development, the zones 
were detected under UV shortwave and also under daylight after spraying with 
anisaldehyde spraying agent and subsequent heating at 100°C for 10 min. 
As a positive control to validate the acid-hydrolysis method, glycyrrhizic acid (a 
triterpene saponin from liquorice; Sigma) was acid-hydrolysed under the same 
conditions as above. The TLC system used was: silica gel GF254 plate; solvent system 
- ethyl acetate: ammonia, 1M: absolute ethanol (60: 27: 13). After development, the 
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zones were detected under UV shortwave and after spraying with anisaldehyde 
spraying agent as above. 
5.8.3 Results and discussion 
Examination of the hydrolysed glycyrrhizic acid showed that effective hydrolysis had 
occurred under these conditions, i. e. the corresponding aglycone glycyrrhetinic acid 
(reference compound from Sigma) was produced. This validated the experimental 
method. 
The TLC zone profiles of karela extracts are shown in Fig. 5.14. From the results, the 
four reference aglycones were not found in the crude water extract (A) or any of the 
extracts (B-G) applied. Thus we can conclude that the compounds responsible for the 
anti-hyperglycaemic effect of the water extract were not the glucosides of the 
corresponding aglycones (5,25-stigmastadienol, momordicine I, (3-sitosterol) which 
were present in the hexane extract. However, other possible sterols or steroids (as 
seen by pink zones on the TLC plate; Fig. 5.14) were observed in the non-hydrolysed 
extracts. However on hydrolysis, none of the reference aglycones were detected, 
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5.9 Investigation 'on the constituents of commercial karela 
capsules 
5.9.1 Introduction 
Two different brands of commercial karela capsules were bought (Appendix 14): 
a) Purchased from "The Herb Room", Santa Cruz, USA. 
b) Purchased from "The Food Hall", Turnpike Lane, London N8, UK. 
Both brands of karela capsules are sold as food supplement. They do not have 
product licences and have made no medicinal claims, such as for the treatment of 
diabetes. From the product label, the US karela capsules were made from freeze- 
dried powder of Momordica charantia whole fruit; whether karela seeds were 
included remains questionable. The UK karela capsules are believed to have been 
produced from karela fruit, though the information provided on the label is less clear. 
However, the origins of karela for both brands are not given. It would be interesting 
to look at the chemical constituents of these karela capsules, and compare with our 
Thai karela. 
5.9.2 Materials and method 
5.9.2(a) Hexane extract 
Ten karela capsules of each brand were used. The contents (dried powder) of the 10 
capsules were combined together for each brand. The powder of each brand was 
individually refluxed with 50ml hexane solvent for 30 min, then the hexane solvent 
was collected after filtration, evaporated to dryness using a rotary evaporator, and the 
residue was redissolved in I ml hexane. The hexane extract of Thai karela (M2) 
prepared earlier (Section 5.2) was used. 
5.9.2(b) TLC 
10µl of each reconstituted hexane extracts (Thai karela (M2) and the 2 brands of 
karela capsules) were applied on RP-18 F254S plate, with solvent system - MeOH: 
CH3CN (2: 1). After development, the plate was sprayed with anisaldehyde spraying 
agent with subsequent heating at 1 00°C for 10 minutes. 
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5.9.3 Results and discussion 
The total amount of karela dried powder in 10 of the US and UK karela capsules 
were 2.194g and 2.053g respectively. The dried powder of UK karela capsules was 
fairly coarse and brown in colour; whereas the dried powder of US karela capsules 
was very fine and yellow-brown in colour. 
The TLC zone profile is shown in Fig. 5.15. The zone profiles for the hexane extracts 
between the US and UK karela capsules were very different, and they were also 
different from that of our Thai karela. It is amusing to observe that the two 
compounds (5,25-stigmastadienol and momordicine I) isolated from the active 
fractions of Thai karela extract were not detected in both karela capsules hexane 
extracts, despite the fact that one of the brands (US karela capsules) claims to 
maintain the biologically active constituents. Although both brands of karela capsules 
are sold as food supplement, if the public is to use them as anti-diabetic remedy, then 
their effectiveness remains questionable. In addition, based on information in Fig. 
5.1, the freeze-dried powder of 10 capsules = about 70m1 karela juice. Thus each 
capsule is only equivalent to about 7m1 of karela juice. According to the 
recommended dosages, one capsule (UK brand) or 1-3 capsules (US brand) should be 
taken daily. In both cases, the doses taken are very low (= about 7-21ml karela juice 
per day). 
Our results showed that the chemical constituents of commercially available karela 
capsules can vary considerably between brands. So far, the author has not seen any 
commercial karela products in market which are sold specifically for the treatment of 
diabetes. However, if this is the case in the future, then the quality control and 
standardisation of active constituents will undoubtedly be the main issue. 
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RP- 18 F254 plate; Application : 10µl 
Solvent system - MeOH : CH3CN (2: 1) 
Detection - 
i) UV shortwave 254nm (zones marked by pencil) 
ii) Anisaldehyde spraying agent 
Keys: HI - Thai karela (M2); H2 - UK karela capsules; H3 - US karela capsules 
m= momordicine I; s=5,25-stigmastadienol 
Figure 5.15: TLC zone profiles of hexane extracts of commercial karela capsules 
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5.10 Discussion and conclusion 
In the present chapter, bioassay-guided fractionation of the crude hexane extract 
using the in vivo nO STZ NIDDM model revealed the anti-hyperglycaemic effects of 
two sub-fractions, M2C and M21. Since the sub-fractions M2C and M21 contained 
components at opposite ends of the TLC zone profile (Fig. 5.2), this suggested that at 
least two compounds within the hexane extract are responsible for the anti- 
hyperglycaemic activity. Further fractionation (by column chromatography and 
repeated preparative thin layer chromatography) of these two sub-fractions led to the 
isolation of 5,25-stigmastadienol and momordicine I, and the identification of 3- 
sitosterol. Both 5,25-stigmastadienol and ß-sitosterol are sterols. ß-Sitosterol is a 
common steroid in plants, and its presence in the aerial parts of whole Momordica 
charantia plant had previously been reported by Lal et al. (1990). 5,25- 
Stigmastadienol is another steroidal compound. On the other hand, momordicine I is 
a tetracyclic triterpenoid (C30), and in accurate terms, it is in fact a cucurbitacin 
triterpenoid (Section 1.3.1(c)) since the methyl group (in this case, the aldehyde 
group) is in C9 rather than in CIO (for steroids). To the best of our knowledge, this is 
possibly the first report of the isolation of momordicine I from karela fruit, though it 
had previously been isolated from the leaves and vines of Momordica charantia 
(Yasuda et al., 1984), with a yield of 0.07%w/w as compared to our approximate 
yield of 0.05%w/w from the fruit. However, the paper (Yasuda et al., 1984) only 
published partial spectral data ('H and 13C NMR) and the complete carbon 
assignment for momordicine I has been reported in our present study. 
Regarding the identity of the active components in karela, we demonstrated that both 
5,25-stigmastadienol and (i-sitosterol significantly improved oral glucose tolerance in 
the nO STZ NIDDM model. In addition, momordicine I is the main component in the 
active sub-fraction M2C, though its anti-hyperglycaemic activity is still to be 
investigated. One reason for not testing momordicine I on oral glucose tolerance was 
that the total amount isolated (about 10mg) was not enough for the in vivo testing. 
Secondly, since momordicine I is a triterpenoid, it was not regarded by Lipha as being 
of sufficient interest for further investigation of its anti-diabetic activity, considering 
the resources that would be needed for this. 
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The isolation of both 5,25-stigmastadienol and ß-sitosterol from an active fraction of 
karela is in agreement with the isolation of the compound charantin in the early 
sixties. Charantin (Fig. 1.19), a 1: 1 mixture of ß-sitosterol and 5,25-stigmastadienol 
glucosides was isolated from Momordica charantia fruit by Lotlikar and Rajarama 
Rao (1960/61). Charantin was claimed to be the active constituent in Momordica 
charantia since its oral or intravenous administration to normal or alloxan diabetic 
rabbits resulted in a significant fall in plasma glucose (Lotlikar and Rajarama Rao, 
1966). It is interesting that in our study, ß-sitosterol and 5,25-stigmastadienol (the 
aglycones of charantin) were found to be the main components in one of the active 
sub-fraction (M21) of crude hexane extract and both compounds were shown to be 
active in OGTT. Our results in Section 5.8 have demonstrated that the water extract 
did not contain the glucosides of the corresponding aglycones found in the hexane 
extract, suggesting that other active compounds are present in the water extract. 
These need to be investigated further. 
Earlier in Section 1.4.3, we commented on the high dosages of charantin used in the 
studies by Lotlikar and Rajarama Rao (1960/61; 1966). The dosages of charantin 
used in Lotlikar and Rajarama Rao's studies were 10-50mg/kg, whereas in our 
present study, only about 5mg/kg (5,25-stigmastadienol) and 3mg/kg ((i-sitosterol) 
were used. Since smaller dosages were needed in our study, there is in fact a stronger 
evidence for the importance of 5,25-stigmastadienol and ß-sitosterol in karela's 
activity. Nevertheless, from the previous discussion in Section 5.7.3, it appears that 
the dose of 5,25-stigmastadienol needed is much higher than an effective dose of the 
juice, suggesting that 5,25-stigmastadienol is not the sole active constituent in karela. 
The same would apply for ß-sitosterol. 
In summary, evidence arising from this bioassay-guided fractionation that there is 
more than one active component in karela is as follows: 
i) The hexane and water extracts were both active, indicating that at least two 
compounds (one non-polar and one very polar) were present. In addition, the 
corresponding glycosides of those aglycones found in the hexane extract were not 
detected in the water extract, suggesting that other active compounds were present 
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in the water extract. 
ii) The hexane extract itself gave 2 well separated active fractions (M2C and M21). 
iii) The doses of isolated compounds needed for an effect were much greater than 
doses present in the crude extract, suggesting the synergistic or additive effect of 
different active components in karela. For example, about 5mg/kg of 5,25- 
stigmastadienol was required to show a positive effect in OGTT, but this is about 
3-4 times greater than its actual amount in the crude hexane extract. 
Our results showed that 5,25-stigmastadienol, ß-sitosterol and possibly momordicine 
I are all involved in the anti-hyperglycaemic activity of karela. However, variation in 
the presence of these compounds in different varieties of karela fruit and seed was 
observed (Section 5.7). This may account for the differences in potency in the anti- 
hyperglycaemic activity among different varieties of karela, and also differences 
between karela fruit and seed as anti-diabetic agent. These compounds were not 
detected in 2 commercial samples of freeze-dried karela (Section 5.9). 
The mode of action of the two active compounds, 5,25-stigmastadienol and [3- 
sitosterol, is still to be investigated. Our results showed that both compounds did not 
stimulate phase I insulin secretion. The other possible modes of action, such as their 
effects on the gut (intestinal glucose uptake inhibitory effect), or on the liver (hepatic 
insulinomimetic or insulin sensitising activity), require further investigation. 
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6.1 General discussion 
An extensive literature review on Momordica charantia L. (Section 1.4) showed 
evidence for its anti-diabetic activity in humans, animals and various in vitro models. 
However, the information on the identity of the active constituent(s) is less clear. 
Although a number of hypoglycaemic principles has previously been proposed, 
none of these appears'to totally satisfy the enquiry. Thus there was clearly a need for 
further study on the active hypoglycaemic principles of Momordica charantia, in 
which particular attention is given to the dose and route of administration. 
The aim of the present study was to use a systematic, relevant approach to isolate and 
identify orally active anti-diabetic phytochemicals in the unripe fruit of Momordica 
charantia, and to elucidate the mode of action. 
The present study has highlighted a few interesting findings which are believed to 
provide a useful scientific contribution to the research on Momordica charantia fruit 
as an anti-diabetic remedy. Some of the findings are novel, whereas others support 
previously published data through the use of a different approach. In this Chapter, an 
attempt is made to summarise the important findings of this study. Suggestions for 
future work are given in section 6.2. 
At the beginning of our laboratory investigations (Chapter 2), we reported that karela 
fruit from different geographical origins (Africa (Kenya and Nigeria), Bangladesh, 
India (Bombay and Jaipur), Thailand and UK) were different in size, shape, colour 
and even had different chemical constituent profiles. Furthermore, our investigation 
(Chapter 3) showed differences in potency in the biological activities between two 
varieties of karela fruit (Thai and Kenyan). Previous studies on Momordica charantia 
fruit have seldom specified the geographical source or cultivar of karela used, which 
may partly account for differences among researchers' results. In Chapter 5, we 
observed that the presence of compounds associated with the activity was somewhat 
variable among different varieties of karela. A comparison of different varieties of 
karela has not previously been reported, thus our study highlighted the importance 
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of recording the origin of karela fruit used for research studies. 
In the majority of previous studies, compounds were isolated from karela fruit with 
no apparent rationale and then tested for their anti-diabetic activities. In addition, the 
doses employed were not compared to the concentration of the substances in the 
original crude extracts. Thus a clear indication of the relevance of the single 
compound to the activity of the whole fruit was not given. Besides, tests were not 
always performed with the oral route of administration, sometimes intravenous 
injections were used, e. g. p-insulin (Khanna et al., 1981). Unlike previous studies, 
our study attempted to use a systematic, relevant approach to isolate the orally active 
constituent(s) in karela. Our aim was also to pay attention to the concentration of 
these constituents in the whole karela juice and further fractions while performing the 
tests. Here, an in vivo bioassay-guided fractionation, using nO STZ NIDDM model 
rats (Chapter 3), was employed to identify the active component(s) in karela fruit. 
Despite previous reports on the hypoglycaemic effect of administration of karela 
juice/extracts in diabetic animals (Sharma et al., 1960; Higashino et al., 1992; Ali et 
al., 1993a), our study showed that both Thai and Kenyan karela did not produce a 
statistically significant effect on basal glycaemia on NIDDM model rats. In contrast, 
from the oral glucose tolerance tests, we confirmed that both varieties of karelä 
exhibited anti-hyperglycaemic activities, though Thai karela had a more pronounced 
effect. Thus our study focused on Thai karela. 
From sequential soxhlet extraction, the most polar (water extract) and the most non- 
polar (hexane extract) of karela were shown to significantly improve oral glucose 
tolerance. Bioassay-guided fractionation of the hexane extract resulted in the 
isolation or identification of three compounds: 5,25-stigmastadienol (approx. 
0.15%w/w yield), momordicine I (approx. 0.05%w/w yield) and ß-sitosterol. This is 
the first report of momordicine I in Momordica charantia fruit, though its presence in 
the leaves and vines of Momordica charantia was previously reported by Yasuda et 
al. (1984). We observed that both compounds, 5,25-stigmastadienol (4.6mg/kg) and 
(3-sitosterol (3.1mg/kg), significantly improved oral glucose tolerance in nO STZ 
diabetic rats. Although it was disappointing not to discover novel anti-diabetic 
compounds, these results did support the earlier proposal (Lotlikar and Rajarama 
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Rao, 1960/61; 1966) that charantin (a 1: 1 mixture of 5,25-stigmastadienol and ß- 
sitosterol glucosides) is an active constituent of karela fruit. It is interesting that a 
much lower dose of 5,25-stigmastadienol (4.6mg/kg) and ß-sitosterol (3.1mg/kg) was 
used in our study as opposed to the relatively high dose of charantin used (10- 
50mg/kg) in the other study. Charantin is often stated to be "the active" constituent of 
karela. It was the high dose administered by Lotlikar and Rajarama Rao (1960/61; 
1966) which led us to question the role of these 2 compounds in the activity of 
karela. Our study strongly suggested that charantin is not the sole active constituent 
in karela. Firstly, another sub-fraction extract (M2C) where momordicine I was 
isolated, as well as the water extract (which did not contain charantin) were also 
active in improving oral glucose tolerance. Secondly, the effective dose of 5,25- 
stigmastadienol used in our study was already 10 times more than the actual amount 
in the juice. However, it is important to note that the doses of 5,25-stigmastadienol 
and (3-sitosterol used were much lower than that of metformin (200mg/kg), a positive 
control in our study. The steroidal (lipophilic) nature of the active compounds may be 
related to the traditional practice of consuming fried karela as anti-diabetic remedy. 
This was shown (Leatherdale et al., 1981) to result in an improvement in glucose 
tolerance in NIDDM humans. This may be due to the fact that consumption of karela 
in a lipophilic matrix may aid the absorption of these sterols. The anti- 
hyperglycaemic activity of momordicine I is still to be investigated. 
From the pharmaceutical industry (Lipha) point of view, since all three compounds 
(5,25-stigmastadienol, momordicine. I and f -sitosterol) are of steroidal/triterpenoidal 
structure, and the fact that uses of high doses of steroids may result in wide range of 
side effects (BNF 1998), their use as lead compounds for development of new orally 
active anti-diabetic agents is not encouraged. However, a recent review article by 
Ling and Jones (1995) on dietary phytosterols (such as ß-sitosterol and stigmasterol) 
concluded that no obvious side effects associated with phytosterols have been 
observed, except in individuals with phytosterolemia, an inherited lipid disorder. It is 
known that phytosterols are generally poorly absorbed from the intestine (Ling and 
Jones, 1995), especially in hyperinsulinaemic NIDDM patients (Sutherland et al., 
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1992). 
The active components of the water extract of karela are still to be investigated. So 
far, it is encouraging to learn that the active compounds present in the water extract 
were not the corresponding glycosides of the aglycones (the three compounds above) 
present in the hexane extract (section 5.8). This suggests the presence in karela of 
other, possibly non-steroidal, active components which may be of greater interest for 
further drug development. 
Phytosterols (such as (3-sitosterol and stigmasterol), as the name implies, are common 
components of a wide range of plants. This raises the question as to whether or not 
all these plants possess anti-hyperglycaemic activities. The reason this is not 
observed may be because firstly, the amount of sterols present is insufficient to 
produce an effect and, secondly, because the effect of the sterols may be enhanced by 
the presence of other related or unrelated compounds which perhaps only occur in 
selected plants, e. g. Momordica charantia. 
Our present study has also contributed useful additional information with regard to 
the mode of action of karela as an anti-diabetic agent. A significant finding arising 
from the present work was the first demonstration of an in vivo insulin secretagogue 
effect (phase I insulin stimulation) by karela (Section 3.2), which supports the 
previous findings of an in vitro insulin stimulating effect by karela (Welihinda et al., 
1982a, b; Ali et al., 1993b; Mosihuzzaman et al., 1994). Previous studies on plasma 
insulin have not shown any effects of karela. The stimulation of phase I insulin 
secretion reported here, may have been missed in earlier studies on humans 
(Leatherdale et al., 1981) or animals (Leatherdale et al., 1981; Day et al., 1990; 
Sarkar et al., 1996), due to the later initial blood sampling times (30 min or more) 
employed previously. In our case, the initial blood sampling time was 10 min and it 
was at this time when the insulin stimulation effect was seen. Though the stimulation 
of insulin release by karela was not clearly observed in a further study (section 3.3), 
this may be due to experimental error (unreliable insulin data) and large fluctuation 
in insulin levels. Thus further investigations should be carried out to confirm this 
mode of action. 
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Apart from the in vivo demonstration of phase I insulin stimulation by karela juice as 
mentioned earlier, the effects of karela extracts on oral, intravenous and 
intraperitoneal glucose tolerance were compared. To the best of our knowledge, this 
is possibly the first IVGTT study carried out on karela. From the results, water 
extract of karela only improved oral glucose tolerance, suggesting that it may work 
primarily on the gut, i. e. inhibiting intestinal glucose absorption. Besides, since the 
water extract only improved oral but not intraperitoneal glucose tolerance (IPGTT 
does not involve gut hormones), it could also co-stimulate secretion of gut hormones, 
such as GLP-1 (glucagon-like peptide) and GIP (gastric inhibitory peptide), resulting 
in glucose-induced insulin secretion. The water extract was also shown to stimulate 
insulin release (Fig. 3.9), though the effect was not as significant as in the whole 
juice. 
The hexane extract of karela was shown to improve both oral and intraperitoneal (but 
not intravenous) glucose tolerance indicating that it may also have some effects on 
the liver, as well as inhibiting intestinal glucose absorption. In fact, alterations in 
hepatic enzyme levels following administration of karela have been reported in 
previous studies (Shibib et. al., 1993). The hepatic effects are more likely to be 
insulin sensitising rather than insulinomimetic since basal glycaemia is not affected 
by karela juice. In our in vivo studies, we observed that the effect of four days 
treatment was almost always better than the effect of single treatment. This 
cumulative effect seen may be due to the changes in hepatic enzymes. 
As with the water extract, hexane extract was shown to stimulate the phase I insulin 
release (though the effect was not significant) in OGTT, again suggesting a possible 
insulin secretagogue action. Separation of the water soluble and lipophilic 
components by extraction may account for the diminished insulin secretagogue 
activity. 
The inhibitory effect of hexane extract of karela on intestinal glucose absorption was 
further investigated, using an in vitro intestinal brush border membrane vesicles 
model (Chapter 4). The hexane extract at concentrations of 0.73µg/µ1 resulted in 
significant inhibition of glucose uptake. Our study suggested that hexane extract may 
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contain active compounds which act like phlorizin that inhibits Na+- 
dependent/glucose transport in the brush border membrane. By estimation, the IC50 
of the hexane extract was between 1-5mg/ml as opposed to phlorizin which has an 
IC50 of 0.05mg/ml. Regarding the value of decreasing glucose supply from the gut in 
the treatment of NIDDM, such compounds could be useful, either given alone or 
combined with other oral hypoglycaemic agents, in reducing postprandial rises of 
blood glucose (like the (x-glucosidase inhibitor acarbose) and smooth out the 24-hour 
blood glucose profiles. The author believes that this is the first time where BBMV 
were used as an in vitro model for studying natural products with intestinal glucose 
uptake inhibitory effect (apart from phlorizin) and this could open a possibility of 
being used in the future as an in vitro model for screening anti-diabetic plants for this 
particular mode of action. 
From our studies it appears therefore, that karela contains a number of active 
constituents, including 5,25-stigmastadienol and ß-sitosterol which are likely to work 
by a range of mechanisms. This lends support to the traditional use of whole karela 
juice in the treatment of diabetes. However, the dose of karela juice used in our in 
vivo studies was 10mlIkg body weight of rat. For a 60kg human, the extrapolated 
dose will theoretically be 600m1. This may suggest that the ordinary recommended 
dose (50m1 karela juice once or twice daily) is not effective. However, such a linear 
extrapolation may not be valid. Also, it must be noted that some human studies 
(Leatherdale et al., 1981; Welihinda et al., 1986) have demonstrated an effect, in 
which cases, the doses of 50m1 and 100mi of karela juice were used respectively. 
Additionally, whilst 50ml karela juice may not have an acute effect, it is possible that 
regular consumption may lead to some biological alterations (such as alterations in 
hepatic enzyme levels) which improve glucose tolerance. Our observation of a 
cumulative effect supports this possibility. 
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6.2 Future work 
As a result of our findings regarding Momordica charantia fruit with respect to its 
anti-diabetic activity, there are now further questions to be answered: 
a) What is the active component(s) present in the water extract of karela that is 
responsible for the anti-hyperglycaemic activity as observed? 
b) Does the hexane extract of karela possess hepatic effects? 
c) What is the mode of action of the sterols in improving OGTT? 
d) Are there any problems of toxicity with prolonged use of karela? 
Thus the author suggests future studies to be carried out in the following areas: 
6.2.1 Further investigations on the phytochemicals present in the water 
extract of karela 
The anti-hyperglycaemic compound(s) present in the water extract of karela should 
be very polar. One possible identity of the active component(s) might be steroidal 
glycosides. However, our results have shown that 5,25-stigmastadienol, ß-sitosterol 
and momordicine I were not detected in the acid-hydrolysed water extract (Section 
5.8). Therefore the identity of the active compound(s) present in the water extract 
remains unknown and worthy of further investigation. 
Since water extract is very polar and it is further complicated by the presence of 
sugars in it, the approach in fractionation of the water extract will be undoubtedly 
different from that for the hexane extract, i. e. different TLC systems need to be used. 
With our success in identifying the active constituents in the hexane extract, it would 
be advisable to fractionate the water extract using the same in vivo bioassay-guided 
fractionation. Any active fractions obtained will be further fractionated until 
individual compounds are isolated. The author suggests to remove the sugars initially 
from the water extract by size exclusion chromatography. 
6.2.2 Further investigations on the mode of action of the hexane extract 
of karela 
In the present research project, the effect of karela juice/extracts on insulin release 
(using the nO STZ NIDDM rat model) and gastrointestinal glucose absorption (using 
in vitro BBMV model) has been investigated. However, the fact that the hexane 
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extract of karela improved both oral and intraperitoneal, but not intravenous, glucose 
tolerance suggested that the extract might have some effect on the liver. Thus further 
investigations should be carried out to see if the hexane extract possesses any hepatic 
insulin sensitising or even insulinomimetic activity. This can be carried out using 
isolated perfused animal liver, isolated hepatocytes or hepatoma cell lines. By using 
these models, the effect of the hexane extract on hepatic enzyme levels, such as 
glucokinase, phosphoenolpyruvate carboxykinase, fructose 2,6-bisphosphate and 
glycogen phosphorylase, can be measured. In addition, the effect on insulin 
sensitivity can also be studied in these models. 
6.2.3 Further investigations on the mode of action of the water extract 
of karela 
Our results suggest that the water extract may stimulate secretion of gut hormones, 
such as GLP-l and GIP. Thus the effect of water extract on levels of these gut 
hormones in portal blood can be measured. 
6.2.4 Further investigations on the mode of action of the sterols 
Our results showed no evidence of increase in insulin secretion by the sterols (5,25- 
stigmastadienol and ß-sitosterol). However, their effects on OGTT, IPGTT and 
IVGTT in nO STZ NIDDM rats can be compared, as well as their effects on intestinal 
glucose uptake using the BBMV model. 
6.2.5 Further investigations on the toxicity of karela juice 
In order to fully evaluate the potential of karela or its components as anti-diabetic 
agents, it will be necessary to investigate their short and long term toxicity. 
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6.3 Conclusion 
Our research on Momordica charantia fruit has strongly supported its traditional use 
for the treatment of diabetes mellitus. Our results have clearly shown that the juice is 
able to improve glucose tolerance but has little acute effect on basal glycaemia. It 
also appears that there is more than one active component in M charantia fruit and these 
may exert their anti-hyperglycaemic effects by various modes of action. The active 
components may act synergistically or additively since separation of fractions 
generally necessitated an increase in dose in order to obtain a similar effect to the 
parent test substance. The author hopes that the active components identified and 
isolated from M. charantia fruit will be used as lead compounds for the development 
of new orally active anti-diabetic agents. In order to achieve this goal, careful 
considerations will be taken on the potency and the toxicity data of the isolated 
compounds. 
Metformin, acarbose and guar gum are marketed anti-diabetic drugs which are all 
derived from natural sources. It is the wish of the author that more natural products 
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Appendix A: Preparation of streptozotocin (STZ) solution for injection 
Buffer for dissolving STZ: 
Solution 1- citric acid (monohydrate) (Sigma) O. 1M 
C6H807. H20 
Solution 2- citric acid (trisodium salt dihydrate) (Sigma) 0.1M 
C6H5O7Na3.2H20 
To make up buffer: 28m1 of Solution 1+ 25.5m1 Solution 2, then made up to 100ml 
with water. The final solution should be at pH 4.5. 
STZ is dissolved in the buffer prior to injection (20mg STZ/ml). 
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Appendix B: Calculation of dosage of pentobarbitone 
Pentobarbitone (Sanofi) 6g/100ml in bottle 
Dosage formula: 
0.2m1 saline (sodium chloride 9g in 1000ml; Meram lab. ) + pentobarbitone (ml) 
as follows - 
for female rats : (weight of rat (g) x 0.8)/1000 
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Appendix 2: A table of the weight of rats used in the experiment of 
dose-response effect of karela juice 
*p<0.05, **p<0.02, ***p<0.01 as compared with control using 
Student's paired t-tests. 
Test substances Weight (mean ± SEM) of rats (g) on: 
Control Day Test Day 1 Test Day 4 
Water IOmIkg 352.0 ± 13.1 366.0 ± 12.6 *** 369.0 ± 11.2 *** 









349.0 ± 13.2 
355.8 ± 6.8 
388.0 ± 16.3 
355.0 ± 7.1 
344.2 ± 15.6 
345.8 ± 11.5 
369.2 ± 10.1 *** 375.0 ± 10.4 *** 
361.0 ± 12.1 
373.3 ± 7.4 *** 
394.0 ± 14.7 
367.5 ± 11.5 
354.2 ± 15.6 *** 
359.2 ± 13.6 *** 
366.0 ± 10.5 *** 
380.0 ± 7.6 *** 
402.0 ± 12.2 
370.8 ± 10.4 *** 
360.8 ± 15.2 *** 
363.3 ± 14.8 *** 
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Appendix 3: Amount of glucose in Thai/Kenyan karela juice which is 
available for absorption after oral administration of the 
juice (at dosage of 15ml/kg) in nO STZ diabetic rat 
model. 
According to the HPLC analysis, Thai and Kenyan karela juice contained 8-11mM and 
7-8mM of glucose respectively. Thus 10mM of glucose will be used in the following 
calculations. 
If we assume the average weight of a nO STZ rat used in experiment was 350g, at a 
dosage of 15ml/kg, 
350g 
i. e. 15m1 x --------- = 5.25m1 of karela juice would be administered to the rat. 
1000g 
How much glucose is present in 5.25m1 of karela juice? 
volume 
No. of moles = ---------------------- x Molarity 
molar volume 
5.25m1 
_ ---------------- x lOmM 
1000ml 
5.25m1 
_ ---------------- x 0.01M 
1000ml 
= 5.25 x1 0'5 moles 
mass 
No. of moles = ------------------ (N. B. molecular weight of glucose = 180.16g) 
molar mass 
mass 
5.25 x 10'5 = --------------- 
180.16g 




Appendix 4: A table showing the different treatment received by the 
nO STZ rats on Control and Test Days. 
Treatment received on Control Day I Treatment received on Test Days 
Water (1Oml/kg) 
0.3% v/v Tween 80 in water (1Oml/kg) 
Water (1 Om1/kg) 
0.3% v/v Tween 80 in water (IOml/kg) 




- as negative control 
0.3% v/v Tween 80 in water (l Oml/kg) 
- as negative control 
Metformin (200mg/kg; 200mg in 10ml 
water) 
- as positive control 
Hexane extract reconstituted in 0.3%v/v 
Tween 80 (10ml(2.2mg)/kg) 
Chloroform extract reconstituted in 
0.3% v/v Tween 80 (10ml(9.8mg)/kg) 
9 
Methanol extract reconstituted in water 
(10ml(151.6mg)/kg) 




Appendix 5: Protein assay for BBMV 
The results of the protein assay for a particular batch of BBMV are presented below. 
Solutions UV absorbance at 595nm: 
Duplicate Mean Corrected 
results values 
504l of solution A+ 95041 of dye reagent (x2) 0.587 0.590 0.0 
0.593 
5041 of solution B+ 95041 of dye reagent (x2) 0.862 0.852 0.262 
0.841 
501il of solution C+ 950µ1 of dye reagent (x2) 1.115 1.103 0.513 
1.091 
50µl of solution D+ 950µl of dye reagent (x2) 1.282 1.292 0.702 
1.302 
50µ1 of solution E+ 950µl of dye reagent (x2) 1.464 1.470 0.880 
1.476 
5041 of solution F+ 950µ1 of dye reagent (x2) 1.549 1.573 0.983 
1.597 
50µ1 of solution G (BBMV -1 in 10 dilution) + 1.325 1.341 0.751 
950µ1 of dye reagent (x2) 1.357 
50µ1 of solution H (BBMV -1 in 50 dilution) + 0.770 0.775 0.185 
950µl of dye reagent (x2) 0.780 
5041 of solution I (BBMV -1 in 100 dilution) + 0.697 0.695 0.105 
950µl of dye reagent (x2) 0.693 
A calibration graph was drawn (see overleaf) in order to determine the protein 
concentration of this batch of BBMV. 
cont. ) 
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Appendix 5 (cont. ): Protein assay for BBMV 
Determination of the protein concentration of this particular batch of BBMV 
Using the calibration graph: 
Solution G-0.33mg/ml; since it is 1 in 10 dilution of original BBMV suspension, 
i. e. 3.3mg/ml 
Solution H-0.07mg/ml; since it is 1 in 50 dilution of original BBMV suspension, 
i. e. 3.5mg/ml 
Solution I- 0.037mg/ml; since it is 1 in 100 dilution of original BBMV suspension, 
i. e. 3.7mg/ml 
By taking the mean of the above three values, the protein concentration of this batch of 
BBMV is 3.5mg/ml. 
N. B. Different batches of BBMV varied in their protein concentration (ranged from 
3.5 - 8.4mg/ml among all batches of BBMV used in this research). 
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Appendix 6: HPLC (High Performance Liquid Chromatography) 
assay for sugars in karela juice/extract 
The amounts of glucose and fructose in three different varieties (Indian, Kenyan and 
Thai) of karela juice, as well as the hexane extract of Thai karela, were quantified. 
Method for HPLC assay 
Glucose and fructose were well-separated from the other components in karela juice 
when using Apex amino (5 micron) column (20cm in length x 0.45mm internal 
diameter) with a mobile phase consisting of acetonitrile: water (80: 20) developed at a 
rate of 2. Oml/min, with a pressure of 1500psi and at room temperature. A refractive 
index detector (ERC-7512) was used for detection. Maltose (0.05g/ml) was used as an 
internal standard. A sample size of 2Oµ1 was injected into the HPLC. A set of 
calibration solutions was made up using varying volumes of glucose and fructose 
mixture (containing 5.000g of glucose and 5.000g of fructose dissolved in 100ml 
water) and a fixed volume (lml) of internal standard solution, and made up to final 
volume of 1Omi using water. The range of concentrations for glucose and fructose 
were 0.25 to 6.0 mg/ml. 
The glucose and fructose content in different varieties of karela juice were analysed. 
The test solutions were prepared by adding Imi of internal standard solution to 9m1 of 
karela juice. In addition, tlie'' hexane extract of Thai karela was also tested for the 
presence of glucose and fructose. The hexane extract solution was prepared by adding 
lml of internal standard solution to the hexane extract residue (amount of residue 
taken was equivalent to that present in IOml of karela juice), and the final volume 
adjusted to lOml with 0.3%v/v Tween 80. 
Results 
From the HPLC chromatogram of test solution, fructose gave a peak at Rt (retention 
time) approximately 2.7min, glucose gave a peak at Rt approximately 3.1 min and 
maltose gave a peak at Rt approximately 6.0min (Fig. A). The ratios of the peak areas 
of glucose or fructose to the internal standard (maltose) of the calibration solutions 
were plotted against the. concentrations of glucose or fructose respectively. Two 
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straight line graphs were obtained (correlation coefficient of 0.981 for glucose; 0.975 
for fructose; Fig. B). 
Results are shown in Table A. Both glucose and fructose were present in all three 
different varieties of karela juice, with a higher concentration of glucose than fructose 
in all cases. The results showed differences in glucose and fructose content among the 
different varieties; also with slight differences between batches within a variety. 
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Appendix 6 (cont. ): HPLC assay for sugars in karela juice/extract 




Kenyan (Batch 1) 
(Batch 2) 




Thai hexane extract 
Glucose concentration Fructose concentration 
(%w/v) (mM) (%w/v) (mM) 
0.151 8.39 0.021 1.14 
0.140 7.79 0.123 6.84 
0.140 7.79 0.052 2.89 
0.150 8.36 0.125 6.94 
0.163 9.05 0.148 8.24 
0.185 10.26 0.126 7.00 
0.159 8.85 0.108 6.02 
0.0 0.0 0.0 0.0 
N. B. These calculated values are means of duplicate results. 
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Appendix 8: NMR and MS spectra for stigmasterol 
a) 'H 400 MHz NMR spectrum (CDCl3) 
b) 13C 100 MHz NMR spectrum (CDC13); full spectrum + DEPT 
c) Electron impact mass spectrum 
d) Fast atom bombardment mass spectrum (matrix: MNOBA + Na) 
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Appendix 9: NMR and MS spectra for compound M2ItC 
Appendices 
a) 'H 400 MHz NMR spectrum (CDC13) 
b) 13C 100 MHz NMR spectrum (CDC13); full spectrum + DEPT 
c) COSY (correlated spectroscopy) spectrum (CDC13) 
d) NOESY (nuclear overhauser enhancement spectroscopy) spectrum (CDC13) 
e) C-H correlation spectrum (CDC13) 
f) Electron impact mass spectrum 
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Appendix 10: NMR spectra for compound M21tB 
a) 'I 400 MHz NMR spectrum (CDC13) 
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Appendix 11: CC-MS analysis data 
a) Electron impact mass spectrum for ß-sitosterol 
b) Electron impact mass spectrum for 5,25-stigmastadienol 
c) Electron impact mass spectrum for stigmasterol 
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Appendix 12: NMR and MS spectra for compound M2Ciii 
Appendices 
a) 'H 400 MHz NMR spectrum (CDC13) 
b) 13C 100 MHz NMR spectrum (CDC13); full spectrum + DEPT 
c) COSY (correlated spectroscopy) spectrum (CDC13) 
d) NOESY (nuclear overhauser enhancement spectroscopy) spectrum (CDC13) 
e) Electron impact mass spectrum 
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Appendix 13: NMR spectra for reference compound Momordicine I 
a) lH 400 MHz NMR spectrum (CDC13) 
b) 13C 100 MHz NMR spectrum (CDC13) 

































































Appendix 14: The product labels for the two commercially available 
karela capsules 
a) Bought from "The Herb Room", Santa Cruz, USA. ($ 9.50 for 45 capsules) 
Fresh Freeze-Dried 
Bitter Melon 
Momordica charantia U-N Whole Fruit 










100% fresh freeze-drying maintains 
the biologically active constituents for 
highest potency and action. 
Suggested Use: As herbal nutrient 
support take 1-3 capsules per day. 
Consult your health care advisor 
regarding the use of herbs during 
pregnancy or with infants. Discon- 
tinue use if unusual symptoms occur. 
Keep out of the reach of children. 
Eclectic Institute Inc., 
Sandy, Oregon 97055-9549 
b) Bought from "The Food Hall", Turnpike Lane, London N8, UK. (£4.99 for 
30 capsules) 
Contents: 30 capsules lw l-11 lulUf ill U Dosage: _ _,.,... 
lnrr-1-nts Karela tak? a, o capsule a aay. D k' , .. ir. wi,.! Itr . yet 
Helps tu rnomtarn breakfast. 
Store in a cool dry place and a hec by !I !c choam cops. iles 
out of direct sunlight. 
I I' 
tonten Kale'. which to 
- 
generations, as Ueen 
Pa; rx: e of more than one country 
ý' puzed for its ealm 9-g 
pfOcemý 
Best before end: March 1998 ^'q""'-" ýg1M1 ' 
ri Ilaturu! ic. .... , ... 
"&ýn äa. un7 
338 
